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ABSTRACT OF THE DISSERTATION 
The Structural Basis of Flaviviridae Interaction with Antibodies and Receptors 
by 
Vincent Christopher Luca 
Doctor of Philosophy in Molecular Biophysics 
Washington University in Saint Louis, 2011 
Professor Daved H. Fremont, Chairperson 
 
Flaviviridae are a family of enveloped, positive-stranded RNA viruses 
responsible for a variety of diseases including encephalitis, hemorrhagic fever and 
hepatocellular carcinoma. The envelope (E) proteins that coat the outer surface of these 
viruses provide the molecular machinery that drives receptor interaction and membrane 
fusion. The assignment of biological functions to specific structural elements of these E 
proteins has proven crucial to the understanding of viral entry into host cells. Clearance is 
dependent upon the presence of neutralizing antibodies that are able to disrupt several 
stages of this process. Given their fundamental role in the viral life cycle, we sought to 
determine the structural basis for envelope protein interaction with antibodies and 
receptors for human pathogens of the Flaviviridae family Japanese Encephalitis Virus, 
Hepatitis C Virus and St. Louis Encephalitis Virus.  
Viruses of the Flavivirus genus within Flaviviridae are grouped into 
serocomplexes with similar clinical manifestations that are defined by cross-
neutralization tests with polysera from heterologous infections. Japanese Encephalitis 
Virus (JEV) is the leading cause of viral encephalitis and prototypical member of the JEV 
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serocomplex. We determined the 2.1Å resolution crystal structure of the JEV E protein 
ectodomain to investigate whether structural features could contribute to our 
understanding of serocomplex-specific pathogenesis. JEV E possesses the three domains 
characteristic of flavivirus envelopes and epitope mapping of neutralizing antibodies 
revealed residues localized to the domain I lateral ridge, fusion loop, domain III lateral 
ridge and domain I-II hinge. The dimer interface, however, is remarkably small and lacks 
several contacts present in other flavivirus E homodimers. Uniquely conserved histidines 
of the JEV serocomplex suggest that pH-mediated structural transitions may be assisted 
by lateral interactions outside the dimer interface in the icosahedral virion. Our results 
suggest that variation of dimer structure and stability may influence the assembly, 
receptor interaction and uncoating of virions.  
St. Louis Encephalitis Virus (SLEV) is another member of the JEV serocomplex 
with similar pathogenesis to JEV. We determined the 4.0 Å structure of the SLEV E 
protein in the post-fusion trimer conformation to compare it with E trimer structures from 
other serocomplexes. SLEV E crystallized as a trimer in the absence of lipids or 
detergents, requiring only low pH. However, its domain arrangement was nearly identical 
to other post-fusion structures. This suggests that viruses can alter dimer assembly but the 
structure of the activated, fusogenic conformation may be more strictly conserved. 
The only member of Flaviviridae known to chronically infect humans is 
Hepatitits C Virus (HCV). HCV is blood borne and carried by roughly 3 percent of the 
world’s population. Clinical manifestations include hepatitis, cirrhosis and hepatocellular 
carcinoma. HCV envelope protein E2 mediates interaction with host receptors CD81 and 
scavenger receptor BI (SR-BI) and is the primary target of neutralizing antibodies. To 
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elucidate detailed biochemical roles for these receptors’ interactions with E2, we 
determined that the E2 ectodomain (sE2) interacts with soluble CD81 large extracellular 
loop (CD81-LEL) with 2:2 stoichiometry, and that this interaction inhibits subsequent 
engagement of SR-BI. We then evaluated the affinity and kinetics of sE2:CD81-LEL 
binding. Interaction between these proteins was enhanced by deletion of hypervariable 
region 1 (HVR1) of E2 and modulated by the genotype from which sE2 was generated. 
Furthermore, neutralization of HVR1-deleted HCV by a cross-reactive antibody was 
enhanced in a genotype-specific manner that correlated with sE2:CD81-LEL affinity 
measurements. Our results suggest that E2 cannot engage CD81 and SR-BI 
simultaneously, that HVR1 obscures conserved CD81 and antibody binding sites, and 
that genotypic variation influences HCV host receptor preference.  
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1.1 Abstract 
 Japanese Encephalitis Virus (JEV) is a mosquito borne pathogen that causes 
30,000 to 50,000 cases of encephalitis and 10,000 deaths annually in Asia. There is no 
specific treatment for JEV infection and while multiple vaccines have been developed, 
licensing issues and safety concerns have restricted their availability in Asia. 
Consequently, generation of additional therapies and cost-effective cell culture vaccines 
is imperative. JEV belongs to the Flavivirus genus of the Flaviviridae family along with 
many other deadly human viruses including Dengue (DV), Yellow Fever (YFV) and 
West Nile (WNV). JEV is an enveloped virus with ~11kb positive-stranded genome that 
encodes a single polyprotein that is cleaved into 3 structural proteins and 7 non-structural 
proteins. Structural protein E is responsible for receptor interaction and membrane fusion. 
An icosahedral arrangement of E homodimers decorates the surface of the mature virion. 
However, a specific host receptor required for infection by JEV or any other flavivirus 
has not yet been identified. The humoral immune response, in particular the generation of 
neutralizing antibodies, is vital to clearance of JEV. Several studies have demonstrated 
that neutralization of flaviviruses is epitope-specific, with the most potent antibodies 
recognizing the lateral ridge of domain III of E. Further delineation of the molecular 
mechanisms of JEV interaction with antibodies and host receptors will therefore prove 
crucial to the control of this important human pathogen. 
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1.2 Transmission and clinical manifestations  
JEV was first identified in 1934 as the causative agent of “summertime 
encephalitis” in Japan when it was isolated from the brain of a fatal human case1,2. The 
primary vector, the Culex tritaeniorhynchus mosquito3, transmits the virus to pigs or wild 
birds that serve as amplifying hosts4. Humans may also become infected as dead-end 
hosts when bitten by carrier mosquitoes. The majority of infections are asymptomatic, but 
more severe clinical manifestations include flu-like symptoms, febrile illness and 
meningomyeloencephalitis5. While fewer than 2% of infections result in encephalitic 
illness6, the fatality rate of these cases ranges from 20%-67%, with children and the 
elderly representing the most susceptible groups7–9. Approximately 30,000 to 50,000 
cases of Japanese encephalitis are reported annually, although actual incidence has been 
estimated to be 175,000 due to substandard medical facilities and data reporting in 
affected regions10.  
 
1.3 Treatment and prevention 
Therapy. Treatment of symptomatic infection with JEV is supportive. In more 
severe cases, this entails assisted feeding or breathing, anticonvulsants for seizure control, 
and osmotherapy for regulation of intracranial pressure. Currently, there is no specific 
antiviral therapy for JEV infection. Directed development of such an agent is unlikely 
given the relatively poor countries most severely affected by JEV, but it is possible that 
broad-spectrum antivirals designed to treat a more widespread, related virus such as 
Hepatitis C may be of greater interest to pharmaceutical companies11.  
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Vaccines. Control of JEV and related encephalitic viruses such as West Nile 
Virus (WNV) and St. Louis Encephalitis Virus (SLEV) is most likely to be achieved by 
preventative approaches such as vaccination and regulation of vectors and amplifying 
hosts2. The first JEV vaccine was developed in Japan from the Nakayama reference strain 
and consisted of formalin-inactived virus isolated from mouse brains12. More recently, 
inactived cell culture derived and live attenuated vaccines from the SA-14-14-2 strain of 
JEV have been developed and utilized successfully in China13, Nepal14 and India15. 
However, despite the existence of these vaccines, they are not universally available in 
Asia due to cost, licensing issues and safety concerns16–19. 
 
1.4 JEV virology 
Genome organization of Flaviviridae. JEV is a member of the Flaviviridae 
family enveloped, positive-stranded RNA viruses. This family contains three genera, 
Flavivirus, Hepacivirus, and Pestivirus. A common feature of all members of 
Flaviviridae is the translation of the RNA genome into a single polyprotein that is 
cleaved into a series of structural and non-structural proteins by both host and viral 
proteases. However, the major differences between these viruses lie in the structural 
proteins located within the 5’ region of the genome20 (Fig 1A-C). Flaviviruses encode 
one envelope protein: E (Fig 1A), Hepaciviruses encode two: E1 and E2 (Fig 1B), and 
pestiviruses encode three: Erms, E1 and E2 (Fig 1C). 
Polyprotein processing. The Flavivirus genus of Flaviviridae contains JEV as 
well as related viruses WNV, Yellow Fever Virus (YFV) and Dengue Virus (DV). The 
genomes of these viruses encode a single polyprotein that is cleaved into 3 structural 
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proteins and 7 non-structural proteins21. The structural proteins are capsid (C), pre-
membrane (prM) and envelope (E). C binds to viral RNA to form a nucleocapsid, prM 
prevents premature fusion with host membranes and E mediates cellular attachment and 
fusion22. The non-structural proteins are NS1, NS2A, NS2B, NS3, NS4A, NS4B and 
NS521 (Fig 1A, 1D). The NS1 protein is unique to flaviviruses and represents the only 
secreted protein encoded by any member of the Flaviviridae family. NS1 has multiple 
functions in the viral life cycle, serving as an inhibitor of complement activation23 and a 
co-factor to the viral replication machinery24,25. NS2A contributes to viral assembly26,27 
and inhibits interferon-driven transcription28. NS3 is a dual-function protease/RNA-
helicase27,29, and NS2B is a co-factor for NS3 protease activity30. NS4A and NS4B both 
influence the interferon response31,32 and NS5 is a methyltransferase25 and RNA-
polymerase33.  
 
1.5 Viral fusion proteins 
Fusion protein overview. The major structural component of the JEV virion is the 
E protein. Flavivirus E proteins belong to a larger category of transmembrane viral fusion 
proteins that coat the outer surface of enveloped viruses. Viral fusion proteins serve as 
molecular machines that facilitate cellular attachment and fusion with the host membrane. 
While they vary dramatically in structure and sequence, the conserved mechanism by 
which they catalyze membrane fusion represents a remarkable example of convergent 
evolution34. The basic process by which this occurs involves a chemical or enzymatic 
activation event that triggers the formation of a trimer with exposed fusion peptides. The 
fusion peptides then insert into the host membrane and drag it together with the viral 
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membrane. Common examples of such an event are the acidic pH encountered in the 
endosome or cleavage by a host protease upon receptor binding or internalization. 
Differences in activation mechanism and three-dimensional structure, however, have led 
to the categorization of these proteins as class I34–36, class II36–38 or class III39.  
Class I fusion proteins. Defining features of class I fusion proteins include a 
predominantly helical structure and proteolytic cleavage of a precursor protein into a 
receptor-binding and fusion protein. Activation of class I proteins leads to formation of a 
trimeric, helical hairpin fusion structure that folds around a central coiled-coil36. The 
prototypical class I fusion protein is influenza hemagglutinin (HA). HA is first translated 
as a trimeric precursor HA0 that is cleaved during viral maturation by host proteases into 
receptor binding protein HA1 and fusion protein HA240–42 (Fig 2A). This cleavage event 
allows the resultant trimer of HA1:HA2 heterodimers to undergo a dramatic 
conformational change upon encountering acidic pH, leading to formation of helical 
hairpins43 (Fig 2B). The hairpins with newly exposed fusion peptides are able to 
penetrate the host lipid bilayer and fuse it with the viral membrane, releasing its contents 
into the cytoplasm. Other notable human pathogen class I fusion glycoproteins include 
HIV gp4144,45 and Ebola gp246,47.  
Class II fusion proteins. Flavivirus E and alphavirus E1 proteins represent the 
class II fusion proteins37. Features that distinguish class II from class I proteins are a 
requisite dimer to trimer structural rearrangement prior to fusion and a distinct beta-
strand rich, 3-domain architecture34,36,37 (Fig 2C). Despite substantial differences in 
amino acid sequence, cellular processing and arrangement on the viral particle, structures 
of E and E1 are strikingly similar43,48–52. The conservation of these domains (the 
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structural details of which are described in 1.6 below) has been well established in crystal 
structures of flavivirus E ectodomains from Tick Borne Encephalitis Virus (TBEV)48, 
DV53 and WNV54,55 as well as alphavirus E1 from Semliki Forest Virus (SFV)49 and 
Chikungunya Virus (CV)56. E and E1 fusion loops are shielded by proteins prM and E2 
respectively to prevent insertion into lipid bilayers during transport to the cell surface. 
prM and E2 are each cleaved by furin57,58 prior to viral budding which generates an 
activated, mature virion capable of fusion after cellular uptake59,60. CryoEM 
reconstructions of mature WNV61, DV52 and SFV51 revealed that E assembles into 
homodimers in flavivirus cryoEM models while SFV E1 and furin-cleaved E2 form 
trimers of heterodimers (Fig 2C). In both cases, this assembly results in burial of the 
fusion loop at the dimer interface, serving a protective role akin to uncleaved prM and E2 
in immature particles. Upon endocytosis and subsequent exposure to the low pH 
environment of the endosome, E/E1 proteins on mature virions dissociate from their 
dimeric partners, undergo a conformational change and rearrange into a homotrimeric 
spike43,50,62 (Fig 2D). This rearrangement brings three fusion loops together at the tip of 
the spike, allowing it to penetrate the endocytic membrane and drive the fusion process.  
Class III fusion proteins. A third class of fusion protein was first identified upon 
determination of crystal structures of the Vesicular Stomatitis Virus (VSV) fusogenic G 
protein63,64 and Herpes Simplex Virus 1 (HSV1) glycoprotein B (gB)65. G and gB have 
no detectable sequence similarity but adopted structurally homologous 5-domain folds 
previously unseen in viral fusion proteins, leading to their distinction as class III39 (Fig 
2E). Three of these domains, domain II, IV and the fusion-loop containing domain I, are 
primarily composed of beta-strands. However, domain III and V are helical, and domain 
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III possesses a helix that forms a trimeric coiled-coil characteristic of class I fusion 
proteins. Class III fusion proteins do not require proteolytic cleavage for activation or a 
capping protein for their fusion loop and remain trimeric in both the pre- and post-fusion 
conformations.  Extensive structural reorganization accompanies the class III post-fusion 
transition. The most substantial motion involves the repositioning of domain I nearly 
180° opposite its pre-fusion orientation, exposing its fusion loop63,65 (Fig 2F).  
 
1.6 JEV envelope glycoprotein structure  
E domain architecture. JEV E possesses the three canonical domains 
characteristic of class II viral fusion proteins (Fig 2C). E proteins share ~35% amino acid 
sequence identity amongst flaviviruses66 and are stabilized by 6 conserved disulfide 
bonds67. Domain I (DI) is a central beta-barrel flanked on opposite sides by domains II 
(DII) and III (DIII). An N-linked glycosylation site at ectodomain amino acid position 
154 within DI is largely conserved and has been suggested to influence receptor 
interaction68, neuroinvasion69 and particle secretion70. Domain II is discontinuous, formed 
by two extended loops that protrude from domain I, and contains the hydrophobic fusion 
peptide at its apex71,72. C-terminal domain III is immunoglobulin-like and connected to 
DI by a flexible linker.  
Structural rearrangements. Crystal structures of E bound to prM in the immature 
conformation73, the pre-fusion dimer,48,53,74 and post-fusion trimer43,62 highlight its many 
structural rearrangements during the viral life cycle (Fig 3A-C). These changes are 
driven by movements around two hinge regions that connect DI-DII and DI-DIII. 
Initially, the fusion loop of the immature E protein is capped by prM, with DI and DII 
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roughly in line with one another (Fig 3A). In this immature conformation, 3 E proteins 
assemble as trimeric spikes with a prM capping each fusion loop.  When the virion 
encounters the low pH of the golgi, these trimers become E homodimers on the viral 
particle but are still associated with prM. Once prM is cleaved and released, DII kinks 
towards an opposing E subunit (Fig 3B), burying its fusion loop and facilitating the 
formation of a flat, antiparallel homodimer (Fig 3B). Upon encountering the acidic pH of 
the endosome, DIII undergoes a dramatic reorientation by swinging 70° toward domain 
II43,59 (Fig 3C). The angle between DI and DII also shifts 30°, returning to a position 
similar to that observed in the prM-bound immature state43. This post-fusion trimeric 
“spike” brings the three fusion loops in close proximity at its tip, allowing for insertion 
into membranes.  
Receptor interactions. Flaviviruses have been proposed to interact with a number 
of prospective cellular receptors, but there is little evidence that supports direct protein-
protein binding or requirement for infection. αVβ3-integrin has been identified as a 
putative WNV and JEV receptor since antibodies raised against it are able to effectively 
inhibit infection in cell culture75. However, cell types lacking detectable expression of 
this integrin are still infectible76–78. Another tentative JEV receptor, heat shock protein 70 
(Hsp70), was proposed based on inhibition of infection by anti-Hsp70 polyclonal 
antibodies but has only been evaluated for a single neuronal cell line (Neuro2a)79. 
Furthermore, lectins DC-SIGN and DC-SIGNR are considered attachment factors for 
DV80 and WNV77. This attachment is mediated by N-linked glycans on the E protein and 
has been confirmed by the cryoEM structure of DV bound to the carbohydrate 
recognition domain of DC-SIGNR81. Despite the identification and characterization of 
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these many candidates, none are required for infection, leaving the nature of a “true” 
flavivirus receptor elusive.  
Stem and transmembrane regions. The E ectodomain possesses a ~50aa C-
terminal hydrophobic “stem” and transmembrane domain that contribute to membrane 
fusion82,83. The stem region lies flat along the viral membrane and is composed of two 
amphipathic helices. It is truncated from soluble E constructs so it is not present in 
available crystal structures84. However, modeling studies have suggested that it forms a 
“zipper” with a groove along the outer edge of domain II and to stabilize the post-fusion 
trimer85. Mutational analysis of the stem region has since confirmed that hydrophobic 
residues of the stem indeed interact with DII and affect trimer stability as well as fusion 
efficiency83. Flavivirus E is anchored to the viral membrane by a two-pass trasmembrane 
helix that is unique amongst viral fusion proteins. The two helices of this transmembrane 
hairpin have been demonstrated to interact with each other, promoting maximum 
trimerization and fusion efficiency82.  
 
1.7 Virion structure 
Immature virion structure. There is currently no available JEV cryoEM structure. 
However, a series of elegant cryoEM studies have delineated the structures of both 
immature and mature structures of related viruses WNV and DV52,60,86,86–88. The cryoEM 
structure of immature DV particles at the neutral pH of the ER revealed a spiky 
decoration of irregular prM-E trimers on its surface. 180 copies of E and prM form these 
~600Å diameter particles, which lack the T=3 quasi-symmetry expected of an icosahedral 
virion86,87 (Fig 4A). An additional DV cryoEM structure has illuminated the structural 
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changes subviral particles undergo when they encounter the acidic (~6) pH of the golgi 
prior to maturation60. Pre-incubation of virus at pH 6.0 reduced DV particle diameter to 
~530Å and arrangement of prM-E complexes shifted from trimeric spikes to flat 
dimers.60 These dimers resembled those found in crystal structures22,48,53,74 and mature 
virions52,61 (Fig 4B). This reversible conformational change exposes regions of prM that 
allow for efficient furin cleavage prior to viral budding out of the cell60. 
Structure of mature virions  After particles are trafficked out of the cell and prM 
is released, they undergo yet another conformational change. CryoEM structures of WNV 
and DV identified a herringbone-like assembly of E dimers52,61. Mature particles are 
~500Å in diameter (Fig 4C), smaller than either immature form. These virions are 
geometrically unusual in that they display icosahedral symmetry but lack traditional T=3 
symmetry52. The monomeric subunits that comprise the 90 E protein homodimers 
observed in cryoEM models are identical at 2, 3 and 5-fold axes of symmetry and thus do 
not have quasiequivalent environments (Fig 4C)89. The E proteins that lie at these axes 
do, however, differ in chemical and stoichiometric environments and can differentially 
interact with antibodies and receptors90,91. For instance, therapeutic monoclonal antibody 
(mAb) E16 neutralizes West Nile Virus by binding the putative receptor-binding DIII92 at 
only the 2-and 3-fold axes but not at the 5-fold axis91. However, E16 neutralizes at a post-
attachment stage of infection and allows for internalization of viral particles93,94, 
suggesting that binding of a surface receptor could occur specifically at the 5-fold axis. 
While the reconstructed models of mature flaviviruses display uniform surfaces, it has 
been reported that a large population of infectious, partially mature “hybrid” particles are 
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released from cells95,96. Determination of the structure and geometry of these partially 
mature species presents a challenging problem due to their heterogeneous composition.  
 
1.8 Antibody neutralization 
Antibody neutralization models. Two models have been proposed to explain 
antibody-mediated neutralization of viruses. The maximum coating model suggests that 
neutralization is dependent only upon the number of antibodies binding to any site on a 
virus, with neutralization occurring when a critical number of sites become occupied97,98. 
This would imply that antibodies with the highest affinity for antigens would neutralize 
most potently. Alternatively, the functional inhibition model states that effective 
neutralization occurs through specific antibody-antigen interaction98. In this case, epitope 
specificity is of utmost importance: antibodies binding to locations on the virion that 
prevent distinct stages of the viral life cycle such as receptor interaction or membrane 
fusion will be more effective than high affinity antibodies binding to irrelevant regions. 
There is evidence to support both theories, and it is possible that antibody neutralization 
is virus-specific and can be a consequence of both mechanisms97,98. 
 Serocomplex classification. Flavivirus infection elicits broadly cross-reactive 
antibodies, but polyclonal sera from infection with one virus only neutralize a subset of 
other viruses. The serocomplex system of classification for flaviviruses is based on this 
observation: membership in each serocomplex is defined by an ability to be cross-
neutralized by polysera from heterologous infections99. Pathogenesis, tropism and clinical 
symptoms are generally conserved within serocomplexes. JEV is the prototypical 
member of the Japanese Encephalitis Virus serocomplex which includes SLEV and 
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WNV, viruses that all cause febrile illness, flu-like symptoms, acute or encephalitis5,99. 
DV, TBEV and YFV also represent three additional serocomplexes, each with distinct 
pathogeneses and tropisms.   
Neutralization of flaviviruses. The humoral immune response plays a vital role in 
the control of flavivirus infection100–102. Understanding the precise molecular 
determinants of neutralization will provide new targets for therapeutic antibody and 
vaccine development such as proteins, domains or peptides. The majority of antibodies 
generated during infection with JEV or other flaviviruses recognize the E protein and 
neutralization is epitope-specific91,93,103–105. Identification of antibodies that bind 
neutralizing and non-neutralizing epitopes on E as well as mechanisms associated with 
recognition of these sites has allowed for the determination of structure-function 
relationships of domains, regions or individual residues. The most widely accepted 
neutralizing epitopes are the fusion loop of DII and the lateral ridge of DIII. However, 
antibody binding at the DI-DII hinge, DI-DIII linker, DI lateral ridge, DII lateral ridge, 
DII dimer interface and DII central interface have been associated with neutralization of 
JEV, DV and WNV 103,105–107 (Fig 5). The most potent neutralizing antibodies typically 
bind DIII and have been associated with blocking attachment and membrane fusion. 
Indirect evidence has implicated DIII in receptor interaction: an anti-DIII antibody, 3H5, 
prevents flavivirus binding to Vero cells108,109. However, WNV therapeutic antibody E16 
allows for internalization of the virion but neutralizes by subsequently preventing fusion 
with the endosome91,93,94. Another class of broadly cross-reactive antibodies recognizes 
the conserved fusion loop epitope. These antibodies also prevent fusion and are generally 
less potent anti-DIII mAbs, potentially because the fusion loop is believed to be 
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inaccessible in mature virions. This so-called cryptic epitope may transiently become 
exposed as a result of E protein motions on the surface of the virion. Indeed, a cryoEM 
structure of an antibody bound to the fusion loop of mature WNV has been solved and 
captured a distorted viral particle, implying that these antibodies are able to access this 
obscured site in some capacity110. 
Antibody dependent enhancement of infection. An important concern in the 
design of therapeutic vaccines or antibodies for control of flaviviruses is the phenomenon 
of antibody dependent enhancement of infection (ADE). A neutralizing mAb will 
effectively prevent infection only upon occupying a critical number of sites on the virion. 
Sub-neutralizing concentrations of these antibodies111,112 or coating by non-neutralizing 
antibodies113 can promote uptake into cells by host Fc-receptors, leading to ADE. While 
JEV, TBEV, YFV and WNV are all susceptible to this phenomenon 114–117 it is most 
pronounced when DV infection of one serotype is followed by heterologous infection 
with a different DV serotype. The more severe symptoms associated with this second 
infection (such as a greater risk for hemorrhagic fever) are believed to be linked to ADE 
resulting from the circulation of antibodies generated against the previous serotype. It is 
postulated that these antibodies would be of lower affinity for the new virus and thus be 
present at sub-neutralizing concentrations capable of enhancing infection. The more 
severe clinical manifestations of DV linked to ADE along with the co-circulation of DV 
and JEV in Asia warrant serious consideration in future vaccine development.   
1.9 Summary 
 JEV E is responsible for receptor interaction and membrane fusion, and antibody-
mediated neutralization of the virus is dependent upon successful inhibition of these 
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functions. Given the presumed relationship between tropism and receptor interaction, I 
sought to investigate whether structural features of the JEV E protein could contribute to 
serocomplex-specific pathogenesis. No structure of a JEV serocomplex E protein has 
been determined in the dimeric or post-fusion trimeric conformation. Therefore, I solved 
the structure of the dimeric JEV E ectodomain. The results have revealed flavivirus 
evolutionary mechanisms for differential recognition of host ligands and highlight 
important differences in dimeric structures from several serocomplexes.   
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Figure 1: Flavivirus polyprotein processing and protein functions. Family 
Flaviviridae contains three genera with different structural proteins. A) Hepaciviruses 
have a core and two envelope proteins E1 and E2. B) Pestiviruses have capsid, Erms, E1 
and E2 proteins. C) Flaviviruses have a capsid, prM and E protein as well as 7 non-
structural proteins. D) Summarized functional roles and localizations of the 10 flavivirus 
proteins.  
5’ 
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Figure 2 Viral fusion protein structures. 
 18	  
Figure 2 legend: Viral fusion protein structures. Structures of the pre-fusion (A) and 
post-fusion (B) conformations of class I Influenza HA2. The helical domain that 
elongates to expose the fusion peptide is colored yellow, fusion peptide green and N-
terminal domains in red and blue. Other HA2 trimer subunits are colored grey. C) 
Structures of the pre-fusion class II flavivirus E homodimer and alphavirus E1-E2 
heterodimer (C), and post fusion E/E1 trimers (D) DI is red, DII yellow and DIII blue. 
The opposing dimeric subunit of the E dimer and E2 of the E1-E2 heterodimer are 
colored grey, and the alphavirus E3 protein cyan. The post-fusion trimers (D) of E/E1 
have a single subunit with colored domains and remaining subunits in grey. The exposed 
fusion loop at the tip of the spike is green. Structures of the pre-fusion (E) and post-
fusion (F) class III VSV G protein. The DI lateral domain is red, DII trimerization 
domain blue, DIII PH domain orange, DIV fusion domain yellow, DV magenta and 
fusion peptide green. Only 1 of 3 trimeric subunits is colored in each panel.  
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Figure 3. Conformational changes of the Flavivirus E protein. A) E protein in the 
immature conformation with fusion-loop (green) capped by prM (grey, space-filled). 
Domains I, II & III are colored red, yellow and blue respectively. The arrow and 
accompanying angle describe the movement of DII about the DI-DII hinge as E adopts 
the mature conformation. B) Mature E homodimer, with one protein colored as described 
in A) and the other in grey. The fusion loop is now capped by the DI/DIII cavity of the 
opposing subunit. The arrow in B) describes the movement of DIII about the DI-DIII 
hinge that accompanies formation of the post-fusion trimer. C) The fusion loop is 
exposed at the tip of the trimeric post-fusion spike. One subunit is colored while the other 
two are grey.  
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Figure 4: Flavivirus virion structures. The top panels display cryoEM densities of 
particles described, central panels are cartoons describing the conformation of E and 
bottom panels are atomic models generated by fitting E and prM into the cryoEM 
densities. A) Immature flavivirus particles assemble in the ER and are comprised of an 
icosahedral arrangement of E trimeric spikes with fusion loops capped by prM. B) As 
particles pass through the trans-golgi network prM is cleaved by furin and the lower pH 
causes them to settle into a dimeric arrangement. C) As the virus matures, the higher pH 
encountered upon secretion promotes the release of prM. In all reconstructions, axes of 
symmetry are labeled. Adapted from refs 22, 60 & 88.  
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Figure 5: Neutralizing epitopes identified on the flavivirus E protein. Epitopes bound 
by antibodies neutralizing JEV, WNV or DV are highlighted in green and displayed on 
the surface of a JEV E protein. DI, DII and DIII are colored faded red, yellow and blue 
respectively.  
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2.1 Abstract 
Japanese Encephalitis Virus (JEV) is the leading global cause of viral 
encephalitis. The JEV envelope protein (E) facilitates cellular attachment and membrane 
fusion and is the primary target of neutralizing antibodies. Herein, we have determined 
the 2.1Å resolution crystal structure of the JEV E ectodomain refolded from bacterial 
inclusion bodies. The E protein possesses the three domains characteristic of flavivirus 
envelopes and epitope mapping of neutralizing antibodies onto the structure reveals 
determinants that correspond to the domain I lateral ridge, fusion loop, domain III lateral 
ridge and domain I-II hinge. While monomeric in solution, JEV E assembles as an 
antiparallel dimer in the crystal lattice organized in a highly similar fashion as seen in 
cryoEM models of mature flavivirus virions. The dimer interface, however, is remarkably 
small and lacks many of the domain II contacts observed in other flavivirus E 
homodimers. Additionally, uniquely conserved histidines within the JEV serocomplex 
suggest that pH mediated structural transitions may be aided by lateral interactions 
outside the dimer interface in the icosahedral virion. Our results suggest that variation of 
dimer structure and stability may significantly influence the assembly, receptor 
interaction and uncoating of virions.  
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2.3 Introduction 
Japanese Encephalitis Virus (JEV) is the leading cause of viral encephalitis 
worldwide, responsible for 30,000-50,000 cases and 10,000 deaths annually in eastern 
Asia. The virus is arthropod borne and naturally cycles between mosquitoes and pigs or 
wild birds but may also be transmitted to humans and horses1. There are multiple 
vaccines for JEV but they are not universally available in Asia due to cost, licensing 
issues and safety concerns2–5. JEV is a member of the Flavivirus genus along with several 
other viruses including West Nile Virus (WNV), Tick Borne Encephalitis Virus (TBEV) 
and Dengue Virus (DV). 
 Flaviviruses are positive-stranded RNA viruses with a 9-12kb genome that is 
translated as a single polyprotein that is cleaved by host and viral proteases into structural 
proteins capsid (C), pre-membrane (prM) and envelope (E) and 7 non-structural proteins. 
Capsid binds to viral RNA and forms a nucleocapsid that is enveloped by an ER derived 
membrane containing E and prM. E proteins are responsible for cellular attachment and 
possess a hydrophobic loop that mediates fusion of viral and host membranes6–11.  
 During its life cycle, the JEV virion undergoes a maturation process that 
continuously shields the fusion peptide from premature insertion into the host cell 
membrane. In an immature virion, E forms irregular trimers with fusion loops capped by 
prM until it is cleaved in the trans Golgi prior to viral secretion12–14. E then rearranges 
into an icosahedral network of flat antiparallel homodimers that bury the loop at their 
interface15,16. Mature virions attach to cells and are taken up into the endosome where the 
acidic environment triggers an irreversible change from dimer to trimeric spikes17–20. This 
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process exposes the fusion loops that penetrate the endosome and drags together host and 
viral membranes, thereby releasing the nucleocapsid into the cell.  
The majority of flavivirus neutralizing antibodies bind E and can inhibit several 
stages of the entry process including attachment and fusion21–26. Infection with a 
flavivirus results in the generation of broadly cross-reactive antibodies, but the polysera 
from a given infection will only neutralize a subset of other viruses. This phenomenon is 
the basis for the serocomplex system of classification in which flaviviruses are placed 
into groups defined by cross-neutralization tests with polysera from heterologous 
infections27. Clinical manifestations of infection are retained within a given serocomplex 
and range from febrile illness to hemorrhagic fever. The Japanese Encephalitis Virus 
serocomplex includes St. Louis Encephalitis Virus (SLEV), WNV and prototypical 
member JEV, all of which are known to cause flu-like symptoms, acute or fatal 
encephalitis27,28. The remaining serocomplexes also exhibit specific tropisms and 
pathogeneses, the most notable of which are represented by Tick Borne Encephalitis 
Virus, Yellow Fever Virus, and Dengue Virus.   
Herein we have determined the crystal structure of the Japanese Encephalitis 
Virus E protein to investigate whether structural features could contribute to our 
understanding of serocomplex-specific pathogenesis. The E protein crystallized as the 
canonical head-to-tail flavivirus E protein dimer but with a notably small interface. The 
JEV E dimer has roughly half the buried surface area of any known flavivirus E structure 
and the majority of its contacts are between the fusion loop and Domain I-III pocket, not 
at the central dimerization region. We suggest that this smaller dimer interface may be 
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the preferred organization of E proteins from viruses in the JEV serocomplex and that it 
provides an effective atomic model for JEV E within mature virions.  
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2.4 Results 
Bacterial expression and refolding of Japanese Encephalitis Virus E protein. 
Recombinant Japanese Encephalitis Virus E protein spanning residues 1-406 of the 
ectodomain was produced in E. coli as inclusion bodies and refolded by methods 
previously described for WNV E29. Briefly, inclusion bodies were solubilized in 
guanidine-HCl and β-mercaptoethanol and refolded by dilution into a buffer containing a 
10:1 ratio of reduced to oxidized glutathione to allow for proper formation of disulfide 
bonds. Soluble E was then purified by size exclusion chromatography and anion 
exchange chromatography. Envelope proteins from JEV, WNV and SLEV were purified 
by this method, proving its effectiveness as a low-cost alternative for production of 
recombinant flavivirus E proteins. 
Structure of Japanese Encephalitis Virus E protein. Crystals of the JEV 
ectodomain diffracted to 2.1Å and the structure was solved with an Rwork of 22% and an 
Rfree of 18% (data collection and refinement statistics in Table 1). Although it was 
refolded from bacterial inclusion bodies, JEV E retained the three-domain organization 
and all five disulfide bonds previously observed in other flavivirus E proteins (Fig 1)16,30–
34. The central domain I is composed of a 9-stranded β-barrel located between the 
extended domain II and the globular domain III. Domain II is formed out of two extended 
loops that protrude from DI, the larger of which is stabilized by three disulfide bonds and 
contains the conserved fusion peptide at its tip. Domain III possesses an Ig-like fold and 
is found at the C-terminus of the ectodomain, connected to DI by a short peptide linker. 
The crystals only contained one molecule in the asymmetric unit, but application of the 
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orthorhombic symmetry operators allowed for the generation of the archetypal flavivirus 
envelope dimer.  
 N-linked glycosylation site. The location and presentation of the glycan linked to 
N154 has been linked to particle infectivity and interaction with putative cellular receptors 
DC-SIGN or DC-SIGNR8,35,36. Recombinant JEV E ectodomain was purified from 
bacterial inclusion bodies by oxidative refolding and therefore lacks this modification. In 
order to evaluate whether the Eo-F0 loop region of JEV E is affected by glycosylation at 
N154, it was was superimposed onto the glycosylated loop of the closely related West Nile 
Virus E structure. The main chain traces in this region overlay residues 144-164 with an 
overall RMSD of only 0.45, suggesting that glycosylation does not significantly affect the 
presentation of this region.  
 The Dimer Interface. The most unusual feature of the JEV E structure is its 
curiously small dimer interface. On the surface of the mature virion, flavivirus E proteins 
exist as an antiparallel dimer with the fusion peptide of DII nestled into a cavity formed 
by DI and DIII on the opposing subunit15. In the DV and TBEV E structures, there are 
extensive contacts across the DII-DII that stabilize this assembly. Several properties of 
the dimer from JEV, DV2, DV3 and TBEV envelope proteins were analyzed using the 
Protein Interfaces, Surfaces and Assemblies (PISA) server (Table 2)37. While the 
secondary and tertiary structure of JEV E is similar to those of other E proteins, it has 
only 44-56% of the buried surface area observed in other flavivirus E dimers (Fig 2). 
Additionally, it is not stabilized by any salt bridges and has far fewer hydrogen bonds 
across the assembly. The JEV E dimer has 843Å2 of total buried surface area, while the 
lowest of any other structure is TBEV E with 1496Å2. Further analysis revealed that the 
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largest disparity lies at the DII-DII interface. At this site JEV E only has 150Å2 buried 
surface area, compared to 534Å2 or greater for all of the other E proteins. The DI-DIII 
pocket that houses the fusion loop has relatively less buried surface area as well, but the 
difference at this surface is at most 0.4-fold, as compared to greater than 3-fold for the 
DII-DII interface. These values reinforce the conclusion that DII-DII contacts are 
deficient in the JEV dimer. The Sc across domain II of JEV E was only 0.372, a value 
below what is believed to signify a relevant protein-protein interaction. The other E 
proteins were found to have an Sc greater than 0.6, in line with other biologically 
significant interfaces. Interestingly, in all E structures the Sc of the fusion loop pocket 
was greater than the DII-DII region, suggesting that the precise fit of this peptide is of 
functional importance.  
 Domain I-II hinge angle. The angle between DI and DII varies substantially 
throughout the viral life cycle. The relative change in hinge angle between JEV E and 
that all other available pre-fusion E protein structures was calculated using Dyndom by 
individually superimposing JEV DI and DII onto those of WNV, DV2, DV3 and TBEV E 
proteins (Fig 3)38.  The most closely related E protein, that of WNV (~75% identity), 
exhibited the largest difference at 16.0º, but this structure is monomeric and likely 
represents a pre-fusion conformation or intermediate that occurs during the trimer 
transition. Of the remaining E proteins, the JEV hinge most closely resembled that of 
TBEV, with a difference of only 3.4º.  This was surprising since the two viruses are only 
38% identical and that JEV E has only about 50% of the buried surface area relative to 
TBEV E. The differences in hinge for DV2 and DV3 E were found to be 8.7º and 9.6º 
respectively. While E molecules require flexibility to drive structural changes essential 
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for infection, it appears they also adjust to accommodate species-specific dimer 
arrangements.  
 Structural Contributions to the Interface. Several loops of the JEV E dimer 
subunits are devoid of contacts present in those of DV2, DV3 and TBEV (Fig 4). Three 
of these segments are specific to DV2 and DV3 E proteins. The first links strands Bo and 
Co of DI and the second is the ‘k-l’ loop of DII (Fig 4A).  In the DV2 and DV3 E 
structures, these peptides stretch across the assembly to pack against the ‘i-j’ loop from 
DII of the opposing subunit (Fig 4A). No residue in any of these regions contributes a 
dimer contact in JEV E and its ‘k-l’ loop actually angles up and away from the interface, 
in stark contrast to the conformation in DV2 E (Fig 4C). TBEV E, on the other hand, 
lacks the contacts found in the DV E proteins but possesses a 6-amino acid insertion 
between the f and g strands of DII (Fig 4B). Five of these six residues were identified as 
contacts in the TBEV E dimer. This insertion lies atop the ‘b’ and ‘j’ strands of the 
antiparallel proteins, so while TBEV has a similar hinge angle to that of JEV it buries 
additional surface area via this insertion.  Sequence alignments of these regions of E 
proteins with known structures highlight their respective dimer contacts (Fig 4D).  
 JEV E Protein Stoichiometry. To assess the oligomeric state of the JEV E protein 
we utilized multi-angle light scattering. This technique directly determines absolute 
molecular weight from intrinsic scattering properties of proteins so it is advantageous 
over methods such as dynamic light scattering or SEC that extrapolate from 
hydrodynamic radius alone. Purified JEV E was loaded onto a SEC column at a 
concentration of 20µM and refractive index change and MALS were observed over the 
elution profile. JEV E eluted as a single peak with an experimentally determined 
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molecular weight of 45.3kD (Fig 5A). JEV E has a predicted molecular weight of 
43.6kD, so while the soluble JEV E ectodomain packed as a crystallographic dimer, our 
observations demonstrate that it is predominantly monomeric in solution. The molecular 
weight of E proteins from WNV and SLEV were also determined in the same fashion. 
WNV E yielded a weight of 44.3kD (predicted 43.4kD) and SLEV yielded a weight of 
39.6kD (predicted 44.2kD), both of which correspond to that of a monomer (Fig 5B-C). 
It has been previously reported that DV2, DV3 and TBEV were solution dimers, so we 
evaluated the oligomeric state of DV2 E to validate our assay (Fig 5D)16,31,32,34. Insect 
cell expressed DV2 E was utilized in these experiments as we have not been able to 
successfully refold DV E proteins from bacterial inclusion bodies. However, previous 
studies have indicated that insect cell expressed WNV E is monomeric in solution, 
suggesting that the single N-linked glycan does not play a significant role in the 
oligomeric state of the soluble ectodomain33. DV2 E indeed had a molecular weight of 
90.3kD (predicted 45.4kD) corresponding to that of a dimer. Thus, E ectodomains from 
the Japanese Encephalitis Virus antigenic complex (JEV, SLEV, WNV) were all found to 
have monomeric molecular weights (Fig 5A-C), while the DV2 E protein exists 
predominantly as a dimer in solution (Fig 5D). The propensity of JEV E to remain as a 
solution monomer is consistent with the smaller dimer interface we observe relative to 
DV2 E.  
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 Superimposition onto the Dengue Cryo-EM model. Determination of the 
cryoEM structures of DV and WNV revealed a framework of E protein dimers within the 
context of virion icosahedral symmetry15,39. In order to determine whether the 
conformation of JEV E found in our structure could, effectively reconstruct a mature 
icosahedral virion, we superimposed E subunits onto the main chain coordinates of DV2 
E dimers from the cryoEM model. The JEV E crystal structure fits adequately into the 
arrangement with the only clash between main chains occurring in the b-c and h-i loops 
at the lateral edge of domain II at the two-fold axis (Fig 6A). This was unexpected given 
that fitting of other structures required the disassembly of E into domains and rigid body 
refinement34. Further analysis of the JEV model revealed the buried surface area between 
predicted dimers of the virion to be 469Å2, yielding a difference of 364Å2 when 
compared to the crystallographic dimer (Fig 6C). The buried dimer surface areas of other 
unliganded E proteins assembled into the virion were 404Å2 for DV2 (pdb 1TG8), 424Å2 
for DV3 (pdb 1UZG) and 975Å2 for TBEV (pdb 1SVB) (Fig 6C). Additionally, aligning 
entire dimers from the crystal structures onto the corresponding cryoEM dimers yielded 
RMSDs of 2.16 for JEV E, 2.43 for TBEV E, 3.35 for DV2E and 2.83 for DV3 E (Fig 
6B). In conjunction with the BSA calculations, this RMSD suggests the JEV E structure 
provides an effective model for its assembly in the mature virion.  
 Localization of histidines. It has been suggested that protonation of histidines at 
acidic pH plays an important role in the flavivirus life cycle, especially during the 
structural transition that leads to membrane fusion. Proposed functions of these residues 
include homodimer dissociation, conformational changes of DIII and trimerization40. 
Mutation of broadly conserved H323 of TBEV E was shown to decrease infectivity but 
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substitution of each of the individual histidines of WNV E did not have an effect, 
suggesting that for some viruses they may act in concert40,41. In JEV E, most are found at 
the dimer interface, DI-III hinge and DI-II hinges, locations relevant to their proposed 
roles.  Others, however, are situated along the lateral ridge on DII and DIII. Four 
histidines: His144, His246, His284 and His319, are entirely conserved in flaviviruses and 
found at the dimer interface and inter-domain hinges. Three others: His81, His395 and 
His397 are poorly represented in most flaviviruses but conserved within the JEV 
serocomplex and positioned at surfaces distal to the dimer interface (Fig 7). Protonation 
of the three serocomplex-specific histidines at this lateral edge would likely have an 
effect on the quaternary arrangement of adjacent subunits based on the modeling of JEV 
E into the DV cryo-EM reconstruction. The conservation at these positions may provide 
additional energy to stabilize JEV E within the icosahedral framework at neutral pH, 
possibly compensating for lost contributions at the dimer interface. At acidic pH, the 
protonation of these His residues outside the dimer interface may be an important 
mechanism for the regulation of viral uncoating. 
 Neutralizing epitopes. Mapping of antibodies onto the three-dimensional 
structures of the West Nile Virus and Dengue Virus E proteins has revealed the 
localization of dominant neutralizing epitopes24. Antibodies that neutralize flaviviruses 
localize to specific regions of the protein that span all three E protein domains, with the 
observation that many of the most potently neutralizing mAbs recognize the lateral ridge 
and ‘A’ strand of DIII22,24,42–45. Several studies have identified individual residues 
essential to recognition of JEV by neutralizing antibodies A3, B2, E3, NARMA3, 503, 
4G2 and E3.326,46–50. We have compiled and highlighted these residues on the crystal 
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structure and mature virion model of JEV E. These fall into four distinct regions: the DI-
DII hinge, DI lateral ridge and DIII lateral ridge, which are exposed in the cryoEM 
structure, and the buried fusion loop (Fig 8A)23,24. Antibodies B2 (I126), NARMA3 (Q52) 
and 503 (Q52, I126, K136, S275) all bind exposed residues in the DI-DII hinge region (Fig 
8C). Antibody A3 (K179) maps to the DI lateral ridge (Fig 8D) and antibodies E3 (G302) 
and E3.3 (I337, F360, R387) recognize the DIII lateral ridge (Fig 8E). Broadly cross-reactive 
antibody 4G2 has been shown to weakly neutralize JEV and interacts with residues 104, 
106 and 107 at the tip of the fusion loop (Fig 8B). The DI-DII hinge, DI and DIII lateral 
ridge epitopes are all largely exposed on the JEV mature virion, the exception being 
epitopes located where DIII packs at the at the inner 5-fold axis. It has been previously 
reported that antibodies binding WNV E at a similar epitope are also inaccessible51. The 
fusion loop epitope is commonly recognized by broadly cross-reactive antibodies and is 
partially buried in the JEV E model virion. This epitope is likely only transiently exposed 
due to motions of E proteins in the virion or in particles that contain E in the immature 
conformation.  
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2.5 Discussion 
 The structure of the JEV E ectodomain was determined to identify unique 
characteristics of this important pathogen. A notable feature of our high-resolution 
structure is the unusual dimeric interface of the E subunits. Measurements of homodimer 
buried surface area, shape complementarity, hydrogen bonds and salt bridges each 
indicate a less substantial interface relative to those of TBEV, DV2 and DV3. We 
determined the oligomeric state of JEV, SLEV and WNV E proteins and found that all 
were solution monomers consistent with our JEV structure as well as two independent 
crystal structures of monomeric WNV E30,33. Our results suggest that flavivirus evolution 
has modulated the E homodimer interface and dimeric affinity, which may substantially 
affect recognition by antibodies and cellular receptors. 
 Cryo-EM structures of mature WNV and DV have revealed a tightly packed 
“herringbone” arrangement of E proteins in which the dimer interface as well as lateral 
ridges of all three domains support a stable icosahedral framework15,39. E protein 
homodimerization has been thought to be a primary building block of the mature 
flavivirus virion, so it was surprising to find that JEV E and related serocomplex proteins 
were solution monomers. An explanation for the disparate dimer properties of the JEV 
envelope could be that it relies upon quaternary contacts among dimers rather than the 
dimer interface per se as principal load-bearing points in the viral chassis. Consistent with 
this hypothesis is the location of the JEV serocomplex’s uniquely conserved histidines at 
the outer edges of the E protein where quaternary contacts would be made with other E 
dimer rafts. While mutation of individual histidine residues does not have a significant 
effect on West Nile Virus infectivity, it has been proposed that protonation of multiple 
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histidines in concert may drive E homodimer dissociation as an essential step in the series 
of conformational changes that lead to membrane fusion40,41. Strikingly, three of nine 
histidines conserved in the JEV serocomplex (Fig 7) are found on the lateral edge of E 
rather than at hinge regions or the dimer interface, suggesting that these viruses may 
utilize pH to regulate structural transitions by breaking non-dimer interfaces.  
 Analysis of contact residues across E proteins revealed specific structural 
differences between the JEV homodimer and that of DV or TBEV. Two DII loops, ‘k-l’ 
of DV2/3 and ‘f-g’ of TBEV, make contributions to the interface that are entirely absent 
in JEV E. The ‘k-l’ loop angles forward in one structure of DV2 E (1OKE) and creates a 
pocket that the hydrophobic ligand n-octyl-β-D-glucoside was observed to bind 
crystallographically31. In the JEV E structure, this loop is splayed away from the interface 
but opens a channel ~15Å in diameter where these contacts would be made in DV2 E 
(Fig 2). These channels are large enough to accommodate the insertion of a host ligand, 
raising the possibility that their presence or absence could influence viral tropism by 
modulating receptor interaction. Alternatively, the major contributor of E dimer contacts 
present in TBEV but not JEV is the ‘f-g’ loop of DII. In TBEV, ‘f-g’ contains a 6-amino 
acid insertion that positions itself atop ‘b’ and ‘j’ strands from the opposing DII and 
appears to latch the subunits together. Other TBEV E serocomplex members Powassan 
Virus and Langat Virus also share this insertion. Notably, a histidine residue H208 is 
conserved at the apex of the loop so protonation at low pH could provide energy to repel 
the molecules apart. 
 While our comparison of E proteins has highlighted differences between the 
crystal structures, serological data suggests that E may adopt a continuum of distinct 
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conformations on the surface of the virion. Structural proteins from flaviviruses, 
picornaviruses, nodaviruses and rhinoviruses are all believed to exhibit flexibility within 
their icosahedral organization43,52–55. Evidence that has arisen from the study of both DIII 
and fusion loop-specific neutralizing antibodies strongly suggests that the cage of 
flavivirus E proteins ratchet through conformations specific to the virus that encodes 
them. It has been reported that high temperature pre-incubation of Dengue Virus with an 
anti-DIII Fab resulted in an unusual, distorted cryo-EM structure in which E was locked 
into a previously unobserved icosahedral assembly55. The antibody recognizes an epitope 
of DIII that is partially masked in mature virions, yet the Fab managed to bind the virion 
and capture this unusual conformation. The West Nile specific antibody E16, on the other 
hand, binds a similar epitope and does not cause any significant changes in the mature 
arrangement upon binding22. The range of motion of E proteins within a mature virion 
could thus be influenced by the packing of the dimer. Another class of antibodies bind the 
fusion loop epitope that is buried in the cryo-EM model of the mature virus particle, 
implying that it must be at least transiently exposed during its life-cycle24,46. 
Unexpectedly, many of these fusion loop antibodies are broadly cross-reactive but do not 
cross-neutralize. JEV and TBEV in particular were found to have a poor correlation 
between the antibody affinity for their recombinant E proteins and neutralization titer, 
strongly suggesting that exposure of this conserved epitope differs from one viral species 
to the next56. One fusion-loop antibody, E53, has even been reported to preferentially 
recognize the E protein spikes that occur in immature virions29. Indeed, partially mature 
virions would be predicted to have the propensity for unique assembly based on the 
number and location of uncleaved prM29,57,58. The resulting permuted distortions of the E 
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protein network likely results in arrangements not represented by the icosahedral 
geometry of reported cryo-EM models. 
 It is becoming increasingly clear that the distinct arrangement of flavivirus E 
protein subunits can affect antibody recognition and neutralization. Recent evidence has 
described a neutralizing Fab with a paratope that cross-links two independent E proteins 
on the surface of the virion.59. While this antibody bound icosahedral axes outside of the 
dimer interface, its discovery supports the notion that specific organization of JEV, DV 
and TBEV E proteins can influence molecular recognition events of the virion. 
Additional factors that may influence E presentation on the particle surface are the 
transmembrane and stem-loop regions not present in the crystal structures60. However, 
their influence does not oppose the hypothesis that quaternary organization or flexibility 
could be distinct for individual flaviviruses.  
 In conclusion, the structure of the JEV E ectodomain has revealed a uniquely 
small dimer interface that may play a role in flavivirus stabilization, immunorecogntion 
and pathogenesis. Features of the protein including its monomeric solution state, 
relatively low buried surface area and location of serocomplex-conserved histidines 
suggest that it is representative of its native state in the virion. Superimposition of JEV E 
onto the DV cryoEM structure of the mature virion results in only a single clash and did 
not require the separation of domains to effectively reconstruct a JEV particle. This 
model also highlights the residues recognized by several classes of neutralizing antibody, 
indicating both surface exposed and buried epitopes. As both clearance and enhancement 
of flavivirus infections strongly depend on antibody recognition of complex E protein 
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epitopes, continued evaluation of intricate structural features of these proteins is essential 
to the design of future therapeutics and vaccines.  
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2.6 Materials and Methods 
Cloning, Expression and Purification of soluble JEV E, SLEV E and WNV E. 
A cDNA encoding ectodomain residues 1-406 of the JEV E from the SA-14-14-2 strain 
protein and those of WNV and SLEV E were cloned into the bacterial expression vector 
Pet21a (+). This vector was transformed into BL21-DE3 (RIL) cells (Stratagene), grown 
in a large-scale 4L culture and induced at an optical density 400nm of 0.8 with 1mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG). After 4 hours the cells were centrifuged 
and pellets were suspended in 50mL solution buffer (50mM Tris pH 8.0, 25% sucrose, 
10mM DTT) and then an equal amount of lysis buffer (50mM Tris pH 8.0, 1% TritonX-
100, 100mM NaCl, 10mM DTT) was added. The mixture was treated with 0.8mg/mL 
lysozyme and sonicated three times for 15 seconds to disrupt cell membranes.  Next, the 
lysate was centrifuged at 10,000xg and the pellet containing the protein inclusion bodies 
was washed 3x with 50mL wash buffer (50mM Tris pH 8.0, 0.5% TritonX-100, 100mM 
NaCl, 1mM DTT) and then once in wash buffer without TritonX-100. Purified inclusion 
body pellets were resuspended in 20mL TE buffer (10mM Tris pH 8.0, 1mM EDTA) and 
2mL aliquots of this slurry were each solubilized in 10mL of 6M guanidine-HCl, 10mM 
Tris pH 8.0 and 20mM β-mercaptoethanol. These aliquots were rapidly diluted by adding 
1mL every 30 minutes drop-wise into a rapidly stirring 1L reservoir of oxidative 
refolding buffer (400mM non-detergent sulfobetaine-201 (NDSB-201), 100mM Tris pH 
8.0, 0.5mM oxidized glutathione and 5mM reduced glutathione) for overnight refolding. 
The refolded protein was concentrated to a volume of 10mL using an Amicon 400 
concentrator with 30kD cutoff membrane and purified on a S200 size exclusion 
chromatography (SEC) column. It was isolated from eluted fractions corresponding to a 
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predicted molecular weight of 20kD, suggesting it interacts with the sephadex beads of 
the column since the purified protein was full-length. This material was further purified 
on a MonoQ anion exchange column. 
Expression and Purification of DV2 E. Residues 1-394 of Dengue Virus 2 E 
ectodomain with an N-terminal honeybee melittin signal sequence were cloned into the 
baculovirus transfer vector pAcUW51. The DV2 E encoding transfer vector was then co-
transfected into SF9 cells grown in serum free Sf-900 II media (Invitrogen) with the 
Flashbac Gold bacmid (Oxford Expression Technologies) to allow homologous 
recombination to generate recombinant baculoviruses. The virus was then amplified by 
passaging the supernatant at ratios of 1:10 into fresh SF9 cultures until titer was sufficient 
for large-scale expression. 5 liters of hi-five cells grown in Express Five (Invitrogen) 
serum free media were then infected with recombinant virus to drive expression of 
secreted DV2 E. The supernatant from the large-scale infection was then filtered with a 
0.2µm cutoff bottle-top filter, concentrated and buffer exchanged into nickel binding 
buffer (300mM sodium citrate, 150mM NaCl and 50mM NaPO4 pH 8.0) using a 
Cetramate tangential flow concentrator with 30kD cutoff membrane. This supernatant 
was then purified by nickel and size-exclusion chromatography.  
Crystallization of JEV E. Soluble JEV E protein was crystallized at 20°C by 
hanging drop vapor diffusion. Drops containing 0.5µL of protein at a concentration of 
10mg/mL were combined with 0.5µL of mother liquor containing 0.1M Tris pH 8.0, 16% 
polyethylene glycol (PEG) 3350 and 0.2M sodium citrate and diffraction-quality crystals 
grew in 3 days. The crystals were cryoprotected by transferring them briefly into a drop 
containing 10% PEG 3350, 25% glycerol, 0.2M sodium citrate, 0.1M Tris pH 8.0 and 
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then cooling them in liquid nitrogen. Data were collected at the Advanced Photon Source 
(APS) beamline 21-ID-F. The data set was processed, integrated, scaled and merged 
using HKL200061. JEV E crystallized in space group I222 with unit cell dimensions 
a=61.1 Å, b=62.4Å, c=243.0Å and contains one molecule per asymmetric unit.   
Structure Determination. The structure of JEV E was solved using molecular 
replacement.  The West Nile Virus E protein (pdb ID 2HG0/2I69) was used as a model in 
Phaser via the PHENIX graphical user interface62. Mutation of amino acid side chains 
and model building was done in Coot63. The model was refined to 2.1Å resolution in 
several steps using PHENIX refine. Initially rigid body refinement of each of the three 
domains was performed followed by atomic refinement and automated addition of 
waters. Coordinates were then uploaded to the TLSID server to obtain domain 
predictions for translation liberation screw (TLS) refinement64,65. The resultant structure 
has a final Rwork of 18.0% and an Rfree of 22.1% and a total of 214 waters. The N-terminal 
403 of 406 amino acids of the E protein construct were built into the model.  
Multi-Angle Light Scattering. JEV, WNV, SLEV and DV2 E proteins (200µg) 
were loaded in sizing buffer (150mM sodium chloride, 20mM HEPES pH 7.4, 0.01% 
sodium azide) onto a size exclusion chromatography column set up in series with a Dawn 
Helios II multi-angle light scattering detector (Wyatt), Optilab rEX (Wyatt) differential 
refractive index detector and photodiode array detector 996 (Waters). The light 
scattering, refractive index change and UV absorbance were each observed over the 
elution profile.  The data was then analyzed with the Astra V macromolecular 
characterization software package (Wyatt) to calculate the molecular weight of each 
protein from the light scattering and refractive index change.  
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2.6.6 Protein structure accession number.  
The coordinates for JEV E have been deposited in the RCSB Protein Data Bank 
(accession code 3P54). 
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Table 1: X-ray data collection and refinement statistics for JEV E protein 
ectodomain 
 
Data collection  
Space group I222 
Cell dimensions  a=61.11 Å, b=62.40 Å, c=243.04 Å 
Resolution (high res shell) 50.0-2.10 Å (2.18-2.10 Å) 
Completeness 99.24% (99.8%)a 
Redundancy 4.3 (4.4) 
I/σ 12.1 (2.0) 
R-merge (I) 0.07 (0.427) 
  
Refinement  
Resolution (high res shell) 30.2-2.10 Å (2.17–2.10 Å) 
R-work reflectionsb (F>0) 25663 (2470)a 
R-free reflections 1284 (136) 
R-work 0.1811 (0.2037) 
R-free 0.2242 (.2294) 
JEV E residues (atoms) 403 (3045) 
Solvent atoms 210 
Estimated coordinate error 0.230 
Wilson B-factor  27.62 Å2 
R.m.s.d. bond lengths 0.009 Å 
R.m.s.d. bond angles 1.098° 
  
a Values in parentheses are for data in the highest resolution shell  
b Statistics as defined in Phenix 
 
 
Table 2: Analysis of E protein dimer interfaces 
 
 
E 
BSA 
(Å2) 
BSA D13-
D2 (Å2) 
BSA DII-
DII (Å2) 
SC: 
total 
SC: 
D13-D2 
SC D2-
D2 
Interface 
residues 
H-
bonds 
Salt 
Bridges 
JEV 
(3P54) 
843.1 346.8 149.4 0.786 0.799 0.372 38 2 0 
DV2-
βOG 
(1OKE) 
1929.2 577.5 825.2 0.719 0.766 0.655 62 17 4 
DV2 
(1TG8) 
1703.0 557.5 613.9 0.735 0.790 0.612 57 20 5 
DV3 
(1UZG) 
1593.2 533.6 534.6 0.654 0.629 0.602 51 12 2 
TBE 
(1SVB) 
1496.2 412.8 672.1 0.702 0.754 0.633 49 8 2 
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Figure 1: Crystal structure of JEV E ectodomain. JEV E possesses the three domains 
characteristic of flavivirus E with symmetry operators that allow for generation of the 
canonical E dimer. JEV E cartoon representation crystal structure with domain I 
highlighted in red, domain II in yellow, domain III in blue and crystallographic dimer 
generated from orthorhombic symmetry in grey. The structure is also shown rotated 90° 
into the page. The fusion loop is colored green and the ‘k-l’ loop and glycosylation site 
are indicated in both structures.  
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Figure 2: Relative buried surface area of dimeric flavivirus E protein structures. 
JEV E has a small dimer interface relative to other E crystal structures. Surface 
representations of known dimeric E protein crystal structures are displayed arranged in 
ascending order of buried surface area. Note the that JEV E and TBEV E have visible 
solvent channels between subunits at the dimer interface, and that these channels are 
absent in DV E dimers with greater buried surface area.shrinking channels between the 
subunits as buried surface area decreases. 
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Figure 3: Comparison of E protein DI-DII hinge angles. The DI-DII hinge angle of 
JEV E is most similar to that of TBEV E. Various crystal structures of E were 
superimposed onto DI of JEV E and the relative angle between DI and DII was 
determined using Dyndom. Proteins are colored according to virus of origin and the 
numbers on the left indicate the difference in angle between DI and DII of each E protein 
and JEV E. The DV3 E protein was omitted for clarity and because it varies by less than 
1 degree from that of DV2 E. 
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Figure 4: Dimeric contact residues in E proteins from DV, TBEV and JEV 
serocomplexes. Multiple loops of domains I and II have dimer contacts in TBEV and DV 
E that are lacking in JEV E. A. Loops colored green contribute to dimer contacts in the 
Dengue Virus and B. Tick Borne Encephalitis E proteins but not in JEV E. C. The 
equivalent loops are colored red in the JEV E structure. D. The sequences corresponding 
to the numbered loops are aligned for all known dimeric E protein structures, with dimer 
contact residues highlighted in green. The parent virus of the E protein its pdb id are 
shown left to the left of each sequence. 
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Figure 5: Multi-angle light scattering evaluation of E protein solution oligomeric 
state. E proteins from viruses of the JEV E serocomplex favor a monomeric solution 
state. Multi-angle light scattering was utilized to calculate the solution molecular weight 
(MW) of JEV E (A), SLEV E (B), WNV E (C) and DV2 E (D) over their elution profile 
on a S200 sizing column. JEV E, SLEV E and WNV E had MW corresponding to that of 
monomers while DV2 E was that of a dimer. The UV absorbance trace is colored black, 
molar mass calculation in blue and fitted molar mass in red. 
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Figure 6: Comparison of E protein crystal structures to DV2 cryo-EM model. A. 
JEV E monomers were superimposed onto E proteins from the DV2 cryoEM 
reconstruction. The enlarged window of E proteins at the 2-fold axis shows the only 
clashing main-chain loops, ‘b-c’ and ‘h-i’, in cyan and magenta respectively. B. JEV E 
and DV2 E crystal structure backbones (green) are overlaid onto artificially generated 
dimers created by superimposing monomers from the crystal structure onto Dengue E 
dimers of the cryoEM model (grey). C. The table describes the buried surface areas from 
the crystal structures, the cryoEM model dimers and the RMSD obtained by aligning the 
crystal structure dimers onto the cryoEM models.  
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Figure 7: Conservation and localization of histidines of E proteins from the JEV and 
DV serocomplexes. Histidines on the lateral edge of DII and DIII are poorly represented 
in flaviviruses but conserved in the JEV serocomplex. Histidines of the DV2 E and JEV 
E proteins are shown in stick representation on one dimer subunit and labeled with their 
residue number for the given virus. Those colored green represent those conserved in all 
flaviviruses, orange are conserved in only the DV2 (top) or JEV serocomplex (bottom) 
and grey are not broadly conserved. Histidines fully conserved in the JEV serocomplex 
but not in other flaviviruses are found on the outer edge of the dimer and marked with an 
asterisk.  
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Figure 8: Mapping of neutralizing epitopes onto the JEV E protein and 
reconstructed virion. JEV E neutralizing epitopes are found at the DI-DII hinge, DI 
lateral ridge, DIII lateral ridge and fusion loop. A. Side chains of residues critical for 
binding by previously identified JEV neutralizing antibodies are colored green and in 
spherical representation. B. 4G2 (G104, G106, L107) maps to the fusion loop. C. B2 (I126), 
NARMA3 (Q52) and 503 (Q52, I126, K136, S275) map to the DI-DII hinge. D. A3 (K179) 
maps to the DI lateral ridge (panel D). E. E3 (G302) and E3.3 (I337, F360, R387) map to the 
DIII lateral ridge. The regions described above have also been mapped onto the model of 
the JEV virion to reveal their arrangement and accessibility in the icosahedral assembly.  
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Chapter 3:  
 
The St. Louis Encephalitis Virus envelope fusogenic trimer 
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3.1 Abstract 
St. Louis Encephalitis Virus (SLEV) is a member of the JEV serocomplex of 
flaviviruses and can cause febrile illness, nausea and encephalitis. We determined the 4.0 
Å structure of its E protein in the post-fusion trimer conformation to compare it with E 
trimer structures from other serocomplexes. SLEV E crystallized as a trimer in the 
absence of lipids or detergents, requiring only low pH. However, its domain arrangement 
was nearly identical to other post-fusion structures. This suggests that viruses can alter 
dimer assembly but the structure of the activated, fusogenic conformation may be more 
strictly conserved. 
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3.2 Cloning, purification and crystallization of SLEV E 
Cloning and purification of SLEV E was carried out as described in 2.5.1. After 
successful refolding, SLEV E was buffer exchanged into 50mM sodium acetate pH 5.5 
and concentrated to ~5mg/mL. SLEV E protein was crystallized at 20°C by hanging drop 
vapor diffusion. Drops containing 0.5µL of protein at a were combined with 0.5µL of 
mother liquor containing 0.1M sodium acetate pH 5.5, 3% polyethylene glycol (PEG) 
8000 and 2% ethylene glycol. Diffraction-quality crystals grew in 3-7 days (Fig 1A). 
Crystals were cryoprotected by transferring them briefly into a drop containing 10% PEG 
8000, 25% ethylene glycol and 0.1M sodium acetate pH 5.5 and then cooling them in 
liquid nitrogen. Data were collected at the Advanced Photon Source (APS) beamline 
ID19. The data set was processed, integrated, scaled and merged using HKL20001. SLEV 
E crystallized in space group I23 with unit cell dimensions a = b = c = 177.34 Å and 
contains one molecule per asymmetric unit.   
 
3.3 Structure determination 
  The structure of SLEV E was solved using molecular replacement. The sequence 
of SLEV E was threaded onto the structure of the post-fusion E trimer from Dengue 22 
(pdb ID 1OK8) using Phyre23. This model was then used for molecular replacement 
using Phaser within the PHENIX graphical interface4. An additional model of SLEV E 
was generated by threading SLEV E onto the JEV E crystal structure (pdb ID 3P54) and 
manually superimposing domains I, II and III onto those molecular replacement solution. 
SLEV has greater sequence identity with JEV E than DV E, so this model was used as a 
reference model during refinement. The structure was refined to 4.0Å resolution in 
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PHENIX by rigid body refinement followed by several rounds of atomic refinement with 
reference model and secondary structure restraints was performed and yielded an Rwork of 
32% and Rfree  of 34% (Table 1).  
 
3.4 SLEV E post-fusion trimer 
 The preliminary crystal structure of SLEV E was determined at refined to 4.0Å 
resolution. The Rwork and Rfree were 32 and 34% respectively, and 383 out of 406 residues 
were built into the model. The loops spanning residues 146-164 was not visible in the 
density. The residues of this loop are also disordered in both post-fusion structures of DV 
E proteins, so this is not unusual2,5. SLEV E adopted the 3-domain architecture 
previously observed in E proteins6. DI is an 8-stranded β-barrel, DII is formed out of two 
extended loops protruding from DI and DIII is a 6-stranded Ig-like domain (Fig 1A). 
Crystals were grown at pH 5.5 and E was found in the post-fusion conformation. There 
was a single E protein in the asymmetric unit, but application of cubic symmetry allowed 
for generation of the trimer (Fig 1A). When DI of SLEV E was superimposed onto DI of 
the DV2 E trimer, the most significant differences were visible in DII, while DIII from 
SLEV E did not vary substantially in orientation relative to DV2 DIII (Fig 1B). Further 
analysis will be carried out upon further refinement, as we do not wish to over-interpret 
our results given the low resolution of the structure. 
 
3.5 Discussion and future directions 
 We have solved the first structure of a post-fusion E protein from the JEV 
serocomplex. It was originally believed that E protein trimerization required both acidic 
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pH and the presence of membranes7. However, the post-fusion structure of DV1 E was 
recently solved in the absence of detergent5. Interestingly, DV2 E2 and TBEV E8 crystals 
grown in presence of lipids or detergents diffracted to high resolution (2.0 and 2.7 Å). 
DV1 E5 and SLEV E structures, on the other hand, are relatively low-resolution (3.5 Å 
and 4.0 Å), implying insertion into membranes provides additional stabilization.  
Attempts to improve the resolution of the SLEV E crystals have been 
unsuccessful. The crystals have a high solvent content (~80%) that was apparent upon 
inspection of the large solvent channels that permeate the lattice (Fig 2). The fusion loops 
are completely buried within a pocket formed by DI-DIII from 3 different E proteins that 
each belong to a separate trimer (Fig 3). Attempts to dehydrate crystals have failed thus 
far. Our next attempt to improve diffraction will be to pursue crystallization of SLEV E 
in the presence of stabilizing lipids or detergents. We obtained a 4.0 Å resolution SAD 
data set with selenomethionine-derived SLEV E and the additional phase information 
will be utilized to improve our model. Future efforts will focus on the comparison of a 
fully refined SLEV E structure to the structures of other class II fusion proteins in the 
post-fusion conformation. 
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Table 1: Data collection and refinement statistics 
Data collection  
Space group I23 
Cell dimensions  a=b=c=177.34Å 
Resolution (high res shell) 50.0-4.00 Å (4.07-4.00 Å) 
Completeness 99.56% (99.5%)a 
Redundancy 11.7 (11.7) 
I/σ 30.5 (7.0) 
R-merge (I) 0.07 (0.488) 
  
Refinement  
Resolution (high res shell) 37.8-4.03 Å (4.17–4.03 Å) 
R-work reflectionsb (F>0) 7383 (698)a 
R-free reflections 388 (36) 
R-work 0.3254 (0.3503) 
R-free 0.3433 (.4021) 
SLEV E residues (atoms) 381 (2917) 
Wilson B-factor  131.70 Å2 
R.m.s.d. bond lengths 0.009 Å 
R.m.s.d. bond angles 1.544° 
  
a Values in parentheses are for data in 
the highest resolution shell  
 
b Statistics as defined in Phenix  
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Figure 1: Crystal structure of SLEV E. A) Cubic crystals grew in 3% PEG 8000, 2% 
ethylene glycol, 0.1M sodium acetate pH 5.5 after 3-7 days. B) SLEV E trimer. DI is 
colored red, DII yellow, DIII blue and fusion loop green. Application of cubic symmetry 
allowed generation of the trimer, with additional subunits colored grey and wheat. C) 
Least-squares superimposition of DI of SLEV E onto DI of DV2 E (grey). Slight 
differences in the angles of DII and DIII relative to DI are visible.  
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Figure 2: SLEV E packing and solvent channels. The SLEV E trimer was formed by 
application of cubic symmetry and packed into a lattice with large solvent channels 
between trimers. A single E subunit is displayed below (outlined box, red ribbon 
structure). The top left panel shows only the E packing arrangement, the right panel 
shows the density and the center panel is the two merged.  
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Figure 3: Fusion loop burial. A) In the absence of detergent, the fusion loops of SLEV 
E packed into a pocket formed by DI and DIII of three E monomers that each belong to a 
separate trimer assembly. DI is shown in red, DII in yellow and DIII in blue. The trimer 
with inserted fusion loop (green) is shown in cartoon representation. DIII is omitted from 
the cartoon representation for clarity. B) The stick representation of the 3 fusion loops is 
displayed. 
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4.1 Abstract 
 Hepatitis C virus (HCV) is a blood borne pathogen that chronically infects 
roughly 3% of the global population. Clinical manifestations include hepatitis, cirrhosis 
and hepatocellular carcinoma. HCV is a member of the Flaviviridae family, a group of 
enveloped, positive-stranded RNA viruses. The current therapy for HCV is a combination 
of interferon-α and ribavirin. This treatment only succeeds in ~50% of cases and often 
leads to more detrimental side effects than those of the disease. The inability to develop a 
preventative vaccine has been linked to many features that shield the virus from antibody 
recognition, including extensive glycosylation and sequence variability of envelope 
proteins E1 and E2. Entry is mediated by direct interaction between E2 and receptors 
CD81 and scaveng3er receptor BI. However, virions also associate with lipoproteins that 
allow for hijacking of the lipoprotein transport machinery to facilitate infection. There is 
no crystal structure for E1 or E2 and their organization on mature virions is unknown. 
Determination of the structural and biophysical basis for HCV receptor interaction should 
illuminate new targets for the rational design of antivirals and antibodies that can inhibit 
HCV at vulnerable stages of the entry process.  
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4.2 Discovery and epidemiology 
 Hepatitis C was first isolated as the causative agent of non-A, non-B viral 
hepatitis in 19891, but genetic “molecular clock” approaches estimate the virus first 
appeared in humans as many as 1,000 years ago2. Transmission of HCV occurs from 
contact with infected blood. The majority of cases have resulted from  needle sharing 
during injected drug use or blood transfusions that occurred prior to screening for the 
virus in 19903. Sexual transmission of HCV is possible but rare4. Up to 75% of those 
infected proceed to chronic infection, although the virus has been deemed the “silent 
epidemic” because a high percentage these individuals clinical symptoms may be delayed 
for several years5,6. There are 8,000-10,000 annual deaths7 linked to HCV infection, a 
relatively small number relative to the 1.5 to 3 million deaths caused by HIV8. However, 
it has been estimated that 170 million people are chronically infected with HCV9, which 
is ~5 times that of those carrying HIV. Therefore, progression of liver disease HCV-
positive individuals poses a massive public health problem.  
 
4.3 Clinical manifestations and treatment 
Symptoms of chronic infection. Many chronic HCV infections are asymptomatic, 
and in some cases their manifestation of clinical symptoms does not occur for 20 or more 
years10. The most common symptoms that do occur include jaundice, fatigue, cirrhosis, 
hepatitis, and hepatocellular carcinoma11. However, even those with asymptomatic 
infection are at risk for progressive liver damage. HCV is currently the leading cause of 
adult liver transplantation in the U.S., but if the antiviral therapy is not able to clear the 
virus prior to the transplant, re-infection will occur.  
 88	  
Antiviral therapy. The current treatment for HCV is a combination of pegylated 
interferon-α and ribavirin12. Viral clearance as a result of this combination therapy is 
~50%, but depends upon the HCV genotype being treated13. Genotype 1 is most 
prevalent in the U.S. and is the most resistant14. Side effects of this lengthy 48-week 
regimen occur in 50% or more patients and range from flu-like symptoms to depression. 
The severity of these side effects relative to the typically mild short-term symptoms of 
HCV infection results in a large degree of patient non-compliance and thus 
discontinuation of treatment15. Promising results have been achieved with an antiviral 
that specifically inhibits the HCV NS2-3A viral protease. In clinical trials, combination 
therapy that included this protease, interferon-α and ribavirin inhibitor resulted in a 
sustained virologic response in 72% of patients16. Several other drugs that specifically 
target other non-structural proteins are also in clinical trials, forecasting a promising 
future for control of HCV17.  
Vaccine development. Development of a prophylactic or therapeutic HCV 
vaccine has been unsuccessful to date. This is largely because of the extensive sequence 
diversity amongst strains or generation of quasispecies within a single host18–20. The only 
preventative vaccine to be evaluated in clinical trials consisted of recombinant HCV E1 
and E2 envelope proteins21. This vaccine was well tolerated and generated neutralizing 
antibodies against HCV. However, this approach is unlikely to succeed given the results 
of several previous studies. For example, it has been established that chronically infected 
individuals often possess high titers of neutralizing antibodies,22 and that E1-E2 vaccines 
tested on chimpanzees do not prevent infection with heterologous strains23. Future 
prophylactic approaches are likely to focus on the use of virus-like particles (VLPs) or 
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inactivated virus, but immunization with these agents still does not address the issue of 
sequence variability. A potentially more promising approach involves complementation 
of the antiviral regimen with a therapeutic vaccine. Augmentation of the immune system 
by recombinant interferon-α is essential to this treatment, so it is apparent that boosting 
the host response can be a successful strategy24. Therapeutic vaccines utilizing 
recombinant HCV E125, core26,27 or non-structural proteins28,29 have been developed with 
and administered with several different delivery systems but none are particularly 
effective30.  
 
4.4 Virology 
HCV is a member of the Flaviviridae family and is the lone representative of 
genus Hepacivirus. There are six major genotypes of HCV, each of which differ by 30-
35% in sequence at the nucleotide level31. HCV is an enveloped, positive-stranded RNA 
virus that possesses a ~9.6kb genome. The genome encodes for a single polyprotein is 
cleaved by viral and host proteases into 3 structural and 7 non-structural (NS) proteins32 
(Fig 1). Core binds to viral RNA and forms the nucleocapsid and been implicated in the 
inhibition of interferon signalling33. Envelope protein 1 and 2 (E1/E2) are transmembrane 
proteins that coat the surface of the HCV virion. These proteins are primarily involved in 
functions that mediate cellular entry such as attachment, receptor interaction and 
membrane fusion34. The p7 non-structural protein is a dual-pass transmembrane protein 
that exhibits ion-channel activity in vitro35,36. NS2 is a membrane protein involved in the 
replication complex and is essential for cleavage at the NS2/3 junction in the 
polyprotein37. NS3 is a multi-function protein with an N-terminal cysteine protease 
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domain and a C-terminal RNA-helicase38. NS4A is co-factor for NS3 and associates with 
the ER through its transmembrane domain39. NS4B is a 4-pass transmembrane protein 
that induces a membranous web involved in formation and budding of HCV virions40–42. 
NS5A is a membrane-associated phosphoprotein that binds to viral RNA43 and NS5B and 
is essential for replication. NS5B is also membrane associated and serves as a low fidelity 
RNA polymerase44,45.  
 
4.5 HCV envelope glycoproteins  
 The surface of the mature HCV virion is decorated with transmembrane envelope 
glycoproteins E1 and E2 that facilitate attachment and membrane fusion. E1 and E2 have 
been proposed to operate as class II fusion proteins (refer to 1.5.3) based on predictions 
that their secondary structure consists primarily of β-strands, and has similar genomic 
organization to flaviviruses. However, their sequences are divergent from any known 
class II protein, and a group of class III fusion proteins rich in β-strand content have also 
been recently discovered46, so this presumption is highly speculative. The majority of 
host neutralizing antibodies recognize E2, however neutralizing anti-E1 antibodies have 
been reported. While E1 and E2 have been studied extensively, several basic features 
including their oligomeric state and assembly in the native virion, membrane topology 
and localization of a fusion peptide remain unclear.  
E1 biochemistry, membrane topology and putative functions. E1 is a 162aa 
(polyprotein aa 192-353) transmembrane protein with poorly understood function. The 
ectodomain of E1 contains 4 N-linked glycosylation sites and the protein has 6 cysteine 
residues that form disulfide bonds (Fig 2A). A proposed function of E1 is to serve as a 
 91	  
chaperone for folding of E247, but several studies have verified that soluble E2 constructs 
adopt a functional fold in the absence of E1 co-expression48,49. Several regions of E1 
have been suggested to contain the HCV fusion peptide. Perhaps most intriguing is the 
hydrophobic central region of E1 that spans polyprotein residues 272-298. This region 
has been proposed by some to serve as a fusion peptide50 and by others a central 
transmembrane domain51. Indeed, there is conflicting evidence that supports both a two-
pass and single-pass transmembrane topology model of E1. Antibodies that bind residues 
313-327 can neutralize HCV, suggesting the region immediately C-terminal to 272-298 is 
exposed on the virion and argues that E1 has a lone transmembrane domain at its C-
terminus52. On the other hand, the same C-terminal region recognized by these antibodies 
also binds the HCV core protein, which is enveloped by the viral membrane and 
inaccessible to host antibodies51. This second finding implies that E1 possesses a 
transmembrane helix at 272-298 as well as its C-terminus. It is possible, especially given 
that HCV envelope protein organization in viral particles is unclear, that these conflicting 
data may be reconciled by the existence of two distinct forms of E1 with one or two 
transmembrane domains. E1 also can potentially mediate HCV entry by associating with 
apolipoproteins B and E (ApoB, ApoE) to direct interaction with the low-density 
lipoprotein receptor (LDL-R)53.  
E2 biochemistry. E2 is a 363aa transmembrane protein (polyprotein aa 384-743) 
responsible for direct interaction with HCV receptors CD8154,55 and SR-BI56,57 and is the 
primary target of neutralizing antibodies. E2 contains 11 N-linked glycosylation sites, all 
of which have been confirmed to be modified by host cells58, and 18 conserved cysteines 
that stabilize its structure by forming disulfide bonds59 (Fig 2B). Lines of evidence 
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supporting the hypothesis that E2 is a class II viral fusion protein are anecdotal and based 
entirely on its localization in the genome and secondary structure content. E2 has no 
significant sequence similarity to any known protein, making structural prediction 
difficult. Regardless of these limitations, a computational model of E2 generated through 
the threading of its sequence onto domains I and II of a flavivirus E protein has been 
published60. Mutation of polyprotein residues 416-430 and 600-620 led to defects in 
HCV pseudoparticle fusion61 and are thus considered candidates for the viral fusion 
peptide. However, in the absence of structural information it is difficult to differentiate 
peptides that physically penetrate host membranes from those that assist in 
conformational changes prior to fusion.  
E2 soluble ectodomain. C-terminal truncation of E2 prior to its hydrophobic stem 
and transmembrane regions results in the secretion of a soluble form of its ectodomain48. 
This recombinant, soluble E2 (sE2), spanning polyprotein residues 384-660, has been 
critical to the discovery of HCV receptors CD8155 and SR-BI57, monoclonal antibody 
generation56 and biochemical studies of envelope protein function. Production of sE2 
leads to the secretion of a monomeric form along with disulfide-linked aggregates48. I 
have reproduced this expression pattern by generating sE2 through recombinant 
baculovirus infection of Hi-Five cells and it is the main protein reagent used in the HCV 
portion of my thesis. Methods described for this purification can be found in 4.7.1. 
Briefly, sE2 secreted into insect cell supernatants was purified by nickel and size 
exclusion chromatography (SEC), and the monomeric fraction obtained from the SEC 
purification was collected and utilized for subsequent experiments (Fig 3). Monomeric 
sE2 is believed to resemble the native E2 ectodomain based on its ability to directly bind 
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host receptors CD8162 and SR-BI57 and inhibit HCV infection when bound to 
hepatocytes49. There is also evidence that HCV particles contain disulfide-linked E2 
aggregates, but soluble forms of these aggregates do not bind CD8163 and few studies 
have investigated their relevance otherwise.  
Hypervariable region 1. The most genetically diverse region of the HCV genome 
is located at the N-terminus of E2 and deemed hypervariable region 164 (HVR1). Despite 
its sequence variability, the length and physiochemical properties of HVR1 are 
conserved65, suggesting it retains structural elements or functional utility (Fig 4). Indeed, 
HVR1 has been implicated in binding to hepatocytes and evasion of the humoral immune 
response. HVR1 binds to heparin sulfate through electrostatic interaction with basic 
residues and this binding may be competitively inhibited by the heparin-binding V3 
variable loop of HIV66,67. Furthermore, deletion mutants of E2 lacking HVR1 lose the 
ability to bind SR-BI57, highlighting its importance for interaction with at least two 
attachment factors. HVR1 was one of the first identified neutralizing epitopes on the 
HCV structural proteins68. Based on this discovery, it was demonstrated that treatment of 
chimpanzees with anti-HVR1 polysera was able to prevent infection with homologous 
strains23. This protection reinforced the biological importance of HVR1 but its variability 
makes it an inherently poor vaccine candidate. HCV lacking HVR1 has increased 
susceptibility to neutralizing antibodies and captures increased amounts of soluble CD81 
in pull-down assays, suggesting it may also play a role in concealing conserved protein 
surfaces from antibodies69.  
Oligomeric state and disulfide connectivity in recombinant E1/E2. 
Understanding of envelope protein arrangement in native HCV virions has been 
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complicated because of substantial differences in the properties of recombinant versus 
virus-incorporated envelope proteins. While there is little structural information available 
for these proteins, the connectivity of the disulfide bonds formed in both E1 and E2 has 
been established. Those formed by E1 were sequential70, with each cysteine forming an 
intramolecular bond with an adjacent cysteine (Fig 2A). The E2 disulfides contained 
sequential and non-sequential linkages, implying they play a role in stabilization of 
tertiary structure59 (Fig 2B). Early assessments of the oligomeric state of transiently 
expressed E1 and E2 observed the formation of a non-covalent heterodimer71. However, 
the story grew more complex upon evaluation of E1 and E2 association in infectious 
particles. These studies revealed a barely detectable fraction of monomeric E1 and E2 
and large quantities of disulfide-linked oligomers, suggesting a web of cross-linked E1 
and E2 proteins encase the native virion72. Furthermore, cell-culture derived virus 
requires reduced (unpaired) cysteine residues in E1 and E2 for infection73. These data 
indicate the disulfide mapping of recombinant E1 and E2 does not recapitulate what is 
present in infectious virus. The poor comprehension of HCV envelope protein assembly 
presents a major concern for the selection of effective immunogens for vaccination.  
 
4.6 The HCV virion 
 The HCV virion is composed of C, the RNA genome and a host derived lipid 
membrane containing E1 and E2. These particles are roughly spherical and measure 
~50nm across74. The association of HCV with lipoproteins such as ApoB, ApoE or HDL 
results in a low particle buoyant density relative to other small RNA viruses75. These 
lipoprotein-associated forms of HCV are referred to as lipoviroparticles. Infection of 
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hepatocytes by lipoviroparticles may be mediated by direct interaction between E1 and 
E2 with a variety host entry factors, or by indirect interaction between lipoproteins and 
cellular lipoprotein receptors76–79.  
 
4.7 Host entry factors 
 A multitude of candidate receptors and attachment factors important for HCV 
infection have been identified (Fig 5). Most of these host factors may be assigned to three 
categories: 4 transmembrane tetraspanins (CD81) and tight-junction proteins (claudins 
1/6/9, occludin), lipoprotein receptors (SR-BI, LDL-receptor), and 
carbohydrates/carbohydrate recognition proteins (heparin sulfate, DC-SIGN, L-SIGN). 
While direct interaction with HCV has only been demonstrated for a subset of these 
molecules, many are still required for productive infection of hepatocytes. 
CD81.  The first identified HCV receptor was tetraspanin CD8162. Tetraspanins 
are a family of 4 transmembrane domain proteins that interact with one another to 
stabilize membranes and participate in signaling. CD81 is also a member of the B-cell 
receptor complex, and HCV can infect B-cells along with hepatocytes80,81. There are two 
extracellular loops in between the transmembrane helices of CD81, the second of which 
is deemed the large-extracellular loop (LEL). The crystal structure of this loop revealed a 
5-helix arrangement and two molecules in the asymmetric unit forming what is presumed 
to be a homodimer82. The interaction of E2 and CD81 has been mapped to the LEL, 
specifically to residue F185 situated on opposite ends of the homodimer83 (Fig 6). Protein 
determinants of E2:CD81 binding have also been mapped to discontinuous regions of E2 
including W420, G436-Y443, Y527, W529, G530 and D53584,85 (Fig 2B). CD81 likely 
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serves as a post-attachment receptor since anti-CD81 mAbs neutralize HCV regardless of 
whether they are applied before or after virus is bound to hepatocytes55. Interaction of 
HCV with CD81 also serves to prime the virus for membrane fusion86.   
Scavenger receptor BI. Scavenger receptor BI is required for HCV infection and 
directly interacts with E257. SR-BI is a two-pass transmembrane protein with N- and C-
termini oriented towards the cytosol. It has a single, ~400aa glycosylated extracellular 
loop and is involved in lipid and cholesterol transport through binding of lipoproteins and 
uptake of foreign substances or organisms. Ligands that interact with the extracellular 
loop are typically negatively charged and include high-density lipoprotein (HDL)87, 
ApoB and ApoE87,88. HCV is often found in serum as a “lipoviroparticle” associated with 
ApoB and ApoE. Therefore, it has been proposed that HCV hijacks the SR-BI transport 
machinery to gain entry into cells, either by engaging SR-BI with E257 or associated 
ApoE76,78. HCV infection is also enhanced by the presence of HDL89,77,90, providing 
further evidence for this mechanism. Unlike what is observed for interaction with CD81, 
binding of HCV to SR-BI occurs at an early stage of infection and specifically involves 
amino acids 70-87 and E210 in the N-terminal half of the extracellular loop91. Deletion of 
HVR1 from E2 ablates SR-BI binding57, indicating it contains at least part of the 
molecular determinants for this interaction. Interestingly, both SR-BI and CD81 are also 
involved in Plasmodium falciparum (causative agent of malaria) infection of 
hepatocytes92, suggesting they may be part of a conserved portal for pathogen entry.  
Tight junction proteins. Claudins 1, 6 and 9 (CLN1, CLN6, CLN9)93,94 and 
occludin (OCLN)95 are tight junction proteins necessary for HCV infection. These 
proteins function as cellular adhesion molecules and each has a 4-transmembrane 
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topology similar to CD81. CLN1/6/9 and OCLN do not directly bind HCV, but appear to 
co-localize with other receptors96 and can facilitate direct cell-to-cell transmission97. 
Antibodies that bind CLN1 block HCV infection98, implying it is in proximity to the 
virus during entry. Indeed, complexes of CD81 and CLN1 have been identified and 
appear to associate with HCV96. OCLN may also indirectly associate with HCV, as it co-
precipitates with E2 from infected cells99. The specific determinants within CLN1 and 
OCLN required for HCV infection have been identified and include the first extracellular 
loop of CLN193 and second extracellular loop of OCLN95. While the exact role of tight 
junction molecules in HCV infection is unclear, discovery of OCLN as an entry factor led 
to the development of the first immunocompetent HCV mouse model. Transgenic mice 
expressing human CD81 and OCLN are susceptible to a single cycle of HCV infection100, 
reinforcing the importance of OCLN for HCV infection despite its inability to directly 
bind virus.   
Other candidate attachment and entry factors. Additional molecules implicated 
in HCV infection are the LDL-receptor76,101, heparin sulfate66,67 and mannose-binding 
lectins DC-SIGN and L-SIGN102. The LDL-receptor likely interacts with HCV in a 
manner similar to SR-BI in which indirect interactions with virion-associated lipoproteins 
facilitates entry76. Binding of HCV to heparin sulfate occurs through interactions with 
HVR1 and enhances viral attachment to hepatocytes67. DC-SIGN and L-SIGN bind 
carbohydrates on E2, allowing HCV to disseminate to proximal hepatocytes upon 
infection of a cell102. However, several different viruses attach to cells through non-
specific interactions with heparin sulfate and mannose-binding lectins, so these are 
typically considered attachment factors and not true receptors. 
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4.8 Role of antibodies in chronic infection 
 The role of neutralizing antibodies in acute and chronic HCV infection is unclear. 
Early experiments were met with paradoxical results: most individuals chronically 
infected with HCV had high titers of neutralizing antibodies but acute infections were 
associated with low titers22. More recent studies, however, reported that spontaneous 
clearance of HCV is consistently linked to rapid induction of neutralizing antibodies 
during the acute phase of infection while those with a delayed response progress to 
chronic infection103,104. It is therefore likely that once a poor initial response allows HCV 
to establish infection, its many immune evasion strategies allow it to persist in the 
presence of neutralizing antibodies.  
 
4.9 Antibody evasion mechanisms 
Genetic variation and hypervariable region 1. HCV employs a variety of 
strategies to evade recognition and clearance by antibodies. Perhaps the most effective is 
the ability of HCV to rapidly vary its sequence due to the low fidelity of RNA 
polymerase NS5B45. In infected patients, a population of quasispecies will emerge18–20 
and a high degree of diversity amongst these species during early infection is predictive 
of a chronic infection105. The most diverse region of HCV is HVR1, a variable region that 
serves a role in cellular attachment67 as well as antibody evasion69. Antibodies that bind 
HVR1 neutralize HCV but do not lead to clearance, presumably due to its frequent 
mutation106. Furthermore, HVR1 is able to obscure conserved neutralizing epitopes from 
recognition69.  
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Glycosylation of E2. Viral N-linked glycans are believed to be flexible and 
structurally indistinguishable from host carbohydrates, so they are rarely targeted 
exclusively by neutralizing antibodies. The presence of several glycans on the surface of 
a virion could therefore sterically inhibit antibody access to protein epitopes. Mutation of 
N-linked glycans at sites N417, N423, N448, N532 and N645 of E2 (Fig 2C) each leads 
to increased neutralization sensitivity107, indicating they are able to shield protein 
surfaces from recognition. All E2 glycans also exhibit microheterogeneity58, meaning 
modification at a single site may is not consistent. This implies that even neutralizing 
antibodies able to recognize carbohydrate epitopes would not effectively bind all 
available sites on viral particles.  
Cell to cell transmission. HCV is able to spread directly from cell to cell upon 
infection of hepatoma and B-cell lines108,109. This means of transmission is independent 
of CD81109 but still requires CLN1 and OCLN109,108, suggesting the virus may pass 
through tight junctions. Cell-to-cell transfer from infected cell lines to uninfected cells 
occurs despite the presence of neutralizing antibodies, representing yet another 
mechanism utilized by HCV to evade the humoral immune response.  
 
4.10 Neutralizing epitopes 
 Several neutralizing antibodies have been mapped to specific sites on E1 and E2. 
Some of the first identified were found to recognize the C-terminal half of HVR1 and 
functioned by blocking cellular attachment. In our own studies, we isolated neutralizing 
antibodies that bind C-terminal residues of HVR1 G397, F403, G406 as well as residue 
R572 within the intergenotypic variable region (igVR)110 and block infection at a post-
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attachment step56. This mapping suggests these two variable regions are within close 
spatial proximity in the structure of E2 (Fig 2C). Additional conserved linear and 
discontinuous neutralizing epitopes have been determined for several antibodies, and are 
most commonly located within E2 polyprotein residue ranges 412-424 or 523-550111–114. 
Binding determinants for CD81 are also located within these regions85, implying that 
HCV cross-neutralization may be achieved through generation of antibodies that 
recognize this site. For unclear reasons, no neutralizing antibodies that bind residues of 
E2 C-terminal to the igVR have been isolated. The epitopes of two anti-E1 monoclonals 
that neutralize HCV have been identified (Fig 2A). The first is located at the non-
conserved N-terminus of E1. This epitope is recognized by antibody H-111, which 
neutralized HCV pseudoparticles by preventing attachment115. The other spans conserved 
residues 313-327 near the C-terminus of E1116. Antibodies that recognize this region are 
able to cross-neutralize several HCV genotypes, which warrants consideration of E1 for 
future vaccine or therapeutic development. 
 
4.11 Generation and characterization of a panel of anti-E2 antibodies 
 In order to study the structural basis for antibody neutralization of HCV, I took 
part in a collaborative effort that led to production of a large panel anti-E2 monoclonal 
antibodies56. I played a significant role in the generation and characterization of these 
antibodies, so the associated publication containing detailed methods and my specific 
contributions is attached (Appendix 1). However, the neutralization mechanisms defined 
in this work guided subsequent experiments in my thesis so they are summarized below.  
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 The goal of our work was to generate neutralizing monoclonal antibodies, map 
them to specific regions of E2 and correlate structural features with neutralization 
mechanism. To initiate this study, I produced sE2 from genotype 1 and 2 for 
immunization of mice (Fig 3). I then generated yeast-displayed E2 constructs for 
screening of hybridoma supernatants. By this method, we isolated a total of 79 
monoclonal antibodies that reacted with E2. I also generated yeast display constructs 
expressing E2 from genotypes 1-6 as well as two C-terminal truncations of E2117. The 
yeast were utilized to evaluate cross-reactivity and map antibodies to one of three regions 
of E2 (Fig 7). Experiments performed by collaborators identified 7 neutralizing 
antibodies, mapped them to individual residues of E2 and determined their ability to 
inhibit E2 interaction with CD81 and SR-BI.  
Our results revealed that the most potent neutralizing antibodies bound region 1 of 
E2 and recognized broadly conserved epitopes or HVR1 (Table 1). One antibody, 
H77.39, blocked interaction with both CD81 and SR-BI. These findings suggested CD81 
and SR-BI could share an overlapping binding site on E2. My subsequent investigation of 
this possibility and the role of HVR1 were inspired by these findings and became a major 
focus of this thesis (Chapter 4).  
 
4.12 Summary 
 Despite the identification of a wide array of HCV receptors and entry factors, 
many essential structural and biophysical details accompanying these interactions have 
not been determined. Therefore, I sought to clarify several aspects of the interplay 
between E2, CD81 and SR-BI. I elucidated the stoichiometry of sE2 and CD81-LEL 
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alone and in complex. I was able to determine the kinetics and affinity of this interaction 
as well as the ability of HVR1 to modulate E2 binding to CD81 and SR-BI. Perhaps most 
interestingly, I established that sE2:CD81-LEL complexes are unable able to engage SR-
BI, suggesting they share a binding site on E2. Future directions will focus on the 
crystallization of E2 in hopes of understanding the structural basis for HCV attachment, 
entry and fusion.   
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Table 1: Summary of neutralizing anti-E2 mAbs. Adapted from ref. 56, Sabo et al. 
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Figure 1: The HCV polyprotein. Structural proteins are colored blue in the schematic, 
non-structural proteins are colored red. Protease cleavage sites are indicated by arrows 
and the host or viral protease that cleaves a given site is listed above each site.  
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Figure 2: HCV E1 and E2. A) A schematic of E1 indicating disulfide linkages (green 
bars connected by black lines), glycans (black Y-shaped protrusions), conserved 
neutralizing epitope (blue, spans 412-424 and 523-550), non-conserved neutralizing 
epitope (red) and hydrophobic region (orange with phi). Polyprotein residues 
corresponding to the termini, disulfides and N-linked sites are labeled. B) Schematic of 
E2 that indicates disulfide linkages (green bars connected by black lines), CD81 binding 
regions (magenta bars) and variable regions (light grey). C) Schematic indicating 
conserved (blue, spans 412-424 and 523-550) and non-conserved (red, spans 384-410 and 
570-580) neutralizing epitopes believed to be within spatial proximity on the E2 surface. 
Glycans are shown as black Y-shaped protrusions . Polyprotein residues corresponding to 
the N-linked sites, cysteines and termini are displayed in B) and C).  
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Figure 3: Purification of soluble E2. The steps of sE2 purification including 
transfection, recombinant baculovirus amplification, affinity chromatography and size 
exclusion chromatography are described. Each arrow indicates a purification or purity 
assessment step. Infected insect cells were tracked and titered by GFP fluorescence given 
the transfer vector utilized encoded a GFP on a second promoter. The SEC profile is 
displayed in the bottom right corner, and fractions corresponding to the numbering across 
the profile were loaded in non-reducing buffer on an SDS-PAGE gel. Disulfide linked 
aggregates are found in fractions 1-3 and therefore only the monomeric sE2 found in 
peak labeled 4 was collected. 
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Figure 4: Conservation of physiochemical properties within HVR1. Several residues 
of HVR1 have specific chemical characteristics65, indicated by the coloring above.  
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Figure 5: HCV receptors. A cartoon representation of HCV entry, HCV 
lipoviroparticles are green with blue spikes. HCV binds attachment factors GAGs, DC-
SIGN or L-SIGN prior to directly or indirectly interacting with lipoprotein receptors 
LDL-R or SR-BI. E2 directly binds to CD81. Tight-junction proteins CLN1/6/9 and 
OCLN are required for infection but their exact role is unclear. Upon some combination 
of associations with these receptors, the HCV virion is taken into cells by clathrin-
mediated endocytosis. 
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Figure 6: Crystal structure and E2 binding determinants of CD81-LEL. Subunits of 
the CD81-LEL dimer are colored magenta and light pink. Helices containing E2 binding 
determinants are colored yellow and green respectively. The plasma membrane is 
approximately oriented along the plane of the page.  
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Figure 7: Yeast surface display constructs of E2. Yeast displayed E2 is linked at the N-
terminus to cell wall protein Aga2, tethering it to the surface. Yeast expressing region I 
(E2 residues 384-520), regions I and II (E2 residues 384-605) or regions I-III (E2 
residues 384-660) were used to map antibody recognition regions by exclusion. An 
example is displayed for antibody H77.28. Dot plots indicate a shift in the yeast 
population when an antibody is able to bind; in this case it requires regions I and II. E2 
(residues 384-660) from genotypes 1-6 were also successfully displayed.  
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Chapter 5:  
 
Hepatitis C E2 interaction with CD81 inhibits binding to 
Scavenger Receptor BI and is modulated by genotype and 
hypervariable region 1 
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5.1 Abstract 
Hepatitis C Virus (HCV) infects roughly 3% of the global population and is the 
leading cause of liver disease in adults in the United States. Infection of hepatocytes 
requires the presence of several candidate cellular receptors, the most thoroughly 
characterized of which are scavenger receptor B1 (SR-BI) and tetraspanin CD81. To 
elucidate the detailed biochemical roles of these receptors’ interactions with the HCV 
envelope protein E2, we first determined that soluble E2 ectodomain (sE2) interacts with 
CD81 large extracellular loop (CD81-LEL) with a 2:2 stoichiometry, and that this 
interaction inhibits subsequent engagement of SR-BI. Affinity and kinetics of sE2:CD81-
LEL binding were then measured by surface plasmon resonance. Affinity of sE2 for 
CD81-LEL was enhanced by deletion of hypervariable region 1 (HVR1) of E2 and acidic 
pH, and modulated by the HCV genotype from which sE2 was produced. Furthermore, 
neutralization of HVR1-deleted HCV by a broadly cross-reactive antibody was enhanced 
in a genotype-specific manner that correlated with sE2:CD81-LEL affinity 
measurements. Taken together, our results suggest that E2 alone cannot simultaneously 
engage both CD81 and SR-BI, that HVR1 obscures CD81 and antibody binding sites, and 
that genotypic variation substantially influences HCV host receptor preference.  
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5.3 Introduction  
Hepatitis C Virus (HCV) is a blood borne pathogen carried by roughly 3% of the 
global population1. Symptoms associated with chronic infection include cirrhosis, 
hepatitis and hepatocellular carcinoma. Currently, there is no vaccine for HCV and 
treatment is a combination of pegylated interferon-α2,3 and ribavirin4, which results in a 
sustained virologic response in only ~45% of cases5. However, this 48-week regimen is 
associated with severe side effects, resulting in a large degree of patient non-compliance 
and thus premature discontinuation of therapy. Recent clinical trials that incorporated an 
inhibitor of HCV protease NS2/3 have reported an increased rate of viral clearance6,7, 
suggesting that development of additional antivirals for a cocktail-based approach is a 
promising strategy for future therapies.  
HCV is a member of Flaviviridae, a family of enveloped viruses with a single-
stranded positive-sense RNA genome. The genome encodes for a polyprotein that is 
cleaved into 3 structural and 7 non-structural proteins by host and viral proteases8,9. The 
core, envelope 1 (E1), and envelope 2 (E2) proteins represent the HCV structural 
proteins. Core binds to the RNA genome and is enveloped by a host lipid membrane that 
contains transmembrane proteins E1 and E2 to comprise the infectious virion. E2 has 
been implicated in receptor interaction and is the primary target for neutralizing 
antibodies10–13, while the function of E1 is poorly understood. The oligomeric state and 
disulfide organization of E1 and E2 in the mature virion are also unclear.  Initial studies 
reported a heterodimeric E1-E2 complex,14 while other more recent work suggests a 
complex network of monomers and disulfide linked oligomers15. A recombinant, soluble 
form of E2 lacking the transmembrane domain and C-terminal stem region (sE2) is 
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believed to adopt a fold similar to full-length E2 and has been a valuable tool in 
functional and biochemical studies16,17. 
Distinct features of the E1 and E2 are able to complicate HCV recognition by the 
adaptive immune system. Extensive glycosylation of both envelope proteins is believed 
to reduce accessibility of neutralizing epitopes18–20. E1 and E2 possess 4 and 11 N-linked 
glycosylation sites respectively and mutation of several N-linked residues has been linked 
to increased susceptibility to neutralizing antibodies18,20. Additionally, E2 encodes for 3 
regions that exhibit considerable sequence variability. The inter-genotype variable region 
(igVR) diverges across each of the 7 or more HCV genotypes21 while hypervariable 
regions 1 and 2 (HVR1, HVR2) display variability between isolates and can even 
contribute to the emergence of quasispecies within a single host22–25. HVR1 consists of 
the N-terminal 27 amino acids of E2 and is a dominant neutralizing epitope22,25,26. 
Despite its high mutation rate, certain features of HVR1 including its length and 
physiochemical properties are conserved27, suggesting it may retain structural elements or 
biological roles important for the viral life cycle. Such roles include mediating viral 
attachment via binding to heparin sulfate28,28 and, along with certain E2 glycans19,20, 
concealment of conserved receptor and antibody binding sites26,29. 
A series of host factors are implicated in HCV infection, the most thoroughly 
characterized of which are tetraspanin CD8111,30 and the HDL-binding scavenger receptor 
BI (SR-BI)10. Other candidate receptors are tight-junction molecules claudins 1/6/931,32 
and occludin33, mannose-binding lectins DC-SIGN and L-SIGN34, LDL-receptor35 and 
heparin sulfate28,36. Direct interaction between E2 with CD8126,37 and SR-BI has been 
demonstrated in several assays38,39, and antibodies that bind either receptor potently 
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inhibit HCV infection40,41. Conserved discontinuous regions and residues of E2 are 
involved in CD81 interaction42,43, while the non-conserved HVR1 represents the putative 
SR-BI binding site44,45. Understanding of the specific kinetic and functional contributions 
of CD81, SR-BI and other receptors in during infection is currently limited. CD81 is 
believed to function at a post-attachment step in the entry process46 and primes the virion 
for membrane fusion47. SR-BI, on the other hand, is involved in cellular attachment38 and 
is able to facilitate HDL mediated enhancement of infection48.  
 Herein, we have deconvoluted the relationship between E2 and receptors CD81 
and SR-BI. Kinetics and affinity between several E2 constructs and CD81 were 
determined to evaluate the impact of genotype, pH and hypervariable region 1 on this 
interaction. Deletion of HVR1 resulted in genotype specific enhancement of binding to 
CD81-LEL, suggesting that the degree by which it obscures this binding site may vary 
substantially between isolates. We also experimentally determined the solution 
oligomeric state of sE2, CD81-LEL and the sE2:CD81 complex to further elucidate this 
crucial stage of HCV infection. Furthermore, CD81-LEL interaction with sE2 prevented 
subsequent engagement to SR-BI, suggesting the presence of a shared binding site for 
both receptors. 
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5.4 Results 
Stoichiometry of sE2:CD81 interaction. Direct biochemical interaction between 
sE2 to CD81-LEL has been demonstrated in several studies11,37,42,43, yet the solution 
oligomeric state of these molecules alone or in complex have not been resolved. We 
utilized multi-angle light scattering (MALS) to determine the molecular weight (MW) of 
sE2 and CD81-LEL over individual peaks resolved by a size exclusion column. This 
direct measurement of MW is advantageous over methods such as dynamic light 
scattering or size-exclusion chromatography that determine molecular weight based on 
extrapolation from hydrodynamic radius alone. The predicted MW of sE2 in the absence 
of glycosylation is 32.1kD (Fig 1A). We determined that MW of sE2 was 36.1kD, 
corresponding to that of a monomer (Fig 1B). This larger value was to be expected given 
that sE2 has 11 N-linked glycan sites of unknown or heterogeneous composition that 
could not be accounted for in the calculation. The predicted MW of the recombinant 
CD81-LEL construct is 13.8kD and the experimental value was that of a dimer (28.5kD). 
To obtain the stoichiometry of the sE2:CD81-LEL complex, we mixed CD81-LEL with 
5-fold molar excess sE2 and then determined the MW of the two resultant peaks 
individually. The MW of the first peak to elute from the column was 34.0kD, 
corresponding to monomeric sE2, as it was expected to be in excess, and the MW of the 
second peak was calculated at 101.8kD (Fig 1C). This value corresponds to a 2:2 
interaction and can be explained by addition of the experimental MW of 2 molecules of 
sE2 (72.2kD) and one dimer of CD81-LEL (28.5kD) that would yield a predicted 
experimental MW of 100.7kD. Also supporting this stoichiometry is the non-
crystallographic homodimeric crystal structure of CD81-LEL49. Residues implicated in 
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E2 interaction are located on opposite faces of the dimer50 so it is unlikely that a single 
E2 protein could encircle the entire CD81 assembly and contact both sides 
simultaneously.  
Effects of genotype, HVR1 deletion, pH, and enzymatic deglycosylation on 
kinetics & affinity of sE2:CD81 interaction. In order to thoroughly establish the 
biochemical relationship between E2 and human CD81, we utilized surface plasmon 
resonance (SPR) to measure affinity and kinetics of interaction under a variety of 
conditions. Elucidation of the stoichiometry of interaction between the two proteins 
allowed for proper orientation on the sensor chip. This entailed immobilization of dimeric 
CD81-LEL as opposed to monomeric sE2 to avoid avidity effects that artificially inflate 
KD values when passing multimeric proteins over an immobilized ligand. The data were 
fitted to a 1:1 kinetic model in accordance with our MALS results that suggested each 
subunit of the CD81-LEL dimer interacts with one sE2 molecule.  
Since it has been proposed that HVR1 obscures the CD81 binding site of E229, we 
evaluated binding of both genotype 1 (H77) and genotype 2 (J6) sE2 and ΔHVR1 sE2 
constructs over immobilized CD81-LEL (Fig 2A). The KD of interaction for genotype 1 
sE2 was 1.01x10-7 M and for genotype 2 was 1.75 x10-6 M (Fig 2B). In this case, 
genotypic variation alone was responsible for a 17-fold difference in affinity. Deletion of 
HVR1 from genotype 1 sE2 resulted in a 2.2-fold increase in KD while deletion of HVR1 
from genotype 2 sE2 yielded a more substantial 8.8-fold enhancement (Fig 2B). This 
difference implies that the extent that HVR1 obscures recognition is modulated by viral 
genotype. The kinetic basis for this change was an increase in on-rate (ka), supporting the 
notion that deletion of HVR1 exposes the CD81 binding site and allows for more rapid 
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engagement by E2. Fitting individual curves corresponding to each sE2 concentration 
revealed no significant increase or decrease in kd (data not shown), indicating that while 
CD81-LEL has two sE2 binding sites there was no evidence for cooperativity.  
Binding experiments were performed as a function of pH in an attempt to observe 
affinity changes that may result as HCV passes through the endosome during its life 
cycle. At pH 6.4 (early endosome) the KD of genotype 1 sE2 for CD81-LEL increased by 
2.9-fold relative to pH 7.4 (Fig 2B). The relative affinity increased further at pH 5.4 (late 
endosome) to 4.4-fold (Fig 2B). At pH 5.4, the enhancement in KD resulted from an 
increase in on-rate but also was accompanied by a more rapid off-rate and therefore a 
decrease in half-life. The biological relevance of this more rapid dissociation could be 
attributed to the consideration that HCV virions likely require disengagement from CD81 
prior to initiating fusion events with the host membrane.  
Enzymatically deglycosylated sE2 was also evaluated for kinetics and affinity of 
interaction with CD81-LEL relative to untreated sE2. A series of three enzymes, Endo 
F1/F3 and PngaseF were used to deglycosylate native sE2. First, sE2 was treated with 
Endo F1/F3, then buffer exchanged into optimal conditions for PngaseF treatment prior 
to addition of this third enzyme. The untreated sE2 construct has a predicted MW of 
~31kD but runs as a diffuse band at ~54kD on a 4-12% SDS gel due to the extensive 
glycosylation (Fig 2C). Upon treatment with these enzymes, sE2 runs at ~38kD, 
indicating a reduction of approximately 60% (16kD) of the glycosylation MW (Fig 2C). 
To control for possible effects of the pH 5.5 buffer required for Endo F1/F3 cleavage, 
sE2 used for comparison in kinetics and affinity measurements was treated with the 
equivalent buffers in the absence of EndoF1/F3/PngaseF. Removal of these glycans only 
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had a small effect on kinetics of affinity of CD81 interaction, increasing 2.3-fold relative 
to the sE2 incubated with buffer alone.  
Enhancement of HCVcc neutralization by a cross-reactive mAb upon HVR1 
deletion. HCV-neutralizing antibodies are significantly less potent relative to those that 
neutralize other members of Flaviviridae39,51–53. This disparity is potentially due to 
concealment of neutralizing epitopes by the variable regions and glycans of E2.  We have 
demonstrated that deletion of HVR1 from sE2 resulted in an enhancement of affinity for 
receptor CD81 that was modulated by the genotype from which it was produced. These 
results led us to conclude that HVR1 obscures the CD81 binding site and neutralizing 
epitopes to different degrees based on properties of the isolate it originated from. To 
evaluate the extent in which HVR1 contributes to this inhibition in the context of the 
HCV virion, we performed neutralization assays using a broadly cross-neutralizing 
antibody H77.39 on both genotype 1 and 2 HCVcc +/- HVR1. This antibody recognizes a 
conserved region of E2 and inhibits CD81 and SR-BI binding. The antibody was more 
potent in both HVR1 deletion viruses, with EC50 increases of 55-fold for the genotype 1 
virus and 253-fold for the genotype 2 virus (Fig 3). This greater enhancement of 
neutralization potential for HVR1 deleted genotype 2 HCV relative to genotype 1 
correlates with the increase in affinity displayed by genotype 2 ΔHVR1 sE2 binding to 
CD81-LEL relative to genotype 1. The fold-change in KD is substantially lower than that 
of the EC50 value, but this is expected given there are many copies of E2 per virion and 
HVR1 could contribute to lateral quaternary interactions with these additional E2 
molecules. 
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CD81-LEL inhibition of sE2:SR-BI interaction. We have previously 
demonstrated that certain HCV-neutralizing antibodies inhibit sE2 interaction with both 
CD81 and SR-BI39. We therefore hypothesized that these receptors may share an 
overlapping binding site. To evaluate whether sE2 is able to bind SR-BI and CD81 
simultaneously, we incubated sE2 with various concentrations of CD81-LEL and 
observed the effect on interaction with CHO cell-expressed SR-BI. Indeed, equimolar or 
greater concentrations of CD81-LEL potently inhibited subsequent engagement with SR-
BI. Bound sE2 was detected by flow cytometry with a fluorescently labeled secondary 
antibody specific to a C-terminal 6x His tag and should not interfere with CD81 or SR-
B1 binding (Fig 4A-B). To control for the possibility that sE2 binding to both receptors 
simply caused steric inhibition of the secondary antibody, we stained sE2 to CHO cells in 
the presence or absence of excess CD81-LEL, washed away excess protein, lysed the 
cells and then performed a western blot to detect the bound sE2. In this experiment, the 
proteins are denatured and separated following staining of the cells and unbound sE2 was 
detected with a non-conformational antibody, eliminating the possibility that recognition 
by the secondary antibody was impeded by the dual engagement of both receptors (Fig 
4C). Staining of wild-type CHO cells with sE2+/- CD81-LEL resulted in a small 
background E2 band, but sE2 staining of SR-BI expressing CHO cells was reduced in the 
presence of CD81-LEL. Our results reinforced the original flow cytometry data and 
support the conclusion that a single E2 molecule does not efficiently bind SR-BI while in 
complex with CD81. 
  Neutralizing antibodies J6.36 and J6.103 bind the C-terminus of HVR1. 
Previous reports indicate that antibodies that bind the C-terminus of HVR1 are able to 
 136	  
neutralize HCVpp26,54. While the detailed mechanism for their neutralization is unclear, it 
has been reported that they are able to prevent attachment to multiple hepatocyte cell 
lines55. We previously characterized antibodies J6.36 and J6.103 for genotype cross-
reactivity, epitope recognition and inhibition of sE2 interaction with receptors CD81 and 
SR-BI39. Each was specific for genotype 2 (J6) E2 and lost binding upon mutation of 
residues G397+R572, F403 and G406. Neither mAb cross-reacted with other HCV 
genotypes and two of four residues bound lie within HVR1; thus, we anticipated that 
their dominant epitope would lie within this region. We evaluated J6.36 and J6.103 for 
binding to GST-fusion constructs that spanned the full HVR1 (residues 385-410 of the E2 
polyprotein) as well as truncations consisting of residues 385-397, 391-403 and 398-410. 
Indeed, both reacted with full length HVR1. Neither bound the N-terminal residues 385-
397. J6.103 recognized the C-terminal 398-410 segment and central 391-403 peptides 
with comparable signal as the full length HVR1. J6.36, on the other hand, gave a robust 
signal for the C-terminal 398-410 peptide but yielded a much lower signal for 391-403 
(Fig 5).  
Deletion of HVR1 ablates sE2 binding to CHO cell expressed SR-BI but not 
CD81. Several studies have demonstrated that HVR1 interacts with SR-BI10,45,56. In order 
to evaluate whether our ∆HVR1 sE2 was properly folded, CHO cells expressing human 
SR-BI or CD81 with E2 from two different genotypes +/- HVR1 (Fig 6).  Indeed, 
deletion of HVR1 from both H77 and J6 sE2 reduced binding to SR-BI dramatically. 
However, we did not observe an increase in binding of ∆HVR1 sE2 to CD81 as was 
detected in our SPR experiments. This may be explained by the fact that the enhanced 
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affinity of ∆HVR1 sE2 for CD81-LEL was primarily due to an increase in on-rate, while 
increased cell staining is attributed to half-life, which is linked to the kinetic off-rate.  
 
5.5 Discussion 
 In our study, we ascertained the binding stoichiometry, kinetics and affinity of the 
soluble E2 ectodomain for the CD81 large extracellular loop. By utilizing a variety of 
modified sE2 constructs and solution conditions, we determined that genotype and 
deletion of HVR1 had the most substantial effects on E2:CD81 affinity, and that acidic 
pH and the enzymatic removal of sE2 glycans played a more modest role. In vitro 
experiments with HVR1 deletion viruses resulted in a dramatic increase in the 
neutralization potency of a broadly cross-reactive antibody that blocks E2:CD81 
interaction, supporting our biochemical results that indicated HVR1 obscures the CD81 
binding site. Deletion of HVR1 from also resulted in ablation of sE2 binding to SR-BI. 
Additionally, we observed that binding of sE2 to recombinant CD81-LEL potently 
inhibits subsequent engagement of SR-BI expressed on the surface of CHO cells, 
suggesting the binding site for these receptors may overlap on the E2 protein.  
An essential step in HCV infection is direct binding of E2 to receptor CD81. 
Several protein determinants that contribute to this interaction have been identified, but 
the oligomeric state of the CD81:E2 complex has not been resolved. Using multi-angle 
light scattering we were able to determine that sE2 and CD81-LEL interact as a 2:2 
complex. A CD81 residue, F185, is critical to E2 interaction50 and maps to opposite ends 
of the LEL homodimer49.  Two E2 monomers would be able to engage this residue with 
little possibility for steric inhibition, and so its location on the CD81-LEL crystal 
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structure is supportive of our stoichiometric data. Analysis of the sE2: CD81-LEL 
affinity measurements did not indicate cooperative binding, so it is yet to be determined 
whether HCV infection requires or is enhanced through bivalent CD81 interaction with 
E2. Arenavirus GP1 represents an example of a viral surface protein that recognizes 
opposing ends of a dimeric receptor (transferring receptor 1) with 2:2 stoichiometry57 but 
kinetic information that would allow for biophysical comparisons of these interactions 
has not been determined. 
A suggested role for HVR1 is the concealment of the conserved CD81 binding 
site of E224,26. However, the specific role of HVR1 in the energetics accompanying the 
E2:CD81 interaction remains unclear. Elucidation of the solution oligomeric states of sE2 
and CD81-LEL allowed us to properly orient them in SPR experiments in order to 
accurately determine their single-site KD. The KD for sE2 from H77 and J6 strains were 
101nM and 1750nM respectively. These values fall within the range observed for 
envelope protein-receptor interactions from unrelated viruses such as HIV58 and 
Measles59. Deletion of HVR1 from sE2 constructs enhanced this affinity, confirming that 
the region indeed obscures the CD81 binding site. However, this increase varied 
substantially between the H77 (~2-fold increase) and J6 (~9-fold increase) strains 
indicating both wild-type affinity for CD81 and the extent to which HVR1 affects this 
interaction are genotype-specific. A more pronounced effect was observed in the 
neutralization of HVR1-deleted HCV by H77.39, an antibody that blocks CD81-E2 
interaction. The EC50 of H77.39 was increased 55-fold and 253-fold for H77 and J6 
respectively, suggesting that HVR1 concealment is genotype-specific in HCV virions as 
well. This large increase in neutralization potential of H77.39 relative to minor increases 
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in sE2:CD81-LEL affinity may be due to amplification resulting from the absence of 
several HVR1 peptides or stabilizing effects exerted by HVR1 in the quaternary structure 
of the virion. 
 Both CD81 and SR-BI bind directly to E2 and are necessary for productive HCV 
infection10,11. Given this requirement, our finding that sE2 engagement of CD81-LEL 
precludes SR-BI binding gives rise to multiple possible models for utilization of these 
two receptors. One model would suggest that the virion interacts with both receptors 
through coordination of two separate E2 proteins, each of which binds only one receptor. 
While this mode of synchronized interaction of viral envelope proteins has not (to our 
knowledge) been previously reported, there is no obvious physical limitation that 
excludes this option. Alternatively, HCV may require a viral or host co-factor that 
mediates interaction of a single E2 protein with CD81 and SR-BI. E1 might fill this role, 
however no soluble, properly folded E1 construct has been reported and previous studies 
with E1-E2 captured from lysates did not observe a substantial increase in CD81-LEL 
binding relative to E2 alone37. Other candidates include host lipoproteins apolipoprotein 
E (ApoE), low-density or high-density lipoprotein (LDL or HDL). Infectious HCV may 
be found as lipoviroparticles associated with ApoE60 and LDL61, and HCV infectivity is 
enhanced in the presence of HDL48. Another feasible scenario is that the acidic pH of the 
endosome or receptor-binding triggers a conformational change that enables one E2 
protein to interact with CD81 and SR-BI. Several viral envelope proteins are primed in 
this fashion, but this mechanism is most notably exemplified by the interaction of HIV 
gp120 with host receptor CD4. Attachment of gp120 to CD4 alters the structure of gp120 
and potentiates subsequent binding to host chemokine receptors58,62–64. Our affinity 
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measurements indicated mild enhancement of sE2:CD81-LEL affinity at low pH so these 
molecules do not likely disengage in the endosome. It is possible that E2 releases from 
SR-BI at acidic pH but we have not been able to test this due to the lack of a soluble form 
of the receptor. 
 Several determinants of CD81 and SR-BI interaction with E2 have been 
identified. Known CD81 binding regions are discontinuous and include residues W420, 
Y527, W529, G530, D53542 and a hydrophobic peptide spanning G436-Y44343. Prior 
studies, as well as results of our staining SR-BI expressing cells with ∆HVR1 sE2 
indicate that HVR1 is necessary for E2 to engage SR-BI. However, pre-incubation of sE2 
with CD81-LEL potently inhibited SR-BI interaction, suggesting these two receptors may 
partially share a binding site on E2. Indirect evidence for the location of this shared site 
may be garnered from the epitope mapping of antibody H77.39 that inhibits E2 binding 
to both receptors. This antibody mapped to residues N415 and N417, which lie directly 
between the C-terminus of HVR1 (polyprotein residue 410) and CD81 binding residue 
W420. Based on the location of the H77.39 epitope, we speculate that the conserved 
region of E2 C-terminal to HVR1 may comprise a portion of this overlapping site. 
Alanine scanning reports have established that mutation of N41542 or N41719 did not 
substantially reduce E2:CD81 binding, but W420 or the 436-433 peptide represent other 
candidate residues in this region.  
As ongoing studies illuminate the antibody evasion strategies employed by HCV 
envelope proteins, it is important to note the many parallels that have emerged to those 
utilized by HIV. Unlike large, chronic DNA viruses such as Herpes Simplex Virus-1 that 
encode for an array of immunomodulatory proteins, HCV and HIV are small RNA 
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viruses with limited genomic space reserved for this purpose. Common features include 
modulation of affinity for host receptors through sequence variation58,62,65 and shielding 
of important envelope protein interfaces from antibody recognition with variable loops or 
glycans20,29,66–68. HIV gp120 can utilize CD4 or either of chemokine receptors 
CXCR4/CCR5 for infection58,62. While gp120 from most HIV strains binds CD4, 
mutations in the V3 loop have allowed monospecific variants to utilize just a single 
chemokine receptor69,70. HCV is believed to require both SR-BI and CD81, but our 
results indicate that affinity of the E2-CD81 interaction can differ by at least 17-fold 
across genotypes. This divergence may represent an evolutionary response to immune 
pressure or a strain-specific fluctuation in HCV preference for receptors akin to what has 
been described for HIV. Given the limited number of HCV strains amenable to cell-
culture production, it is entirely possible that undiscovered strains have distinct receptor 
requirements. The HCV HVR1 and HIV V3 variable regions can also bind with heparin 
sulfate to augment cellular attachment28,36,71,72 and are targeted by neutralizing 
antibodies26,54,65,72. By utilizing variable regions for important functional roles, these 
viruses can retain structural integrity while evading antibody recognition.  
 In conclusion, we have resolved several previously unknown biochemical and 
molecular details of the interplay between E2, CD81 and SR-BI. Delineation of the 2:2 
binding stoichiometry of the E2:CD81 complex has clarified an important aspect of HCV 
attachment and entry. Furthermore, we have resolved the kinetics and affinity of this 
interaction and established that concealment of receptor- and antibody-binding sites by 
HVR1 is genotype dependent. We have also determined that sE2 engagement of CD81-
LEL prevents subsequent interaction with SR-BI, suggesting that these receptors share an 
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E2 binding site. Alternately, HCV may sequentially engage its receptors in stages as it 
becomes internalized. If HCV E2 indeed possesses an overlapping binding site for these 
receptors, it presents an intriguing target for inhibitor, therapeutic antibody or vaccine 
development. Taken together, our findings raise the question of whether HCV, like HIV, 
has strain-specific preferences for receptor interaction. Given the limited number of HCV 
isolates that replicate in cell culture, it is possible that undiscovered strains do not require 
all of the established receptors. As structural information emerges on the HCV envelope 
proteins, it is expected that many of these questions will be resolved and stimulate the 
development of novel therapeutics. 
 
5.6 Materials and methods 
Cloning expression and purification of sE2 and ΔHVR1 sE2. Residues 384-661 
of genotype 1 (H77) or residues 385-661 of genotype 2 (J6) E2 ectodomain with an N-
terminal honeybee melittin signal sequence were cloned into the baculovirus transfer 
vector pAcUW51. Since the yield of H77 sE2 was initially poor for this construct, a 
mutation of unpaired cysteine C652 to serine was introduced to increase secretion from 
insect cells (REF). HVR1 deletion constructs (ΔHVR1 sE2) spanning these same regions 
of the H77 and J6 isolates but lacking residues 387-410 (H77) or 388-410 (J6) were also 
generated. Residues 384-386 and 385-387 of these constructs were retained to allow for 
proper cleavage of the signal peptide by signal peptidase. The E2 encoding transfer 
vectors were co-transfected into SF9 cells grown in Sf-900 II media (Invitrogen) with the 
Flashbac Gold bacmid (Oxford Expression Technologies) to permit homologous 
recombination for production of recombinant baculoviruses. The virus was then 
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amplified by passaging the supernatant at ratios of 1:10 into fresh SF9 cultures until titer 
was sufficient for large-scale expression. 5 liters of Hi-five cells grown in Express Five 
(Invitrogen) media were infected with recombinant virus to drive expression of secreted 
sE2. The supernatants from the large-scale infections were then filtered with a 0.2µm 
cutoff bottle-top filter, concentrated and buffer exchanged into nickel binding buffer 
(300mM sodium citrate, 150mM NaCl and 50mM NaPO4 pH 8.0) using a Centramate 
tangential flow concentrator with 30kD cutoff membrane. The supernatants were finally 
purified by nickel and size-exclusion chromatography.  
Cloning expression and purification of CD81-LEL. Residues 114-203 of human 
CD81 were cloned from a cDNA into a Pet28a(+) vector modified with a thrombin 
cleavable C-terminal BirA biotinylation sequence and 6x His tag. This bacterial 
expression vector was transformed into BL21-DE3 (RIL) cells (Stratagene), grown in a 
large-scale 6L culture of luria broth (LB) supplemented with 50mg/L kanamycin and 
induced at an optical density 400nm of 0.8 with 1mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). After 4 hours of induction the cells were centrifuged and 
pellets suspended in solution buffer (50mM Tris pH 8.0, 25% sucrose, 10mM DTT).  
Next, an equal amount of lysis buffer (50mM Tris pH 8.0, 1% TritonX-100, 100mM 
NaCl, 10mM DTT) was added. The lysate was supplemented with 0.8mg/mL lysozyme 
and sonicated to disrupt cell membranes.  The lysate was then centrifuged; the 
supernatant was discarded and the inclusion body pellet was washed 3x with wash buffer 
(50mM Tris pH 8.0, 0.5% TritonX-100, 100mM NaCl, 1mM DTT) and once in wash 
buffer without TritonX-100. Purified inclusion bodies were solubilized in 6M guanidine-
HCl, 10mM Tris pH 8.0 and 20mM β-mercaptoethanol. Aliquots of this solution were 
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diluted in oxidative refolding buffer containing 400mM L-arginine, 100mM Tris pH 8.0, 
0.5mM oxidized glutathione and 5mM reduced glutathione for overnight refolding. The 
refolded protein was concentrated using an Amicon 400 concentrator with 10kD cutoff 
membrane and purified on a S200 size exclusion column. 
Enzymatic deglycosylation of sE2. 1mg of H77 sE2 was buffer exchanged into 
Endo F digestion buffer (0.1M acetate pH 5.5) and protease inhibitor cocktail (Sigma) 
was added to a final concentration of 1x in a total volume of 100µL. 1 unit of Endo F1 
and Endo F3 (Sigma) were each added to the digestion, which was allowed to proceed for 
6 hours at room temperature. Next, 20uL of 1M Tris-HCl pH 8.0 was added to the 
reaction along with 2500 units of Pngase F and incubated at room temperature overnight. 
sE2 was subsequently purified by nickel chromatography to remove the glycosidases.  
Cloning expression and purification of GST-HVR1 fusion proteins. HVR1 
peptides spanning residues 385-410, 385-397, 391-403 and 398-410 of the J6 isolate were 
cloned into the PGEX-4T-1 vector which encodes for an N-terminal GST tag. DNA 
inserts were generated by ordering complementary, overalapping primers (IDT) with 
BamHI and XhoI sites encoded at the 5’ and 3’ ends (relative to the coding region of the 
sequence) respectively. Double-stranded inserts were generated by boiling equimolar 
concentrations of each primer mixed together and letting the solution cool to room 
temperature. PGEX-4T-1 was cleaved at BamHI and XhoI, restriction sites allowing for 
in frame cloning of the HVR1 inserts, gel purified and ligated with the various HVR1 
constructs.  
 GST-HVR1 peptides were expressed as soluble fusion proteins in 1L cultures of 
BL21 DE3 (RIL) cells (Stratagene) by inducton with 1mM IPTG upon reaching an OD of 
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1.0. Expression was allowed to proceed for 4 hours after induction, after which cells were 
lysed in B-PER lysis buffer (Pierce), clarified by centrifugation at 10,000g for 30 minutes 
and purified by affinity chromatography with glutathione linked agarose.   
Multi-angle light scattering. CD81-LEL or sE2 protein (200µg) was individually 
injected onto an HPLC and flowed over a sizing column while multiple parameters were 
measured. The light scattering, refractive index change and UV absorbance were 
observed over the elution profile via the Dawn Helios II multi-angle light scattering 
detector (Wyatt), Optilab rEX (Wyatt) differential refractive index detector and 
photodiode array detector 996 (Waters) respectively. These data were analyzed with 
Astra V macromolecular characterization software (Wyatt) to calculate the molecular 
weight (MW) of each protein from the light scattering and refractive index change. In 
order to determine the MW of the sE2:CD81-LEL complex, 100µg CD81-LEL was 
mixed with 500µg of sE2 and each of the two resultant peaks in the elution profile 
(representative of excess sE2 and complex) was processed as described above.  
Surface plasmon resonance. CD81-LEL was coupled to a CM5 sensor chip using 
standard amine chemistry to a level of 200 response units (RU). Various concentrations 
of sE2 +/- HVR1 from genotypes 1 and 2 were passed over the chip at 60µL/min until 
reaching equilibrium. This required 240 seconds for genotype 1 and 60 seconds for 
genotype 2. All curves were reference subtracted from a control flow cell containing 200 
RU of amine coupled murine anti-Kb antibody to account for non-specific interaction. 
The chip was regenerated with 0.1M glycine pH 2.7 after sE2 binding to remove any 
protein that remained bound. This regeneration condition did not result in any observable 
loss of subsequent binding during the runs. Binding experiments were performed on a 
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Biacore T-100 instrument in HBS-EP buffer pH 7.4 (10mM Hepes, 150mM NaCl, 3mM 
EDTA, 0.005% Tween-20). When varying pH conditions to measure its effects on 
kinetics of genotype 1 sE2:CD81-LEL interaction, HBS-EP was adjusted to pH 6.4 or 5.4 
with 1N hydrochloric acid. For each experiment, a minimum of 5 curves were fitted to a 
1:1 kinetic binding model in order to determine ka, kd and KD using the Biacore T-100 
evaluation software.  
 Neutralization of HCVcc and ΔHVR1 HCVcc. Neutralization of chimeric 
viruses +/- HVR1 with genotype 1a(H77)-2a(J6) specific core-NS2 sequences was 
assessed by focus forming unit assay: 50 to 400 TCID50 of HCV were incubated 1 h at 
37°C with MAb H77.39 or an isotype control and then incubated with cells for 3 h. After 
48 h cells were immunostained for NS5A as previously described [54]. FFU counting 
was automated using ImmunoSpot Series 5 UV Analyzer [58]. Percent neutralization was 
calculated by relating FFU counts to mean of six-replicates incubated in the absence of 
antibody (virus only). Neutralization data were analyzed as variable slope dose-response 
curves using GraphPad Prism 4.0 and IC50-values were interpolated by the software. 
 ELISA for detection of antibody binding to HVR1. 200ng of each GST-HVR1 
fusion protein were diluted into 100µL of coating buffer (0.5 M carbonate bicarbonate 
buffer, pH 9.6), loaded into a 96-well Maxisorp plate (Nunc) and allowed to incubate 
overnight at 4°C. Wells were washed 3x with PBS + 0.05% Tween and blocked for 1 
hour at 37°C with PBS + 1% BSA, then washed 3x again. Wells containing a GST-HVR1 
protein or BSA alone were then incubated with 500ng of either J36 or J103 antibody in 
100µL PBS + 1% BSA for 30 minutes at 4°C. Wells were next washed 3x and treated 
with a peroxidase conjugated anti-mouse Fc polyclonal antibody for 30 minutes at 4°C 
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for secondary detection. Finally, wells were washed 3x to remove excess secondary 
antibody and developed with 150µL of 3, 3′ ,5 ,5′-Tetramethylbenzidine (TMB) substrate 
for 5 minutes at room temperature. This experiment was performed in duplicate three 
independent days and a representative experiment was reported.  
E2 binding to receptor-expressing CHO cells. To assess whether CD81-LEL 
could inhibit binding of sE2 to SR-BI, CHO cells expressing SR-BI were detached with 
PBS supplemented with 4 mM EDTA and 10% FBS and washed three times in medium. 
Cells (105) were pelleted in a V-bottom plate and incubated with 0.5µM of genotype 1 
(H77) sE2 pre-mixed with varying concentrations of CD81-LEL (0-16 µM). Cells were 
washed, incubated with an Alexa Fluor 647-labeled penta-His antibody (Qiagen) for 20 
min on ice, washed again, and binding analyzed on a FACSArray flow cytometer 
(Becton-Dickinson) using FloJo software (Tree Star). Binding of 1µM sE2 and ΔHVR1 
sE2 was detected using the same staining protocol in the absence of CD81-LEL.  
Statistical analysis. All data were analyzed using Graphpad Prism software 
(version 4.0) . 
Western blot for detection of E2 binding to SRB1 expressing CHO cells. 105 
wild type CHO cells as well as those expressing human CD81, SR-BI or no recombinant 
receptor were stained with 4µM H77 sE2 alone or pre-mixed with 32 µM human CD81-
LEL in PBS+1% BSA. Cells were washed three times with PBS, resuspended in 50µL 
PBS+1% Tween-20 and 50µL SDS loading buffer + 10mM 2-mercaptoethanol and lysed 
by sonication. 30µL samples were loaded onto a 4-15% precast polyacrylamide gel 
(Biorad) and then transferred to a PVDF membrane using the iBlot system (Invitrogen). 
The membrane was blocked with PBS+0.1% Tween-20  containing 5% non-fat dry milk 
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(Biorad) for 30 minutes and then non-conformational murine anti-E2 antibody H77.36 
was added to a concentration of 10µg/mL and incubated for 30 minutes. The membrane 
was then washed three times in PBS+0.1% Tween-20 and stained with goat anti-mouse 
Fc peroxidase-conjugated secondary antibody (Sigma) for 30 minutes at a 1:25,000 
dilution. The blot was again washed 3 times, dried and samples were detected using the 
ECL western blotting detection reagent (GE Healthcare) after a 30 second exposure on 
CL-Xposure film (Pierce). 
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Figure 1: Oligomeric state of sE2 and CD81-LEL alone and in complex. Solution 
molecular weight of CD81-LEL (A), sE2 (B) and the two proteins in complex (C) were 
determined by multi-angle light scattering over their elution profiles from a size-
exclusion column. In panel “C”, each peak was evaluated independently. The molecular 
weight of peak 1 corresponded to a 2:2 CD81-LEL:sE2 complex and peak 2 is 
corresponded to sE2, which was in excess. The black trace represents UV absorbance, red 
and blue represent the molar mass and fitted molar mass across the peaks. 
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Figure 2: Affinity and kinetics of sE2:CD81-LEL interaction. A) Selected sensograms 
are displayed, red curves are the raw data and the black curves are 1:1 kinetic fits. CD81-
LEL was immobilized on a sensor chip and H77 or J6 sE2 +/- HVR1 was flowed over the 
surface to evaluate kinetics and affinity. H77 sE2 was also tested at pH 6.4 and 5.4, and 
after deglycosylation. The row designated H77 E2 (deglyc ctrl) contains the parameters 
for sE2 exposed to the equivalent buffers conditions as the enzymatically treated protein. 
B) SDS-page gel analysis of untreated sE2 or sE2 treated by EndoF3 alone, Endo F1 and  
F3, or Endo F1, F3 and PngaseF.  
A 
B 
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Figure 3: Neutralization of J6 and H77 HCVcc +/- HVR1 by a broadly cross-
reactive antibody. Broadly cross-reactive antibody H77.39 blocks sE2 interaction with 
CD81 and was tested for neutralization of H77 and J6 virus +/- HVR1. Bracketed values 
to the right of the chart of EC50 values represent increase fold-increase over the 
neutralization of ΔHVR1 virus over wild-type virus. 
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Figure 4: Soluble CD81-LEL inhibits sE2 engagement of SR-BI. A) Inhibition of sE2 
binding to CHO cells expressing SR-BI was tested by staining in the presence of various 
concentrations of CD81-LEL and detecting by flow cytometry. B) Data from (A) is 
expressed as percent inhibition of sE2 binding to SR-BI expressing cells v. concentration 
of CD81-LEL. C) Western blot of lysates from WT CHO cells or CHO cells expressing 
CD81 or SR-BI stained with sE2 or sE2 + CD81-LEL (designated by +LEL). Bound sE2 
was detected with non-conformational anti-E2 antibody H77.36. 
 153	  
 
 
 
 
 
 
 
 
 
Figure 5: Neutralizing antibody recognition of HVR1. HVR1 or truncations of HVR1 
were fused to GST was detected by monoclonal antibodies J6.36 or J6.103. BSA alone 
served as a negative control.  
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Figure 6: Binding of sE2 and ∆HVR1 sE2 to CD81 and SR-BI. CHO cells expressing 
SR-BI or CD81 were stained with sE2 or ΔHVR1 sE2 from H77 or J6 strains. Bound sE2 
was detected with an anti-6x His antibody.  
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Chapter 6:  
 
Conclusions and future directions 
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6.1 Abstract 
 The focus of this thesis was the establishment of a structural basis for antibody 
and receptor interactions with Flaviviridae Japanese Encephalitis Virus and Hepatitis C 
Virus. To this end, I determined the high-resolution dimeric crystal structure of JEV E, 
which provided insight into the mechanisms of serocomplex-specific pathogenesis in 
flaviviruses. Additionally, I was able to resolve several biochemical features of the 
interplay between HCV envelope protein E2, antibodies and host receptors CD81 and 
SR-BI. Studies of these interactions indicated that E2 cannot simultaneously engage both 
receptors and that sequence diversity within E2 may contribute to receptor preference. 
Future studies will focus on identification of specific residues involved in the putative 
shared CD81/SR-BI binding site on E2 and determination of the kinetics and affinity of 
E2 interaction and membrane-bound receptors. I speculate that crystallization of E2 will 
require generation of new constructs that more closely resemble its conformation in the 
native virion. Finally, I have discussed the need for new therapeutics and reviewed 
antivirals that have been garnered from advances in the understanding of virus structure 
and entry. 
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6.2 Conclusions and summary: JEV E structure 
JEV is an important human pathogen and the leading global cause of viral 
encephalitis. Cross-neutralization tests have allowed for classification of flaviviruses into 
serocomplexes1 with specific tropisms and pathogeneses. Our results have illuminated 
structural and biophysical features of flavivirus E proteins that may contribute to 
serocomplex-specific pathogenesis. The high-resolution crystal structure of JEV E 
revealed a dimer interface that is remarkably small relative to those of other known 
dimeric E structures. This interface had only ~50% of the buried surface area found 
between other E homodimers. JEV E lacks many of the contacts found at the central DII-
DII dimerization region of other E structures. The surface area it does bury is almost 
exclusively within the DI-DIII pocket that houses the fusion-loop, highlighting the 
evolutionary requirement to shield this peptide from prematurely inducing fusion.  
Given the sparse JEV E dimer interface and monomeric crystal structure of WNV 
E2,3, we hypothesized that reduced dimerization propensity may be serocomplex-specific. 
Indeed, we found that JEV E, WNV E and SLEV E were predominantly monomeric in 
solution while DV2 E was dimeric. We resolved the oligomeric states of these proteins 
by multi-angle light scattering, which allows for direct experimental determination of 
molecular weight. Utilization of this technique was of particular importance since 
oligomeric state determination by techniques such as SEC and crystallography has 
yielded inaccurate results for E proteins. Our own JEV E crystallized as a dimer but 
favored monomers in solution, and extrapolations based on molecular weight standards 
using SEC have been unreliable3.  
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Quaternary interactions between E proteins on the surface of virions can influence 
binding of antibodies and cellular receptors. The epitope of WNV-neutralizing antibody 
CR4354 is found across two adjacent E proteins, indicating that the specific assembly of 
E on the virion can contribute to immune recognition4.  DIII is believed to play a role in 
flavivirus attachment and entry5,6 and packs in 3 distinct chemical environments on the 
mature virion7. However, anti-DIII antibody E16 binds only 2 of these 3 environments 
but allows for virion attachment and entry8,9. This implies that only a pentameric 
arrangement of DIII at the 5-fold axis is required for receptor interaction at the cell 
surface.  
It has become increasingly clear that E protein organization plays a significant 
role in host recognition of flaviviruses. Our findings therefore implicate the assembly and 
dimerization affinity of E proteins in serocomplex-specific pathogenesis. 
  
6.3 Conclusions and summary: HCV receptor interaction 
 Extensive characterization of a large panel of anti-E2 antibodies has provided 
insight towards mechanisms of effective neutralization of HCV. The most potent 
neutralizing antibodies bound the N-terminal region I of E2, could be cross-reactive or 
strain-specific and were able to inhibit interaction with CD81, SR-BI or both10. These 
findings led us to further investigate the specific molecular determinants responsible for 
E2 interaction with these two receptors.  
 Since our H77.39 antibody was able to strongly inhibit sE2 binding to both CD81 
and SR-BI, we wanted to investigate whether these receptors may share a binding site on 
E2. We pre-bound sE2 to CD81-LEL and were indeed able to block subsequent binding 
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to SR-BI. Currently we are only able to speculate as to where on E2 the binding sites of 
SR-BI and CD81 may overlap. Our own work and that of several others have identified 
HVR1 (E2 residues 384-410) as a requirement for SR-BI interaction11,12. Residues W420 
and 529-535 are required for E2:CD81 interaction13, so reasonable prediction is that the 
W420 or other conserved residues in close proximity to HVR1 may comprise the shared 
site. Another possibility is that an event accompanying HCV entry, such as a receptor- or 
acid-induced conformational change, allows E2 to link both receptors or disengages it 
from one so it may bind the other. We are in the process of investigating whether the 
reverse of our findings, pre-binding of E2 to SR-BI, will block CD81:E2 interaction. 
 While direct binding of E2 to CD81 has been extensively characterized, some 
basic biochemical features of this interaction are unknown. We determined the solution 
oligomeric state of sE2, CD81-LEL and the sE2:CD81 complex. CD81-LEL formed a 
homodimer that was engaged by 2 monomeric sE2 proteins to form a 2:2 complex. This 
stoichiometric information allowed us to properly orient the two proteins in SPR 
experiments that measured the kinetics and affinity of this interaction. Binding was non-
cooperative, and CD81-LEL and sE2 bound with an affinity comparable to that observed 
for other viral envelope proteins with cellular receptors. The interaction was strengthened 
mildly by low pH (5.4) and enzymatic removal of glycans from sE2, but these increases 
are unlikely to be of biological relevance.  
 Two of our neutralizing antibodies bound HVR1 of E2, a region that plays several 
roles in the HCV life cycle. Deletion of HVR1 from sE2 led to enhancement of CD81-
LEL binding, and this increase in affinity was genotype specific. Additionally, 
neutralization of HVR1-deleted virus by our broadly cross-reactive mAb H77.39 was 
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enhanced and correlated with the genotype-specific increase in affinity observed in our 
SPR experiments. Taken together, these results indicate that the extent that HVR1 
conceals the CD81 binding site and conserved neutralizing epitopes varies across HCV 
genotypes.   
 
6.4 Future directions: HCV receptor interaction 
Kinetics and affinity of sE2 interaction with membrane bound receptors. While 
our results have clarified some aspects of E2 interaction with receptors, several questions 
remain. The 2:2 complex of sE2 and CD81-LEL formed in solution, but it is unclear 
whether bivalent engagement of CD81 by HCV in a cellular system is necessary for 
infection. Furthermore, the interaction of E2 with full-length CD81 or SR-BI in cell 
membranes may not be identical to what is observed in solution. In the immediate future, 
it is realistic to believe we can determine the affinity of sE2 for SR-BI and CD81 
captured from cell lysates to better recapitulate the native interaction. This could be 
achieved by biolayer interferometry because the technique bypasses the sensitive fluidics 
of SPR instruments.  
Purification of E1-E2 complexes. A major concern in studies of HCV entry is the 
inability to generate a soluble E1-E2 complex with properties similar to E1-E2 in wild-
type virus. Little is known about the function of E1, including its influence on E2 
receptor binding. Even basic features of E1 such as its membrane topology are unclear. 
Unfortunately, the oligomeric state of E1 and E2 virions is also poorly understood so 
development of a functional E1-E2 complex will likely require a trial and error approach 
with truncations, leucine-zippered heterodimers or linkers. Another potential strategy 
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would be to purify E1 and E2 with trypsin treatment of virus grown in serum-free media 
(to eliminate contaminating lipoproteins associated with particles). This approach has 
been used successfully in purification of TBEV E14, but the relatively low titer of cell-
culture produced HCV could hamper such efforts. 
 Identification of individual E2 residues involved in SR-BI interaction. CHO 
cells expressing SR-BI allowed us to test our anti-E2 antibodies for inhibition of E2:SR-
BI binding, but will also provide us with an excellent tool to identify the molecular 
determinants of this interaction in future experiments. While HVR1 has been proposed to 
bind SR-BI11, HVR1 peptide alone is not sufficient for E2:SR-BI binding (data not 
shown). Staining of these SR-BI expressing CHO cells with mutants of sE2 known to 
have null CD81 binding activity may allow us to identify residues involved in an 
overlapping binding site. One ideal example is a mutant of the W420 residue only 10aa 
upstream of HVR1 in primary sequence and ablates CD81 binding15. The specific SR-BI 
binding determinants within HVR1 are also undefined. Our antibodies J6.36 and J6.103 
each block this interaction and map to G397, F403 and G406 of E210, providing a series 
of candidate residues for mutation.  
 
6.5 Future directions: Flaviviridae and structural biology  
Flavivirus structures. The structural biology of flaviviruses has been studied 
extensively. Currently, there are available crystal structures of one immature E protein 
bound to prM16, 5 in the pre-fusion conformation3,17–19 and 3 in the post-fusion 
conformation20–22. Also, cryoEM structures and constructions have been determined for 
immature viruses at neutral23,24 and acidic25 pH and mature viruses alone7,26, bound to 
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antibodies27,27 and bound to the DC-SIGN attachment factor28. The final frontier in 
regards to structure determination of whole flavivirus virions will most likely be the 
result of advances in technology that allow for single molecule reconstruction at near-
atomic resolution29. A large percentage of particles released by infected cells are partially 
mature, meaning they incorporate uncleaved prM proteins30. A single-particle 
reconstruction that reveals the structure a partially mature virion, or even the structure of 
a single fully mature particle could resolve many unanswered questions in the realm of 
flavivirus structural biology. For example, such a reconstruction may finally explain how 
neutralizing antibodies recognize buried epitopes such as the fusion loop. The discovery 
of a true cellular receptor that interacts with E would also generate new avenues for co-
crystallization studies, but the requirement or existence of such a molecule is speculative. 
 Determination of HCV envelope protein structures. Many of my efforts were 
directed toward the crystallization of HCV E1 and E2 but were met with little success. 
While crystallization of a given protein is never guaranteed, one can provide several 
arguments based on the available literature as to why no group has succeeded in 
determining a structure of E1 or E2. The paradigm for envelope glycoprotein 
crystallization was established by Kwong et al. and led to successful determination of the 
HIV gp12031.  The techniques were directed at minimizing the degrees of heterogeneity 
and conformational flexibility inherent to viral fusion proteins. Deletion of variable 
loops, mutation of N-linked glycosylation sites, enzymatic removal of glyans and 
stabilization with Fabs are the main strategies used to accomplish this goal. While 
mutation of more than a single N-linked glycosylation site on E2 was found to 
dramatically reduce yield, I was able to produce HVR1-deleted sE2, enzymatically 
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remove ~70% of its glycan molecular weight and complex it with Fab. Screening sE2 
modified or complexed by these methods did not yield protein crystals. These methods 
were popularized many years ago, and have utilized in attempts to crystallize E2 by many 
groups besides our own; so it would seem there are additional complicating factors that 
prevent crystallization. 
One hypothesis to explain no group has successfully crystallized E2 is that sE2 
may be secreted as a heterogeneous population with varying degrees of unpaired and 
paired cysteines. Constructs of E2 span residues 384-660 and have been disulfide mapped 
to reveal the connectivity between the cysteines of purified sE2 monomers32. However, it 
has been determined that infectious HCV particles contain disulfide-linked E1 and E2 
oligomers and require the presence of reduced cysteines33,34. It is also widely reported 
that production of sE2 results in secretion of disulfide linked aggregates. Our own 
experiments have confirmed this result and have even found that monomeric sE2 can 
form disulfide-linked oligomers after extended periods of refrigeration (data not shown). 
Future efforts to crystallize E2 will be more likely to succeed once an appropriately 
folded conformation of E2 or an E1-E2 complex is isolated.  
 
6.6 The future of antiviral therapy for Flaviviridae 
 There are intriguing economical and philosophical questions regarding the utility 
of antiviral therapies that target specific Flaviviridae proteins. The existence of approved 
vaccines for YFV and JEV35 is likely to limit efforts by pharmaceutical companies to 
focus efforts on these viruses. Few other arthropod-borne flaviviruses represent global 
health threats except for DV, which infects ~50 million people annually36. As there are no 
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approved vaccines or specific treatments for DV infection, it is one of the only 
flaviviruses likely to be a target for design of specific antivirals.  
Hepatitis C chronically infects roughly 170 million people, however the number 
of annual incidences has declined by ~90% since 1990 due to screening of donated blood 
and organs. The decline in new infections, ~50% success rate of existing therapies and 
delayed onset of symptoms make HCV a unique case for pharmaceutical development. 
Essentially, there exists a massive population of infected individuals but minimal spread 
of the virus, prompting the urgent need for treatments that augment the effectiveness of 
the current regimen. If infected individuals may be cured before the onset of damaging 
symptoms, a massive public health crisis could be averted. Vaccination against DV and 
HCV has been unsuccessful, possibly due to antibody-dependent enhancement linked to 
heterologous DV infection37 and extensive genetic variability of HCV38, so future 
development of antiviral compounds or therapeutic antibodies remains a priority.  
 Several recent discoveries, however, may lead to the effective control of 
Flaviviridae. Antibodies or compounds that target host receptors and broad-spectrum 
antiviral compounds are two promising strategies. Preventing interaction with required 
host factors is advantageous in that it circumvents the issue of viral diversity. Extensive 
characterization of HCV cellular receptors has provided several potential candidates for 
such an approach. Indeed, antibodies that bind CD8139, SR-BI40 and CLN141 and a 
compound that targets SR-BI42 each are able to inhibit HCV infection of hepatocytes. 
Furthermore, Plasmodium falciparum utilizes both CD81 and SR-BI for invasion of 
hepatocytes43,44, suggesting molecules that target this entry pathway may be broadly 
applicable. While no required receptor for members of the flavivirus genus has been 
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identified, the successful inhibition of HCV infection by these methods should encourage 
future searches.   
Several broad-spectrum antiviral compounds that neutralize enveloped viruses 
have also been identified. One example of such an agent, LJ001, inhibits infection of 
cells by flaviviruses, paramyxoviruses and filoviruses amongst others and is believed to 
function by binding viral membranes to disrupt fusion45. Another molecule, squalamine, 
inhibits DV2 and Hepatitis B Virus infection in vitro and YFV and MCMV in vivo by 
neutralizing the negative charge of host membranes in a manner that is believed to inhibit 
viral replication46. An especially promising drug, T-705 (Farapirivir) protects mice from 
lethal infection with influenza A viruses and is currently in phase II clinical trials47.  
The failure to develop several vaccines for many important human viruses 
illuminates the need for detailed understanding of the structure and entry of Flaviviridae. 
Extensive characterization of these processes has led to the discovery of many new viral 
and cellular proteins amenable to targeting by antibodies or pharmacological agents. 
Therapies that use a multi-pronged approach to boost the immune response, disrupt 
receptor interactions and directly target viral components are foreseeable in the near 
future and may help to eradicate these difficult to treat pathogens.   
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Neutralizing Monoclonal Antibodies against Hepatitis C Virus 
E2 Protein Bind Discontinuous Epitopes and Inhibit Infection 
at a Post-Attachment Step  
 
 
 
 
The research within this appendix consists of data that are published in the Journal of 
Virology. 
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Fremont, DH, Diamond, MS. 2011. Neutralizing Monoclonal Antibodies against 
Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Post-
Attachment Step.  
 
My personal contributions to this manuscript were: i) Cloning, purification and 
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E2 from genotype 1-6 and C-terminal E2 truncations iii) Preliminary staining of yeast 
displayed E2 C-terminal truncations and genotypes 3-6 with the panel of hybridoma 
supernatants. Writing of the manuscript and the majority of experiments were carried out 
by Michelle Sabo. 
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A1.1 Abstract 
 The E2 glycoprotein of hepatitis C virus (HCV) mediates viral attachment and 
entry into target hepatocytes and elicits neutralizing antibodies in infected patients. To 
characterize the structural and functional basis of HCV neutralization, we generated a 
novel panel of 78 monoclonal antibodies (MAbs) against E2 proteins from genotypes 1a 
and 2a HCV strains. Using high-throughput focus-forming reduction or luciferase-based 
neutralization assays with chimeric infectious HCV containing structural proteins from 
both genotypes, we defined eight MAbs that significantly inhibited infection of the 
homologous HCV strain in cell culture. Three of these bound E2 proteins from strains 
representative of HCV genotypes 1-6, and one MAb, H77.39, neutralized infection of 
strains from five of these genotypes. The two most potent neutralizing MAbs in our 
panel, H77.39 and J6.36, inhibited infection at an early post-attachment step. Receptor 
binding studies demonstrated that H77.39 inhibited binding of soluble E2 protein to both 
CD81 and SR-B1, whereas J6.36 blocked attachment to SR-B1 and modestly reduced 
binding to CD81. Using yeast surface display, we localized epitopes for the neutralizing 
MAbs on E2. One of the strongly inhibitory MAbs, J6.36, showed markedly reduced 
binding when amino acids within the first hypervariable region (HVR1) and at a site 
~200 residues away were changed, suggesting binding to a discontinuous epitope. 
Collectively, these studies help to define the structural and functional complexity of 
antibodies against HCV E2 protein with neutralizing potential.  
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A1.3 Introduction 
Hepatitis C virus (HCV) is a blood-borne, hepatotropic virus that infects ~170 
million people worldwide. Approximately 70% of infected individuals progress to 
chronic liver disease, which carries an increased risk of cirrhosis and hepatocellular 
carcinoma1. In general, treatment of chronic HCV is complicated by resistance due to 
extensive genetic diversity. HCV has been classified into seven major genotypes, which 
differ by ~30% at the nucleotide level2, and this positive-sense, single-stranded RNA 
virus has a capacity for rapid evolution of variant viruses during persistent infection. The 
current treatment, pegylated IFN-a2a and ribavirin, has variable side effects and response 
rates depending on the virus and host genotype3. No vaccine is currently available, and 
pre-clinical development has been hampered by a lack of understanding of which 
conserved epitopes on the HCV structural proteins should be targeted. 
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 HCV contains a ~9.6kb RNA genome that is translated as a single polyprotein and 
then cleaved by viral and host proteases into structural proteins (core, E1, E2), p7, and 
nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B)4. Viral attachment 
and entry is mediated by the envelope glycoproteins, E1 and E2. Four attachment or entry 
receptors that are required for infection of hepatocytes have been identified including 
CD815, scavenger-receptor B1 (SR-B1)6, and the tight junction proteins claudin-1 
(CLDN1)7, and occludin (OCLN)8. The importance of E2 binding to the large 
extracellular loop of CD81 has been established in vitro5,9–12, and interactions between E2 
hypervariable region 1 (HVR1) and SR-B1 have been reported6,13,14. The structural basis 
of binding of E2 to its cognate cell attachment factors, however, is poorly understood, in 
part because high-resolution structures of the HCV glycoproteins or intact virion have not 
been solved.  
 The role of the humoral immune response in controlling HCV infection in patients 
remains controversial, as patients with persistent infection develop high-titer antibodies 
that do not appear to clear infection1. Nonetheless, there are emerging data that classes of 
monoclonal and polyclonal antibodies against HCV have protective activity. Binding to 
CD81 by soluble forms of E2 (sE2, truncated proximal to the transmembrane domain) is 
inhibited by antibodies that also neutralize infection of pseudotyped HCV particles 
(HCVpp) derived from the structural proteins of multiple genotypes15,16. Perhaps more 
convincing, experiments in chimpanzees and chimeric mice have shown that passive 
transfer of anti-E2 antibodies protects against infection17–19, and immunization with E1-
E2 virus-like particles and E2 glycoprotein in chimpanzees induces protective 
antibodies18,20,21. Moreover, in a comprehensive study of neutralizing MAbs derived from 
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infected patients, MAbs that bound regions comprised of amino acid residues 396–424, 
436–447 and 523–540 on E2 neutralized HCVpp derived from multiple genotypes18. 
Thus, anti-E2 antibodies apparently can restrict HCV infection, although the exact steps 
(attachment, entry, or fusion) in the viral entry process that are inhibited and the 
corresponding E2 binding epitopes have not been elucidated.   
 To gain more insight into the molecular and structural basis of anti-E2 antibody 
neutralization of HCV infection, we generated a panel of 78 mouse monoclonal 
antibodies (MAbs) against soluble, recombinant E2 proteins derived from genotypes 1a 
(H77 strain) and 2a (J6 strain) HCV strains. These MAbs were analyzed for inhibitory 
activity against infectious HCV in cell culture and assessed for mechanism of action with 
respect to inhibition of ligand binding on the cell surface. By combining this functional 
analysis with a high-throughput yeast surface display mapping strategy, we identified 
neutralizing MAbs that bound to distinct regions of E2, including MAbs that recognized 
determinants with discontinuous epitopes with primary sequences greater than 150 amino 
acids apart. These experiments suggest that neutralizing MAbs blocking distinct stages of 
the HCV cell entry process recognize discontinuous epitopes on the E2 protein. 
 
A1.4 Results 
MAb generation. Previous studies have demonstrated that HCV-specific 
monoclonal and polyclonal antibodies, particularly those that recognize the E2 protein, 
can control HCV infection in vitro and in vivo17,18,20,37–39. However, only a few of these 
antibodies have been characterized for their ability to inhibit at different stages of HCV 
infection or mapped to epitopes at the amino acid level. To better define the structural 
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basis of antibody neutralization of HCV, we generated a new panel of anti-HCV MAbs 
by immunizing BALB/c mice with soluble, recombinant E2 protein that was expressed in 
insect cells and derived from either genotype 1a (H77 strain, amino acids 384-664) or 
genotype 2a (J6 strain, amino acids 385-664) viruses. After five independent splenocyte-
myeloma cell fusions, we subcloned 37 MAbs from genotype 1a-immunized mice and 41 
MAbs from genotype 2a-immunized mice, all with reactivity against the E2 structural 
glycoprotein of HCV.   
Neutralizing activity of anti-E2 MAbs. To study the inhibitory capacity of 
genotype 1a MAbs in cell culture, we utilized an H77-JFH1 chimeric infectious virus that 
contains genotype 1a core-NS2 sequence in the JFH1 background, with a compensatory 
Q221L mutation in NS3 (pHJ3-5)23,24. For high-throughput screening, we adapted a 
focus-forming unit (FFU) assay with Huh-7.5 cells such that infectious foci were scored 
objectively on an ELISPOT reader and the reduction in number of FFU was assessed 
after pre-incubation of virus with individual MAbs (Fig 1A). We performed a single 
endpoint focus reduction neutralization test (FRNT) using neat antibody supernatant (~10 
mg/ml) and identified 13 MAbs that inhibited infection by 40% or greater (Fig 1B). 
Candidate neutralizing MAbs were purified by immunoaffinity chromatography and 
tested for inhibitory activity with a more complete dose-response curve (Fig 1C). We 
confirmed that five MAbs (H77.16, H77.28, H77.31, H77.39 and H77.56) had 
reproducible neutralizing activity, and determined the concentration of MAb at which 
50% of foci were inhibited (EC50 value) (Fig 1C). Of these MAbs, H77.16 and H77.39 
showed the greatest inhibitory activity, with EC50 values of ~3.4 µg/ml and ~1.1 µg/ml, 
respectively.   
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To evaluate the neutralizing activity of MAbs generated against E2 derived from 
the genotype 2a HCV strain, we utilized a genotype 2a J6/JFH1/JC1 infectious chimera 
of HCV that contains a Renilla-luciferase reporter gene inserted immediately upstream of 
NS2A cleavage site22. All 41 MAbs that bound the genotype 2a E2 protein were purified 
and assessed for inhibitory activity over a broad range of concentrations to determine the 
concentration of antibody that reduced luciferase expression by 50% (EC50 value) (data 
not shown). We identified two antibodies, J6.36 and J6.103 that efficiently neutralized 
infection, (Fig 1D) with J6.36 having an EC50 value below 2 mg/ml. Notably, no 
significant difference in inhibitory potency of a given neutralizing MAb was observed 
when the luciferase and FRNT assays were directly compared (data not shown).  
Cross-reactivity of anti-E2 MAbs. HCV is comprised of six epidemiological 
important genotypes with ~70% nucleotide identity2. A better understanding of the 
specific epitopes that are conserved and recognized by inhibitory antibodies may 
facilitate the design of future vaccines. To begin to address this, we assessed how 
genotype variation affected MAb reactivity using recombinant E2 proteins displayed on 
yeast (1a, H77; 2a, J6; 3a, UKN3a; 4a, UKN4a; 5a, SA13; and 6a, UKN6) and 
neutralization capacity with chimeric HCV strains (1a, H77; 2a, J6; 3a, S52; 4a, ED43; 
5a, SA13; and 6a, HK6a) containing the non-structural proteins (NS3-NS5B) of the 
genotype 2a JFH1 strain and structural proteins, p7, and NS2 from strains representative 
of HCV genotypes 1-6.  
 (a) Binding to different HCV genotypes. The ectodomain of E2 from individual 
strains corresponding to HCV genotypes 1-6 was expressed on the surface of yeast, 
incubated with MAbs, and analyzed for binding by flow cytometry. Four of the eight 
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neutralizing MAbs were broadly cross-reactive and recognized all five (H77.16, H77.36, 
and H77.39) or four of the five (H77.56) heterologous genotypes (Fig 2 and Table 1). 
Three of the neutralizing MAbs (H77.31, J6.36, and J6.103) bound to yeast expressing 
only the homologous E2.  
(b) Cross-neutralizing potential of MAbs. As MAb binding capacity to 
recombinant viral structural proteins does not always directly correlate with neutralizing 
potential40, we evaluated the inhibitory activity of several of the cross-reactive MAbs 
against HCV virus of other genotypes. Initially, single endpoint focus reduction assays 
were performed with high concentrations (50 mg/ml) of purified MAbs generated against 
genotype 1a or genotype 2a that cross-reacted with genotype 2a or genotype 1a E2, 
respectively (Fig 3A and 3B). Of the cross-reactive MAbs generated against genotype 1a 
E2, only H77.39 neutralized the genotype 2a virus. Of the cross-reactive MAbs generated 
against genotype 2a E2, only J6.27 inhibited genotype 1a HCV infection (Fig 3B and 
3C). This was surprising because J6.27 lacked neutralizing activity against the genotype 
2a strain against which it was generated (Fig 3C); this pattern of enhanced neutralizing 
activity of cross-reactive antibodies against the heterologous virus also has been observed 
with MAbs against distantly related flaviviruses41,42. H77.39 inhibited the genotype 2a 
virus with an EC50 value of ~5 mg/ml (Fig 3D), which was comparable to that observed 
with the genotype 1a virus (see Fig 1C). We subsequently tested whether H77.39 
neutralized infection of a panel of chimeric viruses that expressed structural proteins from 
the remaining heterologous HCV genotypes. H77.39 dose-dependently inhibited HCV 
infection of genotypes 3a, 4a, and 5a but showed reduced activity against a virus 
containing structural proteins of genotype 6a (Fig 3E).        
 189	  
Mechanism of MAb neutralization. Antibody neutralization may involve 
different stages of viral infection including attachment, internalization, or fusion43. To 
begin to understand how our inhibitory MAbs blocked infection, we performed pre- and 
post-attachment neutralization assays and binding studies to the CD81 and SR-B1 
receptors.  
 (a) Pre- and post-attachment assays. To identify the stage of infection at which 
MAbs neutralize infection, we adapted a pre- and post-attachment inhibition assay 
originally developed for flaviviruses44–46. Purified anti-E2 MAb was incubated with virus 
before or after attachment at 4°C to Huh-7.5 cells, and infection was measured by a 
single endpoint focus reduction assay. Of the nine neutralizing MAbs tested, two 
(H77.39, and J6.36) significantly reduced infection compared to the negative control 
MAb (WNV E16) when added after viral absorption to a cell monolayer, suggesting 
blockade of a post-attachment step (Fig 4A-D). Interestingly, both anti-CD81 and anti-
SR-B1 MAbs also inhibited infection after viral adsorption, confirming previous results 
in Huh-7.5 cells which suggested that HCV binds to CD81 and SR-B1 after initial 
attachment47,48. Inhibition of infection at a post-attachment step by H77.39 was 
confirmed by performing more complete dose-response curve analysis (Fig 4E).   
  (b) MAb inhibition of sE2 binding to receptors. Given that anti-CD81, anti-SR-
B1, and several anti-E2 MAbs all blocked after HCV attached to Huh-7.5 cells, it was 
difficult to discern whether some antibodies blocked binding to individual HCV 
receptors. To address this, we developed a binding assay for soluble E2 (sE2) to CHO 
cells that ectopically expressed human CD81 or SR-B1. CHO cells were transduced with 
a lentiviral vector encoding CD81 or SR-B1 fused to GFP. Surface staining of intact cells 
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with anti-CD81 and anti-SR-B1 MAbs confirmed high-level receptor expression (Fig 
5A), as did analysis of cells for GFP fluorescence (data not shown). Binding of genotype 
1a (Fig 5B) and genotype 2a (Fig 5C) sE2 to CD81 and SR-B1 expressing CHO cells 
(solid histograms), but not control CHO cells (outlined histograms) was confirmed by 
flow cytometry. To determine whether sE2-CD81/SR-B1 receptor interactions could be 
disrupted by anti-E2 MAbs, neutralizing or control (anti-WNV E16) MAbs were pre-
incubated with sE2, added to wells containing CHO cells expressing CD81 or SR-B1, 
and loss of binding was assessed by flow cytometry (Fig 5D). The neutralizing MAb 
H77.39 significantly blocked (>70%, P < 0.01) sE2 binding to both CD81 and SR-B1. In 
comparison, H77.31 also reduced binding of sE2 to both receptors, although inhibition of 
SR-B1 binding was more modest (~40%, P = 0.04) compared to that seen with CD81 
(>80%, P = 0.003). Conversely, J6.36 efficiently inhibited sE2-SR-B1 binding (>80%, P 
= 0.0002) yet only modestly (~50%, P < 0.05) diminished sE2-CD81 binding. H77.16 
and J6.103 blocked sE2 binding to only a single receptor, with both efficiently reducing 
(>75%, P = 0.0005) binding to SR-B1 (Fig 5D). Three neutralizing MAbs, H77.28, 
H77.56, and J6.27, did not inhibit significantly sE2 attachment to either CD81 or SR-B1, 
suggesting that these may block an alternate attachment or entry step (Fig 5E).   
Epitope localization of MAbs. To correlate the function of the anti-E2 MAbs with 
structure of the HCV E2 protein, we localized their epitopes using a previously validated 
yeast surface display mapping assay31,41,45. Initially, COOH-terminal truncated versions 
of E2, based on those described previously34, were displayed on the surface of yeast and 
MAbs were tested for immunoreactivity by flow cytometry (Fig 6 and Table S1). 
Neutralizing MAbs showed different requirements for binding. H77.16, H77.39, J6.36, 
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and J6.103 bound to a region bracketed by amino acids 384-520 of genotype 1a and 384-
518 of genotype 2a E2 (designated “region I”), whereas H77.28, H77.31, and J6.27 
required amino acids 521-605 of genotype 1a or 519-603 of genotype 2a E2 (designated 
“region II”) for binding. In contrast, MAb H77.56 required the full E2 ectodomain (1-
664), suggesting that it interacts with amino acids 606-664 alone or requires a 
conformation of E2 that this region stabilizes. MAbs that neutralized efficiently at a post-
attachment step, H77.39 and J6.36, both bound to region I of E2.   
 To localize MAb epitopes more clearly, we used error-prone PCR mutagenesis 
and yeast surface display to create a library of H77 and J6 E2 variants to define 
individual amino acid binding residues of neutralizing and non-neutralizing MAbs. Yeast 
that lost expression of individual MAb epitopes were sorted by flow cytometry and 
plasmids were recovered, sequenced, and tested for reactivity against a select panel of 
MAbs (Fig 7 and Tables 2 and 3).  
H77.39, the most potent and highly cross-neutralizing MAb, showed markedly 
reduced binding when residues N415 and N417 of E2 were changed (Fig 7A and Table 
2). Two neutralizing MAbs (J6.36, and J6.103) required a pair of mutations for 
significant loss of binding. J6.36 and J6.103 lost binding with changes in HVR1 and a 
more distal region of E2; mutation of residues G406, F403, or a combined mutation at 
residues G397 and R572 abrogated MAb binding. Single mutations of G397 and R572, 
however, did not affect binding (Fig 7B and Table 3). Similarly, H77.16 showed weakly 
reduced binding when a serine was introduced at residue G406 (Fig 7A), but complete 
loss of binding when residue G530 was altered in combination with G406S. However, 
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complete loss of H77.16 binding also was observed when residue G406 was mutated to 
an aspartic acid residue.   
The neutralizing MAbs that were quantitatively weaker in our neutralization 
assays, H77.31 and J6.27, showed decreased binding when residues in the putative CD81 
binding region (amino acids 523-53549) were changed. H77.31 binding to E2 on yeast 
was lost when residues W529, G530, and D533 were mutated, whereas J6.27 binding was 
abolished when amino acids A524 and W529 were altered. The remaining two weakly 
neutralizing MAbs (H77.28 and H77.56) showed reduced binding with changes at 
residues R543 and C552, respectively (Fig 7A and Tables 2 and 3).  
Some non-neutralizing MAbs also were mapped. Several non-neutralizing MAbs 
(H77.27, H77.36, J6.2, J6.6, J6.15, J6.39, and J6.85) shared residues that impacted 
binding of H77.31 or J6.27 (Tables 2 and 3), and a few (J6.2, J6.6, J6.40, and J6.101) 
had total or partial loss of binding to residue G406, which was identified as an important 
recognition residue for the neutralizing MAbs H77.16, J6.36 and J6.103. In addition to 
G406, J6.2, J6.40 and J6.101 recognition was also affected by mutation of residue H617, 
thus defining another discontinuous epitope, albeit one that is not apparently involved in 
neutralization (Fig 7 and Tables 2 and 3). Additional residues that uniquely affected 
binding by non-neutralizing MAbs included G470 (H77.14 and H77.23), Y443 (J6.60), 
and H617 (J6.30).   
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A1.5 Discussion  
In this study, we generated a novel panel of 78 MAbs against the E2 proteins of 
HCV genotypes 1a and 2a, analyzed them functionally for inhibition of HCV infection, 
and localized epitopes using yeast surface display of truncated and substituted forms of 
the E2 protein. We defined MAbs that mapped to distinct regions of E2, neutralized 
infection at different stages, and differentially affected CD81 and SR-B1 engagement. 
Our mapping data also suggests a tertiary interaction between the HVR1 and the COOH-
terminal membrane proximal regions of E2, which provides new insight into the 
quaternary structural aspects of neutralization by functionally relevant antibodies.   
Prior mapping studies of anti-E2 MAbs have utilized peptide binding10,50, phage 
display51, alanine scanning mutagenesis of recombinant E1-E2 18,37,39,52 or E253, or 
generation of neutralization escape mutants54 to localize antibody binding sites. In 
comparison, we used a forward genetic mutational approach coupled with yeast surface 
display to identify mutants in the context of the entire ectodomain of E2 protein in an 
unbiased manner. Three of our nine neutralizing MAbs required amino acid mutations 
greater than 100 amino acids apart in the linear sequence for loss of binding, suggesting 
that discontinuous regions of E2 come together to create functionally important antibody 
epitopes. H77.16 showed a loss-of-binding phenotype when mutations in the HVR1 
(G406S) and the more COOH-terminal residue (G530A) were paired, suggesting that 
H77.16 binds a conformational epitope. Although complete loss of binding could be 
achieved with a single less conserved mutation (G406D), the more conserved G406S 
change required a second mutation at a discontinuous site (G530) for loss-of-binding. 
This finding, which suggests that the HVR1 interacts with more COOH-terminal 
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residues, is consistent with MAb competition studies with recombinant proteins that 
suggested that amino acids 396-424, 436-447, and 523-540 comprise an antigenic region 
(designated “antigenic region-3”) within E218, and with sequencing results of MAb AP33 
escape variants, which identified non-contiguous amino acid residues (N415 and E655) 
as factors in the loss of neutralization phenotype54. Additionally, these data support the 
recently described model of HCV E2 based on the three domain structure of class II E 
proteins in Flaviviridae and Togaviridae, which predicts that the HVR1 proximally 
apposes the proposed HCV Domain I (D1)55 (Fig 8B). 
Two other neutralizing MAbs, H77.31 and J6.27, also recognized residues within the 
third segment of antigenic region-3 (A524, W529, G530 and D533) but did not show a 
loss-of-binding phenotype when amino acids within segment 1 (396-424) were changed.  
These two MAbs less potently neutralized infection and were less cross-reactive. In 
comparison, human anti-HCV MAbs (A8, 1:7, and CBH5) that share epitopes in this 
region37,56 have been characterized as inhibitory and cross-reactive (Table 4). Although 
further analysis is required, the differences in function of the mouse and human MAbs 
could be related to affinity or possibly, that the human MAbs bind additional sites and do 
not exclusively recognize the linear epitope centered at residues G523-D535, as was 
suggested in previous studies15,56. 
The neutralizing MAbs J6.36 and J6.103 also mapped to a discontinuous epitope, 
requiring residues within the HVR1 (G397, F403, and G406) and the more COOH-
terminal residue R572. Although neutralizing MAbs (9/2710,57 and AP21351) have been 
mapped to the HVR1, to our knowledge, MAbs that bind residues at or near R572 have 
not been identified. The MAb 9/27 does not block binding of sE2 to CD8110,57 although it 
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did inhibit HCV VLPs interaction with CD8116, suggesting that it also may recognize a 
conformational or possibly oligomeric epitope. 
The MAb in our study with the greatest inhibitory activity, H77.39, localized to two 
amino acids, N415 and N417, that are highly conserved among all HCV genotypes58,59. 
N415 and N417 were defined previously as possible binding residues for MAbs AP33 
and 3/1139,54,58 (Table 4). Residue N417 comprises part of a highly conserved N-linked 
glycosylation site60,61 that is implicated in obscuring antibody-mediated neutralization59. 
H77.39, as well as AP33 and 3/11, are thus unique in mapping to an N-linked glycan that 
is paradoxically hypothesized to impair antibody recognition.  
To relate binding epitopes to function, MAbs were tested for their ability to inhibit 
sE2 engagement with the HCV cognate receptors CD81 and SR-B1. The MAbs J6.36, 
J6.103, and H77.16, which recognized residues within the HVR1 as well as the more 
COOH-terminal region, blocked sE2-SR-B1 binding6,13,14. These results are consistent 
with data suggesting the HVR1 participates in SR-B1 binding, and that the HVR1-
specific MAb 9/27 inhibits sE2-SR-B1 interactions6,14. Although J6.36 did not map to 
any of the predicted CD81 binding residues49, it partially inhibited binding to CD81. 
J6.36 could map to additional amino acid residues (within the CD81 binding site) not 
identified in our study or steric hindrance could mediate this partial inhibition. In the 
recently modeled E2 structure55, the J6.36 interaction residues lie in proximity to the 
HCV D1, which is predicted to contain key CD81 binding residues49,55 (Fig 8B). 
Conversely, H77.31, which potently inhibited CD81 binding and maps to residues 
(W529, G530) involved in CD81 binding49 partially inhibited SR-B1 engagement despite 
a lack of contact residues in the HVR1. The inability of J6.103 to inhibit binding to CD81 
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despite localizing to the same residues as J6.36 could be explained by overlapping but not 
identical MAb footprints or perhaps differences in affinity of interaction.  
Only one MAb, H77.39, potently inhibited sE2 binding to both CD81 and SR-B1. 
Interestingly, H77.39 did not map to residues within known SR-B1 or CD81 binding 
regions, suggesting that it may recognize a site that once occupied, can sterically prevent 
receptor engagement. This concept is supported by studies showing that N415 and N417 
can obscure the CD81 and SR-B1 binding sites58,59. Finally, the E2 model recently 
proposed by Krey et al predicts that residues N415-N417 lie at the junction of the HVR1 
and D1 (Fig 8B), in proximity to both HVR1 and the CD81 binding residues located 
within C and D loops of D149,55.   
 Pre- and post-attachment neutralization studies provided additional insight into 
the relative potency of MAbs. Studies with distantly related Flaviviruses have shown that 
MAbs inhibiting at a post-attachment step tend to have greater inhibitory activity in vitro 
and in vivo because they require reduced virion occupancy for neutralization31,45,46,62,63. 
Indeed, our two most potent MAbs, H77.39 and J6.36, neutralized infection in the post-
attachment assay. Nevertheless, J6.103 shared apparent binding epitopes with J6.36, yet 
did not neutralize efficiently when added after attachment. This discrepancy may be 
explained by J6.36 having additional amino acid contacts not identified in our study.  
 MAb binding to conserved residues may not directly predict cross-binding or 
cross-neutralizing capabilities36,40. Despite mapping to highly conserved residues, MAbs 
H77.31, J.36 and J6.103 failed to cross-react with any other strains tested, and J6.27 was 
cross-reactive with only two of the strains tested. In comparison, MAb H77.16 was 
highly cross-reactive, but still did not neutralize heterologous strains. In contrast, H77.39 
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cross-reacted with genotypes 1-6 and neutralized chimeric virus representative of all 
strains except genotype 6. The inability of H77.39 to neutralize the genotype 6 chimeric 
virus may be explained by the presence of a mutation in one of the recognition residues, 
N417T64. This mutation is rare in natural HCV isolates49,58, but was required for 
adaptation of the HK6a/JFH1 chimera in vitro64. Mutations at N415 are rare49,58 and 
attenuating in the context of HCV infection54.    
 Generation of an HCV vaccine has been impeded by the lack of a structural 
understanding of the epitopes on E2 that should be targeted by inhibitory antibodies. 
Although direct structural confirmation is necessary, our data suggests the existence of 
discontinuous epitopes that are recognized by antibodies that inhibit CD81 and SR-B1 
binding. The yeast surface display antibody mapping data also provides support for a 
recently proposed structural model of E2 in which the residues comprising the CD81 
binding region lie within a single domain of b-pleated sheets that contains the HVR1 as 
an N-terminal extension55. The epitopes defined by the MAbs H77.16, J6.36, and J6.103 
suggest that the HVR1 might lie in proximity to this domain, creating an conformational 
epitope (Fig 8B), which could be a useful target for vaccines and therapeutic antibodies.    
 
A1.6 Materials and methods 
Cells and viruses. Huh-7.5 cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Equitech), non-
essential amino acids (Gibco), and antibiotics (penicillin G and streptomycin) at 37°C in 
a 5% CO2 incubator. SF9 cells were cultured in Grace’s Insect cell medium (Gibco) 
supplemented with 10% FBS at 28oC. HI-5 cells were cultured in Ex-cell media (Gibco) 
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at 27oC. CHO cells were grown in Ham’s F12 medium (Gibco) supplemented with 10% 
FBS (HyClone) at 37°C.  
 The genotype 2 J6/JFH1/JC1 HCV chimera that expresses luciferase22 was a 
generous gift from Apath Inc. The HJ3-5 H77/JFH1 chimera, which expresses the core-
NS2 segment of the genotype 1a polyprotein within a genotype 2a background has been 
described23,24. The genotype 1a H77/JFH125, genotype 2a J6/JFH126, genotype 3a 
S52/JFH127, genotype 4a ED43/JFH125, genotype 5a SA13/JFH128, and genotype 6a 
HK6a/JFH127 infectious HCV recombinants used in cross-neutralization studies also have 
been described. 
 To generate virus stocks from infectious cDNA clones, plasmids were linearized 
and RNA transcription was performed using the T7 DNA-dependent RNA polymerase 
(MEGAscript Kit, Ambion). Infectious HCV RNA (2 mg) was electroporated as 
described26, and virus was harvested at 48, 72, and 96 hours, sterile filtered (0.2 mm 
filter, Corning Inc), and buffered with 10mM HEPES pH 7.2 (Mediatech, Inc.). Virus 
was stored at 4°C for up to 6 weeks protected from light or aliquotted at -80°C. Virus 
titration on Huh-7.5 cells was performed by TCID50 assay as previously described26.   
Generation of CHO cells stably expressing HCV cell entry factors. Human SR-
BI and CD81 genes were expressed in CHO cells via lentivirus transduction in the 
context of pTRIP, a self-inactivating lentiviral provirus that expresses no HIV proteins 
but instead employs an internal cytomegalovirus (CMV) promoter to express cloned 
genes. An intermediate plasmid, called TRIP-GFP-linker, was generated as a backbone 
into which SR-BI and CD81 were cloned (all entry factor templates were kindly provided 
by C. Rice, Rockefeller University, NY). TRIP-GFP-linker was generated by amplifying 
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the GFP sequence with the forward oligonucleotide 5’-CGC AAA TGG GCG GTA GGC 
GTG and reverse oligonucleotide 5’-CTC GAG CTA GTC GAC TTC GAA ACT AGT 
GCT AGC CCG CGG CTT GTA CAG CTC GTC CAT GCC.  This PCR product was 
digested with restriction enzymes BamHI and XhoI and ligated into the TRIP-GFP 
plasmid digested with the same enzymes. The human SR-BI sequence was amplified with 
forward oligonucleotide 5’-CCG CGG ATG GGC TGC TCC GCC AAA GCG and 
reverse oligonucleotide 5’-GCT AGC CAG TTT TGC TTC CTG CAG CAC from the 
previously described TRIP-hu-SR-BI plasmid8, to generate TRIP-GFP-hu-SR-BI-linker. 
This PCR product was digested with SacII and NheI and ligated into similarly digested 
TRIP-GFP-linker. The human CD81 sequence was amplified from an expression 
construct, TRIP-GFP-hu-CD816, with forward oligonucleotide 5’-GCT AGC ATG GGA 
GTG GAG GGC TGC ACC and reverse oligonucleotide 5’-ACT AGT GTA CAC GGA 
GCT GTT CCG GAT. This PCR product was digested with NheI and SpeI and ligated 
into similarly digested TRIP-GFP-linker, to generate TRIP-GFP-hu-CD81-linker. 
 Pseudoparticle production was performed as previously described  by co-
transfection of three plasmids encoding a TRIP provirus containing a transgene, HIV 
Gag-Pol, and the VSV-G glycoprotein. 293-T cells were seeded at 1.8 x 106 cells/well 
into a poly-L-lysine (Sigma)-coated six-well plate. Transfection was performed the next 
day using a total of 1.5 mg of DNA plasmid, with 6 ml of TransIT-LT1 transfection 
reagent (Mirus). Supernatants were collected 24, 48, and 72 h post-transfection, filtered 
(0.45-mm pore size), and mixed with 100 ml of 1 M HEPES buffer. All transductions 
were performed in the presence of 4 mg/ml Polybrene (Sigma). Receptor expression was 
verified by flow cytometry using the following protocol: cells were lifted using PBS 
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supplemented with 4 mM EDTA and 10% FBS, washed, and pelleted in a V-bottom 
plate. Cells (105) were incubated with either 20 mg/ml of mouse anti-hu-CD81 (BD 
Biosciences) or rabbit anti-hu-SR-B1 (Ab-Cam) for 30 minutes on ice, washed, and then 
incubated with goat anti-mouse IgG or goat anti-rabbit IgG secondary antibody 
conjugated to Alexa Fluor 647 (Molecular Probes). Cells were washed twice and receptor 
expression was analyzed on a FACSArray flow cytometer (Becton-Dickinson) using 
FloJo software (Tree Star).   
Cloning, expression, and purification of recombinant HCV E2. The E2 protein 
ectodomain of strains H77 (aa 384-661)29 or J6 (aa 385-661) was cloned into a 
baculovirus expression vector (pFastBac derivative) from plasmids containing the 
structural proteins of H77 (gift of M. Gale, Jr., University of Washington) or the 
infectious J6/JFH1/JC122 viral genome (gift of Apath, Inc). The baculovirus expression 
vector adds a honeybee melittin signal peptide at the NH2 terminus and a thrombin-
cleavable His6 tag and stop codon at the COOH-terminus. Recombinant baculoviruses 
expressing HCV E2 ectodomains were generated as described previously30, amplified in 
SF9 cells, and used for large scale infection of Hi-5 cells under serum-free conditions. 
Supernatant was concentrated and buffer exchanged into binding buffer (300 mM sodium 
citrate, 150 mM sodium chloride, 50 mM sodium phosphate pH 8.0) using a Centramate 
tangential flow concentrator. E2 was purified by sequential nickel-affinity and size-
exclusion chromatography and monodispersed fractions of monomeric protein were 
collected and used for subsequent studies. 
Generation, purification, and labeling of anti-HCV MAbs. MAbs were 
generated by five independent splenocyte-myeloma fusions as described31. Mice were 
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immunized via an intraperitoneal route with sE2 produced from either genotype 1a (H77) 
or 2a (J6) HCV strains after complexing with RIBI Adjuvant System (Corixa Corp) or 
complete Freund’s adjuvant (Sigma Chemical). Mice were boosted between two and five 
times with homologous HCV sE2 protein complexed with either incomplete Freund’s 
adjuvant (Sigma), RIBI Adjuvant System (Corixa), or Sigma Adjuvant system (Sigma), 
depending on commercial availability, until adequate titers (>1:2500 by ELISA) were 
achieved. Mice with the highest serum titers were boosted intravenously with purified 
sE2 (50 mg) three days prior to fusion of splenocytes with P3X63Ag8.53 myeloma 
cells32. Hybridomas producing anti-HCV E2 antibodies were identified after binding to 
Saccharomyces cerevesiae yeast expressing sE2 on their surface by flow cytometry, 
subcloned by limiting dilution, and isotyped by ELISA. For large-scale production, 
MAbs were generated from ascites or adapted to growth in Hybridoma Serum Free 
Media (Gibco) and purified using protein A or G affinity chromatography (Pierce). In 
some experiments, MAbs were labeled with Alexa Fluor 647 (Molecular Probes) or 
NHS-FITC (Pierce) MAb labeling kits according to the manufacturer’s instructions.   
Virus neutralization assays. Neutralization of HCV infection by viruses 
containing genotype 1a structural proteins (H77/JFH1) was assessed by a focus forming 
unit (FFU) assay. Serial dilutions of HCV-specific MAb, control MAb (WNV E1631), 
anti-human CD81 (clone JS81, BD Biosciences), or anti-human SR-B1 (clone 396, Ab-
Cam) were pre-incubated with 2.4 x 102 FFU of virus for one hour at 37°C. Virus-MAb 
mixtures were added to Huh-7.5 cells (1.2 x 104 cells per well) in a 48-well tissue culture 
plate pre-coated with poly-L lysine (Sigma). After 72 hours, cells were fixed with 
methanol (0oC), and incubated sequentially with a mouse anti-NS5A (APA-1, 40 ng/ml)26 
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(a generous gift of Apath, Inc.) and secondary goat anti-mouse HRP diluted 1:3000 
(Sigma). FFU were visualized using the True Blue Peroxidase Reagent (KPL) and 
quantitated using an S5 Biospot Macroanalyzer (Cellular Technologies Ltd). EC50 values 
were determined using non-linear regression analysis (Graph Pad Prism 4).   
 Neutralization of the genotype 2a (J6/JFH1/JC1) HCV was assessed by luciferase 
assay. Serial dilutions of HCV-specific or control MAbs were pre-incubated with the 
J6/JFH1/JC1 virus that expresses luciferase (102 FFU) for one hour at 37°C and then 
added to Huh-7.5 cells (104 cells per well) in a 96-well black flat bottom polystyrene-
treated microplate (Corning). After 48 hours, cells were lysed and luciferase was detected 
using the Renilla Luciferase Assay System (Promega) according to the manufacturer’s 
instructions.  EC50 values were determined using non-linear regression analysis (Graph 
Pad Prism 4).   
 Neutralization of chimeric viruses with genotype 1a-6a specific core-NS2 
sequences was assessed by FFU assay with the following modifications: 50 to 400 
TCID50 of HCV were incubated 1 hour at 37°C with MAb H77.39 or an isotype control 
and then incubated with cells for 3 hours. After 48 hours, cells were immunostained for 
NS5A as previously described33. FFU counting was automated using ImmunoSpot Series 
5 UV Analyzer27. Percent neutralization was calculated by relating FFU counts to mean 
of six-replicates incubated in the absence of antibody (virus only). Neutralization data 
were analyzed as variable slope dose-response curves using GraphPad Prism 4.0 and 
EC50 values were interpolated by the software. 
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Pre-and post virus attachment assays. To assess the ability of MAbs to inhibit 
H77/JFH1 virus at pre- and post-attachment steps, FFU assays were modified as follows. 
For the post-attachment assay, pre-chilled cells were incubated with 4.8 x 102 FFU of 
virus for one hour at 4°C. Cells were washed thrice with cold DMEM to remove unbound 
virus and MAbs (diluted to 50 mg/ml in media and pre-warmed at 37°C) were added and 
the cells shifted to 37°C. After one hour, a 1:1 MEM-methylcellulose overlay with 4% 
FBS was added to prevent viral spread. For the pre-attachment assay, 4.8 x 102 FFU of 
virus were pre-incubated with 50 mg/ml of media for one hour at 37°C and then added to 
pre-seeded Huh-7.5 cells.   
 To assess the ability of MAbs to inhibit J6/JFH1/JC1 at pre- and post-attachment 
steps, the luciferase assay was modified in the following manner. 48-well tissue culture 
plates were pre-coated with poly-L lysine (Sigma) and seeded with 1.2 x 104 cells per 
well.  For the post-attachment assay, 4.8 x 102 FFU of virus was added to pre-chilled 
cells and “spinoculated” for 45 minutes at 400 x g at 4°C, followed by a 15 minute 
incubation at 4°C.  Cells were washed and pre-warmed MAbs and methylcellulose were 
added as described above. For the pre-attachment assay, 4.8 x 102 FFU of virus were pre-
incubated with 50 mg/ml of MAb for one hour at 37°C and then added to pre-seeded 
Huh-7.5 cells. Cells from both the pre-and post-attachment assay were lysed after 48 
hours and transferred to a 96-well black-bottom plate and luciferase was detected using 
the Renilla Luciferase Assay System (Promega) according to the manufacturer’s 
instructions. 
Cross-reactivity and mapping analysis of MAbs using yeast surface display. To 
assess MAb cross-reactivity with other HCV genotypes, the ectodomain of the E2 genes 
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from genotype 1a (H77, amino acids 384 to 660), genotype 2a (J6, amino acids 385 to 
664), genotype 3a (UKN 3A13.6, amino acids 385 to 667), genotype 4a (UKN 4.21.16, 
amino acids 392 to 663), genotype 5a (SA13 NIH, amino acids 384 to 663) and genotype 
6a (UKN 6, amino acids 385 to 668) was amplified by PCR with BamH1 and XhoI sites 
for cloning added at the 5’ and 3’ ends, respectively.  The PCR products were cloned as 
downstream fusion proteins to the Aga2 gene in the pYD1 vector (Invitrogen) for 
expression on the surface of yeast. To determine the relative binding regions on E2 of 
specific MAbs, COOH-terminal truncation constructs, based on previous studies34 were 
generated for genotypes 1a and 2a corresponding to regions I (amino acids 384 to 520 in 
genotype 1a and 384 to 518 in genotype 2a) or I and II (amino acids 384 to 605 in 
genotype 1a and 384 to 603 in genotype 2a) and displayed on the surface of yeast.   
 Expression constructs were transformed into Saccharomyces cerevisiae strain 
EBY10035 using the S.c. EasyComp transformation Kit (Invitrogen). Individual yeast 
colonies were grown to logarithmic phase at 30°C in tryptophan-free yeast selection 
media containing 2% glucose. Protein expression was induced by cultivating yeast for an 
additional 48 to 72 hrs in tryptophan-free media supplemented with 2% galactose at 
20°C. Yeast cells were washed with PBS containing 1 mg/ml BSA (PBS/BSA) and 
incubated with 40 ml of MAb (neat supernatant or 20 mg/ml purified diluted in PBS) for 
30 minutes on ice. Yeast were washed in PBS/BSA, incubated with goat anti-mouse IgG 
secondary antibody conjugated to Alexa Fluor 647 (Molecular Probes) for 30 minutes on 
ice, washed, and analyzed on a FACSArray flow cytometer (Becton-Dickinson) using 
FloJo software (Tree Star).   
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 Random mutant libraries of E2 were generated from genotype 1a (H77 strain) and 
genotype 2a (J6 strain) genes by error-prone PCR using a GeneMorph II random 
mutagenesis kit (Stratagene). Libraries were ligated into the pYD1 vector and 
transformed into XL2-Blue ultracompetent cells (Stratagene) with ~5.7 x 105 and 5.5 x 
105 transformants for genotypes 1a and 2a, respectively. Screening of the libraries for 
loss of binding variants was performed as described31,36. In brief, yeast expressing E2 
variants that lost specific binding to individual MAbs were sorted using two-color flow 
cytometry. To eliminate mutations that abolished surface expression of E2, yeast were 
stained sequentially with the Alexa Fluor 647-conjugated individual MAb, followed by a 
FITC-conjugated oligoclonal pool of the cross-reactive MAbs J6.1, J6.2, J6.16, J6.39, 
J6.51, and J6.101 for the genotype 1a library and J6.2, J6.14, J6.15, J6.39, J6.51, and 
J6.99 for the genotype 2a library on ice for 30 minutes. Yeast that stained positively for 
the oligoclonal pool but negatively for the MAb of interest were collected, cultivated, and 
iteratively sorted. In some cases, sorting was performed using MACS LS magnetic 
columns (Miltenyi Biotech). In brief, ~107 yeast cells were pelleted and resuspended in 
MACS buffer (PBS + 0.5% BSA+ 2mM EDTA) containing a 1:50 dilution of a FITC-
labeled MAb of interest for 30 minutes, washed, and then incubated with 10 ml of anti-
FITC microbeads (Miltenyi Biotech) on ice for 15 minutes. Yeast were washed and 
passed over a MACS LS column and the flow-through collected. After four to five 
rounds, yeast were plated and individual colonies were tested for binding to individual 
MAbs by flow cytometery. For clones that lost binding to the desired MAb of interest, 
the plasmid was recovered using a Zymoprep yeast minipreop kit (Zymo Research), 
transformed into XL1-Blue competent E. coli, purified using a QIAprep spin miniprep kit 
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(Qiagen) and sequenced. In cases where more than one mutation was detected, site-
specific mutagenesis using the Quick Change II Mutagenesis kit (Stratagene) was used to 
generate individual mutations within the E2 protein to define the mutant of interest.  	  
Inhibition of CD81 and SR-B1 binding. To assess the ability of neutralizing 
MAbs to inhibit binding of sE2 to CD81 and SR-B1, 50 mg/ml of purified MAb was pre-
incubated with 20 mg/ml H77 E2 or J6 sE2 for 30 minutes at 37C. CHO cells expressing 
HCV receptors were detached with PBS supplemented with 4 mM EDTA and 10% FBS, 
and washed three times in medium. Cells (105) were pelleted in a V-bottom plate, 
resuspended with MAb-protein mixture, and incubated on ice for 30 minutes. Cells were 
washed and then incubated with a pool of Alexa Flour 647 labeled anti-E2 MAbs (J6.1, 
J6.2, J6.39, J6.51, H77.30, and H77.34 for the detection of H77 E2; and J6.2, J6.39, 
J6.51, J6.60, and J6.101 for the detection of J6 E2) for 20 minutes on ice. Cells were 
washed twice and sE2 binding was analyzed on a FACSArray flow cytometer (Becton-
Dickinson) using FloJo software (Tree Star).   
Statistical analysis. All data was analyzed using Graphpad Prism software 
(version 4.0). For neutralization assays and receptor-binding assays, an unpaired t-test 
was used to determine statistical significance.  
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Table 1: Binding of MAbs to HCV E2 from different HCV genotypes 
Binding to genotypea:  MAb 
1a(H77) 2a(J6) 3a(UKN 3) 4a(UKN4) 5a(SA13) 6a(UKN6) 
J6.1 +++ +++ +++ +++ +++ +++ 
J6.2 + +++ +++ +++ − − 
J6.6 + +++ + − − − 
J6.7 +++ +++ +++ + +++ +++ 
J6.8 + +++ − − − − 
J6.9 +++ +++ − − +++ − 
J6.12 +++ +++ +++ +++ − − 
J6.13 − +++ − − − − 
J6.14 +++ +++ +++ + + +++ 
J6.15 − +++ +++ +++ +++ +++ 
J6.16 +++ +++ +++ − +++ − 
J6.21 +++ +++ − − − − 
J6.23 + +++ − − − − 
J6.25 − +++ − − − − 
J6.27 +++ +++ +++ − − − 
J6.30 +++ +++ +++ +++ +++ +++ 
J6.33 +++ +++ +++ +++ +++ +++ 
J6.34 +++ +++ + + +++ + 
J6.36 − +++ − − − − 
J6.39 +++ +++ +++ − − − 
J6.40 − +++ + − − − 
J6.42 + +++ +++ +++ − − 
J6.48 − +++ − − − − 
J6.49 − +++ − − − − 
J6.51 + +++ + +++ − − 
J6.56 +++ +++ +++ + +++ +++ 
J6.58 +++ +++ +++ +/− +++ − 
J6.60 − +++ − − − +++ 
J6.62 +++ +++ +++ + +++ + 
J6.67 +++ +++ + − +++ − 
J6.68 + +++ − − − − 
J6.75 +++ +++ +++ +++ +++ +++ 
J6.76 − +++ − − − − 
J6.81 +++ +++ +++ − +++ − 
J6.85 − +++ +++ +++ +++ +++ 
J6.86 + +++ +++ +++ − − 
J6.91 + +++ − − − − 
J6.98 − +++ + +++ − − 
J6.99 − +++ − − − + 
J6.101 +++ +++ + +++ − +++ 
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Binding to genotypea:  MAb 
1a(H77) 2a(J6) 3a(UKN 3) 4a(UKN4) 5a(SA13) 6a(UKN6) 
J6.103 − +++ − − − − 
H77.1 +++ − − − − − 
H77.7 +++ +++ +++ +++ +++ +++ 
H77.8 +++ − − − − − 
H77.9 +++ − − − − − 
H77.11 +++ − − − − − 
H77.12 +++ +++ − − +++ − 
H77.13 +++ − − − − − 
H77.14 +++ − − − − − 
H77.16 +++ +++ +++ +++ +++ +++ 
H77.17 +++ − − − − − 
H77.18 +++ − − − + − 
H77.19 +++ − − − − − 
H77.22 +++ − − − − − 
H77.23 +++ − − − − − 
H77.27 +++ +++ − − + − 
H77.28 +++ +++ − − + − 
H77.29 +++ +++ − − + − 
H77.30 +++ − − − − − 
H77.31 +++ − − − − − 
H77.32 +++ + +++ − +++ − 
H77.33 +++ − − +++ − − 
H77.34 +++ − − − − − 
H77.35 +++ − − − − − 
H77.36 +++ +++ +++ +++ +++ +++ 
H77.37 +++ − − − +++ − 
H77.38 +++ − − − − − 
H77.39 +++ +++ +++ +++ +++ +++ 
H77.42 +++ − − − + − 
H77.43 +++ − − − − − 
H77.44 +++ − − − +++ − 
H77.45 +++ − − − − − 
H77.46 +++ − − − +++ − 
H77.47 +++ +++ − − − − 
H77.50 +++ − − − − − 
H77.53 +++ − − − +++ − 
H77.55 +++ − − − +++ − 
H77.56 +++ +++ +++ +++ − +++ 
↵a +++, strong binding (40 to 100%) to yeast expressing E2; +, weak binding (15 to 
40%) to yeast expressing E2; −, no appreciable binding detected. The data are a summary 
of 3 to 5 independent experiments.  
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Table 2. Summary of MAb binding to genotype 1 mutants expressed on the surface 
of yeast 
 
 
 
 
 
 
Values shown were obtained by dividing the total fluorescence product (percent positive 
population x mean fluorescence intensity) of a mutant for a given MAb by the total 
fluorescence product of the wild type E2 for a given MAb. This value was then divided 
by the total fluorescence product of a mutant for an oligoclonal pool of MAbs by the total 
fluorescence product of WT E2 for the olicoglonal pool (to control for E2 binding) and 
multiplied by 100. Values in bold indicate complete loss of binding, with reductions in 
MAb binding greater than or equal to 80% for a given mutation.  Underlined values show 
partial loss of binding, with a reduction between 50 and 79%. The results are the average 
of three independent experiments for each mutant and each antibody. Poly-protein amino 
acid numbering was determined by alignment with the H77 strain using Sequence 
Location tool on the Los Alamos HCV database  (http://hcv.lanl.gov/cgi-
bin/LOCATE/locate.cgi) 
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Table 3: Summary of MAb binding to genotype 2 mutants expressed on yeast 
 
 
Values shown were obtained by dividing the total fluorescence product (percent positive 
population x mean fluorescence intensity) of a mutant for a given MAb by the total 
fluorescence product of the wild type E2 for a given MAb. This value was then divided 
by the total fluorescence product of a mutant for an oligoclonal pool of MAbs by the total 
fluorescence product of WT E2 for the olicoglonal pool (to control for E2 binding) and 
multiplied by 100. Values in bold indicate complete loss of binding, with reductions in 
MAb binding greater than or equal to 80% for a given mutation.  Underlined values show 
partial loss of binding, with a reduction between 50 and 79%. The results are the average 
of three independent experiments for each mutant and each antibody. Poly-protein amino 
acid numbering was determined by alignment with the H77 strain using Sequence 
Location tool on the Los Alamos HCV database  (http://hcv.lanl.gov/cgi-
bin/LOCATE/locate.cgi) 
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Table 4: Previously characterized anti-E2 MAbs with available mapping 
information 
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Figure 1: Identification of neutralizing anti-E2 antibodies against HCV.  
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Figure 1 legend: Identification of neutralizing anti-E2 antibodies against HCV. A. 
Examples of MAb neutralization as judged by a reduction in the number of FFU using 
the Biospot Macroanalyzer. Spot counts are labeled below each well and well numbers 
are labeled above. Wells 1 through 8 represent decreasing (3-fold) concentrations of the 
neutralizing MAb H77.39 (starting concentration of 50 mg/ml). Well 9 shows infection in 
the absence of MAb, and well 10 is an uninfected well. Data are representative of three 
independent experiments performed in duplicate. B. MAb supernatant was mixed with 
the H77-JFH1 chimeric HCV for one 1 hour at 37°C and Huh-7.5 cells were infected. 
Three days later, neutralization was determined by FFU assay. MAb supernatants that 
decreased the number of FFU to 40% or less (below the solid black line) than the 
negative control MAb (anti-WNV E122) were purified for testing in full dose-response 
analysis. Data is pooled from three independent experiments performed in duplicate. C. 
Serial dilutions of genotype 1a specific purified MAbs were mixed with H77-JFH1 
chimeric virus and neutralization was assessed. Efficient neutralization was observed for 
five (H77.16, H77.28, H77.31, H77.39 and H77.56) genotype 1a specific MAbs but not 
for the negative control MAb (data not shown). EC50 values were calculated after non-
linear regression analysis. Data is pooled from of at least three independent experiments 
performed in duplicate. D. Increasing concentrations of purified genotype 2a specific 
MAbs (J6.36 and J6.103) were mixed with J6-JFH1-JC1-luciferase-expressing virus. At 
48 hours, neutralization was assessed in Huh-7.5 cells by monitoring luciferase 
expression. EC50 values were calculated after non-linear regression analysis. Data is 
pooled from at least three independent experiments performed in duplicate. In this Figure, 
all error bars represent the standard error of the mean. 
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Figure 2: Identification of MAbs that bind heterologous HCV genotypes using yeast 
display of E2 protein. 
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Figure 2 legend: Identification of MAbs that bind heterologous HCV genotypes 
using yeast display of E2 protein. The E2 ectodomain gene from six strains 
corresponding to HCV genotypes 1-6 was cloned into the PYD1 vector and expressed on 
the surface of yeast (see Materials and Methods). Yeast expressing HCV E2 were 
incubated with MAb supernatants and binding was assessed by flow cytometry.  
Representative histograms from all neutralizing MAbs (H77.16, H77.28, H77.31, 
H77.39, H77.56, J6.27, J6.36 and J6.103; solid black histograms) and negative control 
MAb (WNV E16; unfilled gray histograms) are depicted. Data is representative of three 
independent experiments.   
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Figure 3: MAb neutralization of heterologous HCV genotypes. MAbs that were 
generated against (A) genotype 1a or (B) genotype 2a E2 proteins were tested for their 
ability to neutralize infection of virus from the heterologous genotype. Purified J6 or H77 
MAbs (50 mg/ml) were pre-incubated at 37°C with H77-JFH1 (genotype 1a) or J6-JFH1-
JC1 (genotype 2a) virus, respectively, and neutralization was assessed as described in 
Figure 1. C-E.  EC50 analysis was performed with (C) J6.27 MAb and H77-JFH1 virus 
(■) or J6-JFH1-JC1 virus (○) or (D) H77.39 MAb and J6-JFH1-JC1 virus (○) or (E) 
H77.39 MAb and H77/JFH1 (■), J6/JFH1(▲), S52/JFH1(▼), ED43/JFH1(♦), 
SA13/JFH1(●) and HK6a/JFH1(□) chimeric viruses. Graphs represent pooled data from 
at least three independent experiments performed in duplicate (A-D) or two independent 
experiments performed in triplicate (E), and error bars represent the standard error of the 
mean. 
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Figure 4: Pre- or post-attachment neutralization. 
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Figure 4 legend: Pre- or post-attachment neutralization. A-D. To determine whether 
MAbs neutralize HCV infection at a post-attachment step, Huh-7.5 cells were pre-chilled 
at 4°C and 480 FFU of (A) genotype 1a (H77-JFH1) or (B) genotype 2a (J6-JFH1-JC1) 
virus was added to each well for 1 hour at 4°C. After three washes with 4°C DMEM, 
saturating concentrations of MAbs (50 mg/ml) were added for 1 hour at 37°C and the 
neutralization assay completed. In comparison, a standard pre-incubation neutralization 
test was performed at 37°C, in which (C) genotype 1a virus or (D) genotype 2a virus and 
MAb were pre-incubated at 37°C prior to addition to cells. Data shown are the average of 
three independent experiments, with error bars representing standard error of the mean.  
Statistically significant difference in neutralization are compared to infection in the 
presence of a negative control MAb (WNV E16): *, p < 0.05; **, p < 0.01; and ***, p < 
0.001. E-F. To confirm the ability of (E) H77.39 to neutralize infection at both pre-and 
post-attachment steps, a dose response curve was performed under both pre-and post-
attachment conditions as described above using H77/JFH1 virus. Solid squares (■) 
represent pre-attachment data and clear squares (□) represent post-attachment data. 
Graphs represent pooled data from at least three independent experiments performed in 
duplicate, and error bars represent the standard error of the mean. 
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Figure 5: Inhibition of sE2 binding to CD81 and SR-B1 by neutralizing MAbs. A. 
Verification of ectopic CD81 and SR-B1 receptor expression on CHO cells. CHO-CD81 
or CHO-SR-B1 cells were incubated with either mouse anti-hCD81 or rabbit-anti-hSR-
B1 (black histograms) or an irrelevant MAb (unfilled gray histograms) for 30 minutes on 
ice. Cells were washed, incubated with the appropriate secondary antibodies, and 
processed by flow cytometry.  B-C. Binding of (B) genotype 1a (H77) E2 or (C) 
genotype 2a (J6) E2 to CHO-CD81 and CHO-SR-B1 but not WT CHO cells. CHO-CD81 
or CHO-SR-B1 (solid black histograms) or WT CHO (unfilled gray histograms) cells 
were incubated with sE2 and binding was assayed by flow cytometry. Data are 
representative of at least three independent experiments. D. Assessment of inhibition of 
sE2 binding to CHO-CD81 or CHO-SR-B1 cells by neutralizing MAbs. sE2 was pre-
incubated with neutralizing MAbs, added to CHO cells, and binding detected by flow 
cytometry. Examples of MAbs that inhibit sE2 binding only to CD81 (H77.31), to both 
CD81 and SR-B1 (H77.39), or only to SR-B1 (J6.103), as well as a negative control 
MAb (WNV E16) are shown. Histograms are representative of three individual 
experiments. Solid black histograms represent sE2 binding in the presence of MAb, red 
histograms represent sE2 binding in the absence of MAb, and shaded gray histograms 
represent sE2 binding to CHO WT cells. E. Graphical representation of sE2 binding to 
CHO-CD81 and CHO-SR-B1 cells in the presence of neutralizing MAbs. Values were 
determined by dividing the fluorescence quotient (mean fluorescence intensity x percent 
positive cells) for E2 binding in the presence of a neutralizing MAb by the fluorescence 
quotient of sE2 binding to either CHO-CD81 or CHO-SR-B1 cells alone. Asterisks 
represent statistically significant difference in sE2 binding compared to the negative 
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control MAb, WNV E16: *, p < 0.05; **, p < 0.01; and ***, p < 0.001. Error bars 
represent the standard error of the mean. Data are pooled from three independent 
experiments.   
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Figure 6: Mapping of anti-E2 antibodies 
using COOH-terminal truncation mutants. 
A.  Scheme of E2 truncations used for 
mapping.  cDNA containing region I (aa 384-
520 and aa 384-518 in E2 of genotypes 1a and 
2a, respectively) I and II (aa 384-605 and 384-
603 in E2 of genotypes 1a and 2a, 
respectively), and the full length ectodomain 
(aa 384-664) were displayed on the surface of 
yeast. B. MAb supernatants were incubated 
with yeast and assessed for binding by flow 
cytometry. Neutralizing MAbs binding to 
regions I (H77.16, H77.39, J6.36, and J6.103), 
II (H77.28, H77.31, and J6.27), and III 
(H77.56) are shown. Solid black histograms 
depict binding of HCV-specific MAbs and 
gray, unfilled histograms represent binding of a 
negative control MAb (WNV E16).  
Histograms are representative of three 
independent experiments.   
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Figure 7: Epitope localization of anti-HCV MAbs. 
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Figure 7 legend: Epitope localization of anti-HCV MAbs. Binding of neutralizing 
MAbs to yeast expressing E2 protein variants. A. Flow cytometry histograms of wild 
type and loss-of-binding genotype 1a E2 variants (G406D, G406S, N410Y, I411N, 
N415Y, N417T, W529R, G530A, D533N, R543G, C552S, and G406S + G530A). 
Representative histograms are shown for the MAbs H77.14, H77.16, H77.28, H77.31, 
H77.39, H77.56 xand WNV E16 (negative control) with WT H77 E2 and each of the 
variants. Data shown are representative of three independent experiments. Red arrows 
indicate >80% loss-of-binding of a specific MAb for a given variant.  B. Flow cytometry 
histograms of wild type and loss-of-function genotype 2a E2 variants (G397E, F403L, 
G406C, A524V, W529C, R572S, H621L and G397E+R572S) with individual 
neutralizing MAbs. Representative histograms are shown for the MAbs J6.27, J6.36, 
J6.101, J6.103 and WNV E16 (negative control) with the wild type E2 and each of the 
variants. Data shown are representative of three independent experiments. Arrows 
indicate >80% loss-of-binding of a specific MAb for a given variant.   
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Figure 8: Localization of MAb binding residues on E2. 
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Figure 8 legend: Localization of MAb binding residues on E2.  A.  Alignment of E2 
sequences from HCV genotypes 1-6 with superimposed mapping of MAb binding 
residues. The sequences of E2 from strains representative of the different genotypes 
(genotype 1a, H77; genotype 2a; J6, genotype 3a, UKN 3; genotype 4a, UKN4a; 
genotype 5a, SA513; genotype 6a, UKN 6) were aligned and colored boxes and symbols 
were used to highlight neutralizing MAb binding residues as follows: red boxes, J6.36 
and J6.103; purple boxes, H77.39; blue underscoring, H77.16; green boxes, J6.27; pink 
circles, H77.31; orange box, H77.28; yellow box, H77.56.  B. Putative model of structure 
of the E2 protein with MAb binding regions highlighted. A scheme depicting a possible 
E2 structure was adapted from Krey et al. (36) to highlight regions involved in MAb 
recognition. N-linked glycosylation residues are labeled in green and amino acids 
numbered in black at intervals. b-sheets in D1 are labeled as previously described (36).  
MAb binding regions are highlighted by colored circles as follows: red circles, J6.36 and 
J6.103; purple circle, H77.39; light blue circles, H77.16; green circle, J6.27; pink circle, 
H77.31; orange circle, H77.28; yellow circle, H77.56. C. Summary of neutralizing MAbs 
described in this study. EC50 values (neutralization against homologous virus), cross-
reactivity to E2 from different genotypes, inhibition of binding to CD81 and SR-B1, 
reactivity with different regions of E2, and loss of binding residues are listed. MAb 
names are color-coded to correspond to panels A and B. 
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Appendix Table 1: HCV E1&E2 constructs, purification and crystallization 
attempts. 
 
Construct and 
polyprotein residues 
Vector Results and 
purification 
Crystallization 
trials 
H77E2 384-660  HTPbac-GFP Secreted, nickel, 
SEC 
alone 
+CD81-LEL 
+H77.16  
+H77.34 
+H77.16&H77.34 
+H77.16, H77.34, 
chymo 
+H77.46 
+H77.55 
H77E2 384-660 C652S HTPbac-GFP Secreted, nickel, 
SEC 
+deglyc  
+deglyc, chymo 
+deglyc, thrombin, 
H77.55, CD81 
+H77.39 
+ deglyc, thrombin 
H77.55, H77.39 
J6E2 385-660 HTPbac-GFP Secreted, nickel, 
SEC 
alone 
+E1frag 
+E1frag, CD81-
LEL 
+CD81-LEL 
+J6.36 
ΔHVR1 H77E2 384-386, 
410-660 
HTPbac-GFP Secreted, nickel, 
SEC 
 
ΔHVR1 J6E2 384-386, 
410-660 
HTPbac-GFP Secreted, nickel, 
SEC 
 
ΔHVR1 J6E2-cys 384-
386, 410-652 
HTPbac-GFP Secreted, nickel, 
SEC 
+deglyc, 
+deglyc+J6.36 
H77E2 short 384-520 HTPbac-GFP Secreted, misfolded - 
H77E2 med 384-605 HTPbac-GFP Secreted, misfolded - 
J6E2 short 385-518 HTPbac-GFP Secreted, misfolded - 
J6E2 med 385-603 HTPbac-GFP Secreted, misfolded - 
H77E2 8cys 384-563 HTPbac-GFP Secreted, misfolded - 
H77E2 10cys 384-580 HTPbac-GFP Secreted, misfolded - 
ΔHVR1 H77E2 8cys 
384-386, 410-580 
HTPbac-GFP Secreted, misfolded - 
ΔHVR1 H77E2 10cys 
384-386, 410-563 
HTPbac-GFP Secreted, misfolded - 
H77E2 384-660 Pet21a(+) Did not refold - 
J6E2 8cys 384-563 Pet21a(+) Did not refold - 
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J6E2 10cys 384-580 Pet21a(+) Did not refold - 
J6E2 12cys 384-596 Pet21a(+) Did not refold - 
J6E2 385-660 Pet21a(+) Did not refold - 
J6E2 short 385-518 Pet21a(+) Did not refold - 
J6E2 med 385-603 Pet21a(+) Did not refold - 
J6E2 8cys 384-563 Pet21a(+) Did not refold - 
J6E2 10cys 384-580 Pet21a(+) Did not refold - 
J6E2 12cys 384-596 Pet21a(+) Did not refold - 
J6E2 cys14-16 590-655  Pet21a(+) Did not refold - 
J6E1 frag 191-262 Pet21a(+) Refolded, disordered - 
J6E1 short 191-269 HTPbac-GFP Secreted, misfolded - 
J6E1 long 191-334 HTPbac-GFP Not secreted - 
    
Yeast constructs    
H77 E2 PYD1 Displayed - 
H77 E2 region 1 PYD1 Displayed - 
H77 E2 region 2 PYD1 Displayed - 
J6 E2 PYD1 Displayed - 
J6 E2 region 1 PYD1 Displayed - 
J6 E2 region 2 PYD1 Displayed - 
J6 E1 short 191-262 PYD1 Displayed - 
UKN 3a13.6 E2 385-667 PYD1 Displayed - 
UKN 4.21.16 E2 392-663 PYD1 Displayed - 
SA13 (5a) E2 384-663 PYD1 Displayed - 
UKN 6 E2 385-668 PYD1 Displayed - 
 
If a crystallization attempt is listed, this indicates the automated or manual setup of at 
least 192 sparse matrix conditions.  
 
Legend: 
+ thrombin: sE2 was incubated with 50U/mg thrombin overnight at 4 degrees 
+ chmyo: 0.1% w/w chymotrypsin was added to the stock prior to screening 
+ CD81-LEL: equimolar CD81-LEL was added to the stock prior to screening 
+ E1 frag: equilmolar refolded E1 192-262 peptide was added to the stock 
+ deglyc: E2 was pre-treated with Endo F1, Endo F3 and PngaseF as described in 4.6.3 
+ H77.XX or +J6.XX: E2 was complexed with sE2 prior to screening 
 
 
